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Abstract
Diabetes is one of America’s leading chronic diseases with comorbidities contributing to
lower health statuses and increased health care costs. While it is known that lowering
HbA1c reduces the deleterious effects of diabetes, the capability to identify people with
diabetes at risk for uncontrolled HbA1c levels or developing comorbidities based on the
compliance rates for different oral antihyperglycemic medication classes (OAMCs) and
financial assistance programs does not yet exist. These quantitative longitudinal
retrospective studies examined the association between medication compliance, using
Proportion of Days Covered (PDC), by OAMC and Medicare financial aid programs, on
predicting HbA1c levels and comorbidities in type 2 diabetics. Jaam’s medication
compliance framework guided sample selection from the 2019 claims database of a large
Managed Care Organization with limited eligibility of only 60% of the population which
had an HbA1c level checked in the past 12 months. Multiple regression analyses revealed
that as compliance rates improve, different OAMC combinations are associated with
significant and variable reductions in A1c levels but with minimal effect strengths not
allowing the linear regression model to be used as a predictive tool. Financial assistance
programs have a small, but statistically significant effect on reducing HbA1c levels,
comorbidities, or improving compliance rates. These studies are the first to investigate
the association between PDC compliance rates for OAMCs on HbA1c and comorbidities.
These findings contribute to positive social change by demonstrating that variable patient
compliance rates for different OAMC medication classes and HbA1c testing should be
considered when prescribing diabetic therapeutic regimens to achieve optimal HbA1c
control and improved health status.
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Part 1: Overview
Introduction
Purpose for Study
Diabetes ranks seventh in the cause of death in the US, with 122 million
Americans actively diagnosed with diabetes or prediabetes; almost one-third of the US
population. Diabetes cases surged between 2008 and 2018 with the incidence highest in
Native Americans and Alaskan Indians. One third of people with diabetes have chronic
kidney disease and fewer than 25% are aware they suffer from this comorbidity.
Currently rates in those aged 10-19 have increased significantly. Only 50% of diabetics
have their HbA1c levels under control at less than 7% (Centers for Disease Control and
Prevention, 2020). One out of every four dollars spent on healthcare in the US is related
to diabetes (Riddle & Herman, 2018). Additionally, diabetes comorbidities, including
Myocardial infarction, End-Stage Renal Disease, Blindness, and Urinary Tract Infections
create additional financial burdens through reduced health statuses. Medication
compliance is a crucial part of any diabetes treatment plan, yet people with diabetes
remain non-compliant in taking their medications. Diabetes is the most expensive chronic
disease to treat, primarily due to the high comorbidity rates and complications.
In 2008, Medicare (CMS) implemented a quality rating system for many
healthcare providers, called the Star Score Ratings, ranging from one to five with one
being a poor rating and five being the highest rating possible. This ranking system
provides consumers a way to compare the quality of care provided by different healthcare
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providers (Cotton et al., 2016). In 2017, state Medicaid programs adopted a quality rating
system called the Medicaid Health Plan Rating System, or HPR, created by the National
Center for Quality Assurance (NCQA) (National Center for Quality Assurance, 2018b).
Under Medicare, Managed Care Organizations (MCO) face a 9% loss in payments low
quality ratings and a 9% bonus payment for a high quality rating with payment in the
form of bonuses and rebates.
NCQA diabetes measures are part of the Healthcare Effectiveness Data and
Information Set, better known as the HEDIS system, based on six domains of care
(National Center for Quality Assurance, 2018a). Diabetes falls under the chronic
conditions domain and includes measures of HbA1c control, annual retinopathy and
nephropathy screening compliance, and controlled blood pressure. Because of the
financial risk that healthcare organizations face if they do not meet their CMS or HPR
HEDIS standards for people with diabetes, there is a need for analytic tools to help these
organizations identify those at risk for high HbA1c levels and minimize the comorbidities
of diabetes.
Theoretical and Practical Relevance
Jaam’s Diabetes Medication Compliance Framework
With over forty years of studies on medication compliance, current frameworks
are still fragmented (Allemann et al., 2016). In 2018, Jaam et al., developed a framework
defining the relationship between the HEDIS CDC diabetes measure and medication
compliance, the core objectives of the studies presented in this dissertation. Clinical
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predictors included are type of diabetes, HbA1c level, comorbidities, glucose control,
duration of diabetes, diabetes-related factors, and classes of blood sugar control
medications taken. The Social Determinants of Health (SDOH) factors such as insurance
type, demographics and health literacy, are included as predictors in the studies presented
here. All these predictors are part of Jaam’s framework shown in Figure 1.
Figure 1
Medication Compliance Framework

Health Literacy

Social Determinant of
Health (SDOH) factors
such as insurance type,
demographics and
health knowledge

HbA1c Level

Medication Adherence

Medication Adverse
Effects
Diabetes Comorbidities

Class of Medication
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Taken from Jaam’s Medication Compliance Framework Jaam et al. (2018)
Current Scientific Understanding
In 2015, diabetes was the seventh leading cause of death in the US.
Approximately 117 million Americans have either diabetes or prediabetes, constituting
almost one-third of the US population. Other disturbing factors related to diabetes include
only one in four people with diabetes know they have the disease, in 2015 there were 1.5
million new diagnoses in those over 18, more men are diagnosed as prediabetic than
women, and diabetes contributes to other diseases such as cardiovascular, stroke,
neuropathies, and kidney disease (Center for Disease Control, 2017).
Healthcare organizations are interested in diabetes because of the financial
challenges presented by quality measures introduced by Medicare. The NCQA HEDIS
measures are used to evaluate the quality of care for 190 million individuals, or 60% of
the US population (National Committee for Quality Assurance, 2018a). HEDIS measure
compliance is part of the calculation of base financial rewards or penalties based on how
well providers perform against NCQA standards. Penalties for Medicare Advantage plans
not meeting quality goals can see reduced payment rates and bonus money loss. Penalties
for Medicaid MCO’s are set by individual states using the HPR system established by the
NCQA. Penalties for not meeting quality standards include payment holdbacks, changes
in the way individuals are assigned to MCO’s, and monetary chargebacks (Rowan et al.,
2021).
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With one-third of the US population having some form of diabetes and the
financial penalties for MCO’s not reaching set quality scores, MCO’s need help
identifying those at risk for uncontrolled HbA1c levels, high rates of medication noncompliance, and for not meeting HEDIS quality standards. The studies in this dissertation
focus on developing and validating methods to help MCO’s identify people with diabetes
that may contribute to low-quality scores, examine the effectiveness of two Medicare
financial subsidy programs, and examine the relationship between medication compliance
and medication class and four of the comorbidities of diabetes.
Scope and Delimitations
The goal of these studies is to show that the Proportion of Days Covered (PDC), a
medication adherence measurement methodology, for individual antihyperglycemic
medications class being taken, and participation in financial assistance programs, can be
used in multiple regressions as a method to identify at-risk individuals for uncontrolled
HbA1c levels and those at risk for the comorbidities of diabetes. If these proposed
analysis are found valid, they give organizations a quick and proactive way to improve
their HEDIS diabetes compliance rates and reduce their financial risks. While there are
studies in the literature discussing the HEDIS PDC measure, there are none on its use
combined with a class of antihyperglycemic medication as a predictor for HbA1c levels.
This study presents an opportunity to fill a gap in the literature that, to date, has not been
studied and could be of significance to health care providers and organizations.
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Participants for these studies were selected using secondary claims data provided by a
large MCO.
Problem Statement
Healthcare organizations that must comply with the HEDIS standards face both
financial and human issues. First, there are financial penalties for not meeting the quality
standards set by Medicare and Medicaid. Second, MCO’s face additional medical costs
created by their members who do not comply with quality standards. The first manuscript
establishes a relationship between medication compliance and six of the nine classes of
oral antihyperglycemic medications and HbA1c levels. The second study establishes the
statistical significance of the relationship between the two Medicare financial subsidy
programs, Low Income Subsidy (LIS) and Dually Eligible Special Needs Program
(DSNP) on HbA1c levels and medication compliance in any of the six classes of oral
antihyperglycemic medications, there is not any significant strength of effect.. The third
manuscript identifies some statistically significant factors for those at risk for four of the
comorbidities of diabetes, blindness, end-stage renal disease, myocardial infarction, or
urinary tract infection based on medication compliance, the class of antihyperglycemic
medication taken, and HbA1c levels.
Health care systems have a vested interest in maintaining a high health status for
all members because of the shift to value and quality-based contracting. Essentially, the
healthier an MCO can keep its members, the higher the financial rewards available from
Medicare or Medicaid. Regressions are tools available for finding those at risk for not
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paying attention to their health. Many health care systems face high costs from people
with type 2 diabetes, primarily due to the disease's complications (Dall et al., 2014).
Medication compliance plays a vital role in diabetes management with low medication
compliance rates and reduced health status leading to suboptimal therapeutic outcomes in
people with diabetes that plays a role in their reduced health statuses (Huang et al., 2018;
Polonsky & Henry, 2016).
Research question/hypothesis for each manuscript
The first two manuscripts examine how medication compliance in six of the
classes of antihyperglycemic medications and Medicare financial subsidy programs and
various covariates such as age, sex, deductible, number of hospital visits, seeing an
endocrinologist, participation in renal and retinal screenings, having a diagnosis of
blindness, myocardial infarction, UTI, or end-stage renal disease, LIS enrollment, DSNP
enrollment, and controlled blood pressure (Feingold, 2019). Manuscript three looks at the
relationship between HbA1c levels, antihyperglycemic medication class, and medication
compliance on blindness, urinary tract infections, end-stage renal disease, and myocardial
infarction. The relationships presented in the first two studies provide evidence for
practitioners treating this diabetes. Study three established that the PDC, HbA1c levels
are a predictors four of the comorbidities of diabetes.
In the first manuscript, we investigate the PDC for participants only taking one of
the antihyperglycemic medication classes during the year. Because we only have a single
HbA1c level during the year, we cannot correlate taking several different medication
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classes to a change in a single HbA1c level. The outcome variable, HbA1c levels, is
continuous, and therefore, multiple regression analyses were performed on this data. This
manuscript's title is "Medication Compliance by Drug Class as a Predictor of HbA1c
Values in Medicare Type 2 Diabetics". The research questions for this manuscript are:
RQ1: What is the relationship between the PDC and the antihyperglycemic class of
medication on HbA1c in Medicare type 2 diabetics while controlling for age, sex,
deductible, number of hospital visits, seeing an endocrinologist, participation in renal and
retinal screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure?
H01: There is no statistically significant relationship between the PDC and the
Biguanides class of medications on HbA1c in Medicare type 2 diabetics while
controlling for age, sex, deductible, number of hospital visits, seeing an
endocrinologist, participation in renal and retinal screenings, having a diagnosis
of blindness, myocardial infarction, UTI, end-stage renal disease, LIS enrollment,
DSNP enrollment, and controlled blood pressure?
H11: There is a statistically significant relationship between the PDC and the
Biguanides class of medications and HbA1c values in Medicare type 2 diabetics
while controlling for age, sex, deductible, number of hospital visits, seeing an
endocrinologist, participation in renal and retinal screenings, having a diagnosis
of blindness, myocardial infarction, UTI, end stage renal disease, LIS enrollment,
DSNP enrollment, and controlled blood pressure.
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H02: There is no statistically significant relationship between the PDC and the
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications and HbA1c values
in Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure.
H02: There is no statistically significant relationship between the PDC and the
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications and HbA1c values
in Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure.
H12: There is a statistically significant relationship between the PDC and the
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications and HbA1c values
in Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure.
H02: There is no statistically significant relationship between the PDC and the
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications and HbA1c values
in Medicare type 2 diabetics while controlling for age, sex, deductible, number of
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hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure.
H03: There is no statistically significant relationship between the PDC and the
Thiazolidinedione class of medications and HbA1c values in Medicare type 2
diabetics while controlling for age, sex, deductible, number of hospital visits,
seeing an endocrinologist, participation in renal and retinal screenings, having a
diagnosis of blindness, myocardial infarction, UTI, end-stage renal disease, LIS
enrollment, DSNP enrollment, and controlled blood pressure.
H13: There is a statistically significant relationship between the PDC and the
Thiazolidinedione class of medications and HbA1c values in Medicare type 2
diabetics while controlling for age, sex, deductible, number of hospital visits,
seeing an endocrinologist, participation in renal and retinal screenings, having a
diagnosis of blindness, myocardial infarction, UTI, end-stage renal disease, LIS
enrollment, DSNP enrollment, and controlled blood pressure.
H04: There is no statistically significant relationship between the PDC and the
Sulfonylureas class of medications and HbA1c values in Medicare type 2
diabetics while controlling for age, sex, deductible, number of hospital visits,
seeing an endocrinologist, participation in renal and retinal screenings, having a
diagnosis of blindness, myocardial infarction, UTI, end-stage renal disease, LIS
enrollment, DSNP enrollment, and controlled blood pressure.
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H14: There is a statistically significant relationship between the PDC and the
Sulfonylureas class of medications and HbA1c values in Medicare type 2
diabetics while controlling for age, sex, deductible, number of hospital visits,
seeing an endocrinologist, participation in renal and retinal screenings, having a
diagnosis of blindness, myocardial infarction, UTI, end-stage renal disease, LIS
enrollment, DSNP enrollment, and controlled blood pressure.
H05: There is no statistically significant relationship between the PDC and the
Meglitinide Analogues class of medications and HbA1c values in Medicare type 2
diabetics while controlling for age, sex, deductible, number of hospital visits,
seeing an endocrinologist, participation in renal and retinal screenings, having a
diagnosis of blindness, myocardial infarction, UTI, end-stage renal disease, LIS
enrollment, DSNP enrollment, and controlled blood pressure.
H15: There is a statistically significant relationship between the PDC and the
individual Meglitinide Analogues class of medications and HbA1c values in
Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure.
H06: There is no statistically significant relationship between the PDC and the
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of medications and
HbA1c values in Medicare type 2 diabetics while controlling for age, sex,
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deductible, number of hospital visits, seeing an endocrinologist, participation in
renal and retinal screenings, having a diagnosis of blindness, myocardial
infarction, UTI, end stage renal disease, LIS enrollment, DSNP enrollment, and
controlled blood pressure.
H16: There is a statistically significant relationship between the PDC and the
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of medications and
HbA1c values in Medicare type 2 diabetics while controlling for age, sex,
deductible, number of hospital visits, seeing an endocrinologist, participation in
renal and retinal screenings, having a diagnosis of blindness, myocardial
infarction, UTI, end-stage renal disease, LIS enrollment, DSNP enrollment, and
controlled blood pressure.
RQ2: What is the relationship between PDC and combinations of antihyperglycemic
class of medications and HbA1c values in Medicare type 2 diabetics while controlling for
age, sex, deductible, number of hospital visits, seeing an endocrinologist, participation in
renal and retinal screenings, having a diagnosis of blindness, myocardial infarction, UTI,
end-stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood
pressure?
H07: There is no statistically significant relationship between the PDC and the
Meglitinide-Biguanide Combinations class of medications and HbA1c values in
Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
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screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure.
H17: There is a statistically significant relationship between the PDC and the
Meglitinide-Biguanide Combinations class of medications and HbA1c values in
Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure.
H08: There is no statistically significant relationship between the PDC and the
SGLT2 Inhibitor - DPP-4 Inhibitor Combinations class of medications and
HbA1c values in Medicare type 2 diabetics while controlling for age, sex,
deductible, number of hospital visits, seeing an endocrinologist, participation in
renal and retinal screenings, having a diagnosis of blindness, myocardial
infarction, UTI, end-stage renal disease, LIS enrollment, DSNP enrollment, and
controlled blood pressure.
H18: There is a statistically significant relationship between the PDC and the
SGLT2 Inhibitor - DPP-4 Inhibitor Combinations class of medications and
HbA1c values in Medicare type 2 diabetics while controlling for age, sex,
deductible, number of hospital visits, seeing an endocrinologist, participation in
renal and retinal screenings, having a diagnosis of blindness, myocardial
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infarction, UTI, end-stage renal disease, LIS enrollment, DSNP enrollment, and
controlled blood pressure.
H09: There is no statistically significant relationship between the PDC and the
Sodium-Glucose Co-Transporter 2 Inhibitor-Biguanide class of medications and
HbA1c values in Medicare type 2 diabetics while controlling for age, sex,
deductible, number of hospital visits, seeing an endocrinologist, participation in
renal and retinal screenings, having a diagnosis of blindness, myocardial
infarction, UTI, end-stage renal disease, LIS enrollment, DSNP enrollment, and
controlled blood pressure.
H19: There is a statistically significant relationship between the PDC and the
Sodium-Glucose Co-Transporter 2 Inhibitor-Biguanide class of medications and
HbA1c values in Medicare type 2 diabetics while controlling for age, sex,
deductible, number of hospital visits, seeing an endocrinologist, participation in
renal and retinal screenings, having a diagnosis of blindness, myocardial
infarction, UTI, end-stage renal disease, LIS enrollment, DSNP enrollment, and
controlled blood pressure.
H010: There is no statistically significant relationship between the PDC and the
Sulfonylurea-Biguanide class of medications and HbA1c values in Medicare type
2 diabetics while controlling for age, sex, deductible, number of hospital visits,
seeing an endocrinologist, participation in renal and retinal screenings, having a
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diagnosis of blindness, myocardial infarction, UTI, end-stage renal disease, LIS
enrollment, DSNP enrollment, and controlled blood pressure.
H110: There is a statistically significant relationship between the PDC and the
Sulfonylurea-Biguanide class of medications and HbA1c values in Medicare type
2 diabetics while controlling for age, sex, deductible, number of hospital visits,
seeing an endocrinologist, participation in renal and retinal screenings, having a
diagnosis of blindness, myocardial infarction, UTI, end-stage renal disease, LIS
enrollment, DSNP enrollment, and controlled blood pressure.
H011: There is no statistically significant relationship between the PDC and the
Dipeptidyl Peptidase-4 Inhibitor-Biguanide class of medications and HbA1c
values in Medicare type 2 diabetics while controlling for age, sex, deductible,
number of hospital visits, seeing an endocrinologist, participation in renal and
retinal screenings, having a diagnosis of blindness, myocardial infarction, UTI,
end-stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood
pressure.
H111: There is a statistically significant relationship between the PDC and the
Dipeptidyl Peptidase-4 Inhibitor-Biguanide class of medications and HbA1c
values in Medicare type 2 diabetics while controlling for age, sex, deductible,
number of hospital visits, seeing an endocrinologist, participation in renal and
retinal screenings, having a diagnosis of blindness, myocardial infarction, UTI,
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end-stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood
pressure.
H012: There is no statistically significant relationship between the PDC and the
Sulfonylurea-Thiazolidinedione class of medications and HbA1c values in
Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure.
H112: There is a statistically significant relationship between the PDC and the
Sulfonylurea-Thiazolidinedione class of medications and HbA1c values in
Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure.
Manuscript two examines participation in Medicare financial assistance programs
as an indicator of income and assets and oral antihyperglycemic medication PDC, while
controlling for covariates, to see if they can successfully predict HbA1c levels. Medicare
sets income levels for participation in the LIS and DSNP programs, and these programs
are mutually exclusive in that an individual can only be in one at a time. Participants are
those not in a subsidy program, those in a LIS program, and those in a DSNP program.
Only participants taking one class of antihyperglycemic medication during the year met
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selection criteria. Linear regression analysis were used to develop our model with HbA1c
as a continuous outcome variable. This manuscript's title is "Dually Eligible, LowIncome Subsidy Enrollment, and Medication Compliance as Predictors of HbA1c in Type
2 Diabetics". The research questions for this manuscript are:
RQ3: What is the relationship between enrollment in a LIS program, DSNP enrollment,
oral antihyperglycemic medication class, PDC, and HbA1c levels in Managed Care
enrollees with type 2 diabetes while controlling for age, sex, diabetes diagnosis time,
length of time in MCO, Plan type, and living in Urban or Rural County?
H013: There is no statistically significant relationship between enrollment in a LIS
program, oral antihyperglycemic medication class, PDC, and HbA1c levels in
Managed Care enrollees with type 2 diabetes while controlling for age, sex,
diabetes diagnosis time, length of time in MCO, Plan type, and living in Urban or
Rural County.
H113: There is a statistically significant relationship between enrollment in a LIS
program, oral antihyperglycemic medication class, PDC, and HbA1c levels in
Managed Care enrollees with type 2 diabetes while controlling for age, sex,
diabetes diagnosis time, length of time in MCO, Plan type, and living in Urban or
Rural County.
H014: There is no statistically significant relationship between enrollment in
DSNP program, oral antihyperglycemic medication class, PDC, and HbA1c levels
in Medicare type 2 enrollees with diabetes while controlling for age, sex, diabetes
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diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural
County.
H114: There is a statistically significant relationship between enrollment in a
DSNP program, oral antihyperglycemic medication class, PDC, and HbA1c levels
in Medicare type 2 enrollees with diabetes while controlling for age, sex, diabetes
diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural
County.
H015: There is no statistically significant relationship between enrollment in LIS
and DSNP programs, oral antihyperglycemic medication class, PDC, and the and
HbA1c levels in Managed Care enrollees with type 2 diabetes while controlling
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, and living
in Urban or Rural County.
H115: There is a statistically significant relationship between enrollment in LIS
and DSNP programs, oral antihyperglycemic medication class, PDC, and the and
HbA1c levels in Managed Care enrollees with type 2 diabetes while controlling
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, and living
in Urban or Rural County.
Manuscript three analyzes oral antihyperglycemic medication class compliance in
the six classes of antihyperglycemic medications, HbA1c levels, and whether they can be
used to predict any of the comorbidities or combinations of comorbidities Managed Care
enrollees with type 2 diabetes. Selection criteria limited participants to those taking only
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one class of antihyperglycemic medication during the year. The data as analyzed using
logistic regression because our outcome variables, comorbidity, or sets of comorbidities,
are binary. This manuscript's title is "Medication Compliance, HbA1c Predicting
Comorbidities in Medicare Type 2 Diabetics". The research questions for this manuscript
are:
RQ4: What is the relationship between the PDC calculated for individual
antihyperglycemic class of medications and HbA1c values and the top four type 2
diabetes comorbidities of Myocardial Infarction, Blindness, End-Stage Renal Disease,
and Urinary Tract infections, both individually and in combination, in Medicare enrollees
with type 2 diabetes while controlling for age, sex, diabetes diagnosis time, length of time
in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County as defined by the Census Bureau.
H016: There is no statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the top
four Medicare type 2 diabetes comorbidities of Myocardial Infarction, Blindness,
End-Stage Renal Disease, and Urinary Tract infections while controlling for age,
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment,
DSNP enrollment, and living in Urban or Rural County.
H116: There is a statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the top
four Medicare type 2 diabetes comorbidities of Myocardial Infarction, Blindness,
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End-Stage Renal Disease, and Urinary Tract infections while controlling for age,
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment,
DSNP enrollment, and living in Urban or Rural County.
H017: There is no statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the top four Medicare type 2 diabetes comorbidities of
Myocardial Infarction, Blindness, End-Stage Renal Disease, and Urinary Tract
infections while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H117: There is a statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the top four Medicare type 2 diabetes comorbidities of
Myocardial Infarction, Blindness, End-Stage Renal Disease, and Urinary Tract
infections while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H018: There is no statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the top four Medicare type 2 diabetes comorbidities of Myocardial Infarction,
Blindness, End-Stage Renal Disease, and Urinary Tract infections while
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controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H118: There is a statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the top four Medicare type 2 diabetes comorbidities of Myocardial Infarction,
Blindness, End-Stage Renal Disease, and Urinary Tract infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H019: There is no statistically significant relationship between the PDC index
calculated for the Sulfonylureas class of medications and the top four Medicare
type 2 diabetes comorbidities of Myocardial Infarction, Blindness, End-Stage
Renal Disease, and Urinary Tract infections and HbA1c values while controlling
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS
enrollment, DSNP enrollment, and living in Urban or Rural County.
H119: There is a statistically significant relationship between the PDC index
calculated for the Sulfonylureas class of medications and HbA1c values and the
top four Medicare type 2 diabetes comorbidities of Myocardial Infarction,
Blindness, End-Stage Renal Disease, and Urinary Tract while controlling for age,
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment,
DSNP enrollment, and living in Urban or Rural County.
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H020: There is no statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the top four Medicare type 2 diabetes comorbidities of Myocardial Infarction,
Blindness, End-Stage Renal Disease, and Urinary Tract infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H120: There is a statistically significant relationship between the PDC index
calculated for the individual Meglitinide Analogues class of medications and
HbA1c values and the top Medicare four type 2 diabetes comorbidities of
Myocardial Infarction, Blindness, End-Stage Renal Disease, and Urinary Tract
infections while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H021: There is no statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the top four Medicare type 2 diabetes
comorbidities of Myocardial Infarction, Blindness, End-Stage Renal Disease, and
Urinary Tract infections while controlling for age, sex, diabetes diagnosis time,
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living
in Urban or Rural County.
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H121: There is a statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the top four Medicare type 2 diabetes
comorbidities of Myocardial Infarction, Blindness, End-Stage Renal Disease, and
Urinary Tract infections while controlling for age, sex, diabetes diagnosis time,
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living
in Urban or Rural County.
H022: There is no statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Myocardial Infarction and HbA1c while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H122: There is a statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Myocardial Infarction while controlling
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS
enrollment, DSNP enrollment, and living in Urban or Rural County.
H023: There is no statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the Medicare type 2 diabetes comorbidity of Myocardial
Infarction while controlling for age, sex, diabetes diagnosis time, length of time in
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MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H123: There is a statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the Medicare type 2 diabetes comorbidity of Myocardial
Infarction while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H024: There is no statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the Medicare type 2 diabetes comorbidity of Myocardial Infarction while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H124: There is a statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the Medicare type 2 diabetes comorbidity of Myocardial Infarction while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H025: There is no statistically significant relationship between the PDC index
calculated for the Sulfonylurea class of medications and HbA1c values and the
comorbidity of Myocardial Infarction in Medicare type 2 diabetics while
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controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H125: There is a statistically significant relationship between the PDC index
calculated for the Sulfonylurea class of medications and the comorbidity of
Myocardial Infarction and HbA1c values in Medicare type 2 diabetics while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H026: There is no statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the comorbidity of Myocardial Infarction in Medicare type 2 diabetics while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H126: There is a statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the comorbidity of Myocardial Infarction in type 2 diabetics while controlling
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS
enrollment, DSNP enrollment, and living in Urban or Rural County.
H027: There is no statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the comorbidity of Myocardial Infarction in
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time,
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length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living
in Urban or Rural County.
H127: There is a statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the comorbidity of Myocardial Infarction in
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time,
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living
in Urban or Rural County.
H028: There is no statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Blindness while controlling for age, sex,
diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP
enrollment, and living in Urban or Rural County.
H128: There is a statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Blindness while controlling for age, sex,
diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP
enrollment, and living in Urban or Rural County.
H029: There is no statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the Medicare type 2 diabetes comorbidity of Blindness
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while controlling for age, sex, diabetes diagnosis time, length of time in MCO,
Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H129: There is a statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the Medicare type 2 diabetes comorbidity of Blindness
while controlling for age, sex, diabetes diagnosis time, length of time in MCO,
Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H030: There is no statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the Medicare type 2 diabetes comorbidity of Blindness while controlling for age,
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment,
DSNP enrollment, and living in Urban or Rural County.
H130: There is a statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the Medicare type 2 diabetes comorbidity of Blindness while controlling for age,
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment,
DSNP enrollment, and living in Urban or Rural County.
H031: There is no statistically significant relationship between the PDC index
calculated for the Sulfonylurea class of medications and HbA1c values and the
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Medicare type 2 diabetes comorbidity of Blindness while controlling for age, sex,
diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP
enrollment, and living in Urban or Rural County.
H131: There is a statistically significant relationship between the PDC index
calculated for the Sulfonylurea class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Blindness while controlling for age, sex,
diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP
enrollment, and living in Urban or Rural County.
H032: There is no statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the Medicare type 2 diabetes comorbidity of Blindness while controlling for
age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS
enrollment, DSNP enrollment, and living in Urban or Rural County.
H132: There is a statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the comorbidity of Blindness in Medicare type 2 diabetics while controlling
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS
enrollment, DSNP enrollment, and living in Urban or Rural County.
H033: There is no statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the comorbidity of Blindness in Medicare
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type 2 diabetics while controlling for age, sex, diabetes diagnosis time, length of
time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban
or Rural County.
H133: There is a statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the comorbidity of Blindness in Medicare
type 2 diabetics while controlling for age, sex, diabetes diagnosis time, length of
time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban
or Rural County.
H034: There is no statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H134: There is a statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H035: There is no statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
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and HbA1c values and the Medicare type 2 diabetes comorbidity of End-Stage
Renal Disease while controlling for age, sex, diabetes diagnosis time, length of
time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban
or Rural County.
H135: There is a statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the Medicare type 2 diabetes comorbidity of End-Stage
Renal Disease while controlling for age, sex, diabetes diagnosis time, length of
time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban
or Rural County.
H036: There is no statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H136: There is a statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
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H037: There is no statistically significant relationship between the PDC index
calculated for the Sulfonylurea class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H137: There is a statistically significant relationship between the PDC index
calculated for the Sulfonylurea class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H038: There is no statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H138: There is a statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the comorbidity of End-Stage Renal Disease in Medicare type 2 diabetics
while controlling for age, sex, diabetes diagnosis time, length of time in MCO,
Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
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H039: There is no statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the comorbidity of End-Stage Renal Disease
in Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis
time, length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and
living in Urban or Rural County.
H139: There is a statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the comorbidity of End-Stage Renal Disease
in Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis
time, length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and
living in Urban or Rural County.
H040: There is no statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Urinary Tract Infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H140: There is a statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Urinary Tract Infections while
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controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H041: There is no statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the Medicare type 2 diabetes comorbidity of Urinary Tract
Infections while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H141: There is a statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the Medicare type 2 diabetes comorbidity of Urinary Tract
Infections while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H042: There is no statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the Medicare type 2 diabetes comorbidity of Urinary Tract Infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H142: There is a statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
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the Medicare type 2 diabetes comorbidity of Urinary Tract Infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H043: There is no statistically significant relationship between the PDC index
calculated for the Sulfonylurea class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Urinary Tract Infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H144: There is a statistically significant relationship between the PDC index
calculated for the Sulfonylurea class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Urinary Tract Infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H045: There is no statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the Medicare type 2 diabetes comorbidity of Urinary Tract Infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H145: There is a statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the comorbidity of Urinary Tract Infections in Medicare type 2 diabetics
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while controlling for age, sex, diabetes diagnosis time, length of time in MCO,
Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H046: There is no statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the comorbidity of Urinary Tract Infections in
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time,
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living
in Urban or Rural County.
H146: There is a statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the comorbidity of Urinary Tract Infections in
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time,
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living
in Urban or Rural County.
Outline of Dissertation
Introduction
With the introduction of quality standards for health care organizations and the
financial penalties associated with not attaining established levels of quality, the need for
appropriate regression analysis for MCO’s has increased. The first study determines the
appropriateness of using the Medicare PDC, as for individual antihyperglycemic
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medications, in identifying those at risk for high HbA1c levels. Having regression
analysis available helps healthcare organizations proactively work with people with
diabetes who are a risk for high HbA1c levels. The second study in this dissertation
establishes that the PDC, calculated for individual antihyperglycemic medications, and
participation in Medicare financial assistance programs can be used to identify
individuals at risk for high HbA1c levels. The third study in this dissertation uses logistic
regression analysis with diabetes comorbidities as outcome variables and individual
HbA1c levels, PDC medication compliance rates, antihyperglycemic medication classes,
and various covariates as predictors.
Social change
Diabetes is a chronic disease that impacts more than one-third of Americans
(American Diabetes Association, 2018d). Medication compliance in people with diabetes
is essential for keeping HbA1c levels under control, and many people with diabetes have
issues with compliance (Kennedy-Martin et al., 2017). Medicare created several financial
subsidy programs covering medication copays and deductibles with one goal of
improving medication compliance. Diabetes comorbidities further complicate dealing
with these individuals. Quality standards for diabetes that many healthcare organizations
must meet complicate the already tricky scenario of managing diabetes. Using the
Medicare PDC calculated for individual antihyperglycemic medications as a predictor of
HbA1c levels, predicting comorbidities of diabetes, and evaluating the effectiveness that
financial subsidy programs have to health care organizations.
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Background
Diabetes
Review of Diabetes
Diabetes refers to a group of diseases related to a defect in the body’s ability to
utilize glucose properly. In the US, 35 million people have been diagnosed with diabetics,
7 million have undiagnosed diabetes, while another 88 million have prediabetes (Centers
for Disease Control and Prevention, 2020). Many people are undiagnosed and unaware
that they are at risk for developing diabetes (National Institute of Diabetes and Digestive
and Kidney Diseases, 2017). Diabetes-related health expenditures increased from $245
billion in 2012 to $345 billion in 2017, one dollar out of every four spent on healthcare in
the US (Riddle & Herman, 2018).
Diabetes can lead to multiple complications, including heart disease, stroke,
nephropathies, retinopathies, dental problems, and neuropathies (National Institute of
Diabetes and Digestive and Kidney Diseases, 2018). In 2013, diabetes was the seventh
leading cause of death in the US, a total that could be underreported. Twenty percent of
all healthcare expenditures are for the treatment of diabetes or any one of its
complications (National Center for Chronic Disease Prevention, 2016).
The American Diabetes Association established a Professional Practices
Committee that developed and annually updates a “Standards of Medical Care in
Diabetes.” The group comprises physicians, educators, dieticians, and others with
expertise in a range of areas related to diabetes (American Diabetes Association, 2018c).
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The standards' recommendations are evidence-based, developed through collaboration,
aligned with the Chronic Care Model, and support improvements in quality of care
through quality improvement strategies. These standards address the Social Determinants
of Health and their role in diabetes (American Diabetes Association, 2018c).
For many years, the standard test for determining a diagnosis of diabetes was a
glucose tolerance test. However, in 2006, the World Health Organization recommended
using the HbA1c, a glycosylated form of hemoglobin, with a measure that indicates
glucose levels for several months. Reported studies use the continuous HbA1c value,
including self-efficacy, medication compliance and health literacy, and a longitudinal
study in the UK that looked at estimating future HbA1c levels (Huang et al., 2018;
Sheppard et al., 2017). In 2011, the ADA recommended an HbA1c value of greater than
6.5% for a diagnosis of Diabetes and have included it as part of their standards (Malkani
& Mordes, 2011; World Health Organization, 2006).
Type 2 diabetes is the most expensive of all the chronic diseases for many
healthcare systems, primarily due to the disease's high rate of complications (Dall et al.,
2014). This cost burden is continuing to grow (Seuring et al., 2015). To complicate this
issue, only 50% of individuals on medications for diabetes fail to achieve adequate blood
sugar control or attain an HbA1c level of less than 7% (Centers for Disease Control and
Prevention, 2020; Polonsky & Henry, 2016).
Types of Diabetes
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There are several types of diabetes. Chronic diabetes includes type one, or insulindependent, and type two, generally treated with oral medications. There are other types of
diabetes, including gestational, that occurs during pregnancy, cystic fibrosis-related
diabetes, and monogenic or genetically related diabetes. A blood test diagnoses diabetes,
looking at fasting glucose levels greater than 120 mg/dl or HbA1c levels greater than
6.5% in all of these forms of diabetes.
Type one diabetes, generally diagnosed in children and young adults, is also
known as juvenile diabetes but can present at any age. It occurs in approximately five
percent of the population and has no regard for body size, ethnicity, or age. In type one
diabetes, the body does not produce any insulin and, as a result, has no way to get glucose
from the blood into the cells (American Diabetes Association, 2019).
Type two diabetes is the most common form and comes from the body's inability
to utilize insulin properly. It appears at any age, but most often in adults (National
Institute of Diabetes and Digestive and Kidney Diseases, 2016b). Type two diabetes
forms slowly, and its onset can be delayed by lifestyle changes such as weight loss or diet
change. In diabetes early stages, the body secretes additional amounts of insulin to make
up for its inability to use it, a condition called insulin resistance. Over time, the pancreas
cannot produce enough insulin and either oral medication or insulin is instituted. The
health status of people with type two diabetes generally worsens over time. The
symptoms of type two diabetes include thirst, frequent urination, feeling hungry or tired,
blurry eyesight, slow healing, and losing weight without trying (Medline Plus, 2016):
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Prediabetes Implications
Individuals with a fasting glucose level above 110 mg/dl to 125 mg/dl and a twohour glucose tolerance test level of 140 – 200 mg/dl are at risk of developing type 2
diabetes, a condition known as prediabetes. The American Diabetes Association further
refined the definition of prediabetes to include an HbA1c level between 5.7% – 6.4%
(Bansal, 2015). However, there is some controversy about the value of using HbA1c
levels to make a diagnosis of prediabetes, with the best diagnostic tool being a two-hour
fasting glucose tolerance test (Maki, 2017). Approximately 10% of prediabetics convert
to diabetics each year (Knowler et al., 2002). Prediabetes puts patients at risk for type 2
diabetes, heart disease, and stroke. Predictors of prediabetes include being overweight,
older than 45, have a parent or sibling with type 2 diabetes, low physical activity, a
previous diagnosis of gestational diabetes, or are African American, Native American,
Latino, or Asian American.
Just because an individual is diagnosed with prediabetes does not mean that they
will transition to diabetes. Changing dietary habits, increasing physical activity, and
reducing stress are all shown to delay or prevent a diagnosis of prediabetes (Centers for
Disease Control and Prevention, 2018b).
The association between prediabetes and macrovascular disease is well
established (H. Hu et al., 2018). Prediabetes in adolescents leads to obesity, high
cholesterol levels, low levels of HDL cholesterol, and elevated liver transaminase
(Casagrande et al., 2018). The risk in people with diabetes for atherosclerotic
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cardiovascular disease (ASCVD) is twice that in prediabetics, and elevated lipoprotein(a)
is more common in prediabetic Caucasians than in African Americans (Saeed et al.,
2019).
Microvascular risks from prediabetics include renal, retinal, and peripheral
problems. The exact mechanism of these complications is unknown, but the metabolic
changes associated with diabetes cause oxidative stresses, inflammation, and vascular
occlusion (Safi et al., 2014). However, these injuries take years to develop with
uncontrolled glucose levels. Therefore, active efforts to change diet and lifestyle can
eliminate or delay the onset of these complications (Brannick et al., 2016).
Prediabetes presents with the same cardiovascular (macrovascular), renal, retinal,
and peripheral nerve (microvascular) damage potential as in people with diabetes, just at
a lower rate. When a patient is diagnosed with prediabetes, it does not necessarily foretell
future diabetes. Diabetes can be stalled or prevented by making lifestyle and dietary
changes. Patients who avoid the progression of prediabetes to diabetes can reduce their
overall healthcare costs, improve their health status and quality of life (Carris et al.,
2019).
Measurement
Blood glucose monitoring is the foundation of diabetes and prediabetes treatment.
Blood glucose level was the traditional method for diagnosing diabetes before accepting
the HbA1c level as a viable measure. Any level over 99 mg/dl is considered pre-diabetes.
Once the blood glucose exceeds 120 mg/dl, a diagnosis of diabetes can be made
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(National Institute of Diabetes and Digestive and Kidney Diseases, 2016a). In 2011, the
ADA endorsed the use of the HbA1c level (Malkani & Mordes, 2011). The advantage of
HbA1c is that it indicates how high the blood sugar level reached over the last two to
three months, based on the lifetime of the red blood cell holding the glucose (Medline
Plus, 2018).
HbA1c was first identified in 1958 and identified as a glycoprotein in 1968. In
1969 elevated HbA1c levels were found in diabetics and was first proposed in 1976 as an
identifier of diabetes (Bookchin & Gallop, 1968; Huisman et al., 1958; Koenig et al.,
1976; Rahbar et al., 1969). Clinically accepted normal levels of HbA1c are below 5.7%,
prediabetes levels are between 5.7% and 6.4%, and diabetes is diagnosed at levels above
6.5% (American Diabetes Association, n.d.).
Blood sugar measurement falls into several categories, invasive and non-invasive
and intermittent and continuous. Invasive techniques are those where a sensor is
implanted into the body and has some means for transmitting glucose levels to an
external monitoring system. Finger prick systems are considered an invasive method and
are the most common measuring method in use. Non-invasive systems are those where
there is no body implantation of sensors to determine glucose levels. Continuous systems
can consistently monitor glucose levels over time, and with intermittent systems, HbA1c
levels are determined at various points in time.
The most common invasive method of monitoring glucose levels is using a
glucometer, an electronic device that measures glucose levels in a blood sample. In
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invasive methods, a drop of blood is applied to a test strip inserted into a device
displaying the amount of glucose present in the sample. These electronic devices must be
recalibrated with each new packet of measurement sticks. Failure to do so can introduce
errors of up to 50 mg/dl. Low health literacy may affect these measurements' accuracy
due to numeracy issues (Ginsberg, 2009; Jun, 2019). Continuous monitoring is generally
reserved for those with type 1 diabetes.
Complications of Diabetes
Primary complications of diabetes come from the micro and macrovascular comorbidities associated with diabetes. The complications include diabetic retinopathy,
nephropathies, neuropathies, and atherosclerosis. Diabetes is a predictor of stroke and
cardiovascular disease (Fowler, 2008). Approximately one-third of the 285 million
diabetics worldwide suffer from diabetic retinopathy, which is the leading cause of vision
loss in adults 20 – 74 years old (Yau et al., 2012). Diabetic retinopathy contributes to
other diabetes complications, including nephropathy, cardiovascular events, and
peripheral neuropathies.
Diabetic neuropathies can be asymptomatic and are not exclusively related to
diabetes. Because the nerve damage from diabetic neuropathies cannot be reversed, the
best plan is prevention (Bourne et al., 2013; Pop-Busui et al., 2017). Diabetic
neuropathies can be non-painful, making patient recognition difficult if they do not
perform regular body checks (Hägg et al., 2013; He et al., 2013; Mottl et al., 2014). The
macro and microvascular effects of diabetes are severe enough that the American
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Diabetic Association recommends the use of low-density lipoprotein (LDL) and
cholesterol-reducing statins for diabetic patients along with lifestyle change (American
Diabetes Association, 2018a).
Cardiovascular comorbidities from type 2 diabetes include myocardial infarction
(MI), atrial fibrillation, and heart failure, with an increased incidence over time (Larsson
et al., 2018). It is now an accepted standard of practice in mitigating comorbidity effects
for physicians to place diabetic patients on a statin. The American Diabetes Association
recommends a target LDL cholesterol of <100 mg/dl, and the HEDIS CDC measures
have a quality standard for those with diabetes, assuring they are on a statin medication
(American Diabetes Association, 2009; National Center for Quality Assurance, 2018c).
While there are studies that examined the relationship between Medication compliance
and some of the comorbidities of diabetes, there are none found that have looked at six of
the classes of diabetes medications, medication compliance with the PDC, and the
comorbidities of diabetes (Giugliano et al., 2018; Shih et al., 2016).
Urinary tract infections (UTI) in people with diabetes are generally attributed to
the kidneys' inability to handle elevated blood sugar values resulting in glucose in the
urine. Spilled glucose is a food source for bacteria present and can lead to overgrowth
and infection. In addition to this, people with diabetes may have immune system
compromises, emptying problems due to neuropathy, and UTI’s in people with diabetes
are generally more severe, last longer, have worse outcomes, and have more cases of
resistant bacteria causing these infections (Nitzan et al., 2015).
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Because diabetes is a complex disease, individuals face self-management
decisions multiple times daily. Some of these decisions can be complex and are directly
related to individual outcomes (Brunisholz et al., 2014). Problem-solving is a difficult
concept to teach and is a daily issue for those with diabetes. Because it is such an
important part of self-management, the American Association of Diabetes Educators
hosted a Problem-Solving Symposium that developed 11 key factors in educating people
with diabetes in dealing with their disease. Several of the key points from that
symposium include problem-solving is a skill set that can be taught, is impacted by the
physician’s problem-solving style, it aligns itself with Continuous Quality Improvement
principles, interventions must address the patient’s highest priority goals, and
recommendations must be practical (Stetson et al., 2010).
Prediabetes is defined as having a blood sugar not high enough to diagnose
diabetes (Centers for Disease Control and Prevention, 2018a). There are no recognized
prediabetes symptoms, which presents problems for those who are not visiting a doctor
regularly. The risk factors for prediabetes include increased BMI, being over 40, having a
relative with diabetes, participating in physical activity less than three times weekly, ever
having been diagnosed with gestational diabetes, and being African American, Latino,
Asian American, or Native American (Centers for Disease Control and Prevention,
2018b).
Among the silent complications common to diabetes are retinopathy and
nephropathy (Esen et al., 2018). Diabetic retinopathy is the number one cause of
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blindness in the US. Because of its insidiousness, people with diabetes may not recognize
that they have diabetic retinopathy until it is in its advanced stages (Center for Disease
Control, n.d.-a). Thus, the need for annual screenings. Vascular changes in the retina
characterize diabetic retinopathy. These changes all contribute to the development of
macular edema from the leaky vasculature of the retina. Of interest is that in people with
type one diabetes, retinopathy does not usually appear until an individual has diabetes for
three to five years. However, in twenty-one percent of people with type two diabetes,
retinopathy has already developed before diagnosis, perhaps due to macular edema and
capillary nonperfusion (Fong et al., 2004).
Diabetic nephropathy is defined by increased albumin secretion in the urine. It
occurs in fifteen to forty percent of people with type one diabetes but less frequently in
type two diabetics (Gross et al., 2005). Forty-four percent of end-stage renal disease
comes from patients with diabetic nephropathy. Nephropathy of any origin may also lead
to an increased chance of stroke (Center for Disease Control, n.d.-b). Smoking may be an
additional risk factor for diabetes developing nephropathy (Jiang et al., 2017).
Socioeconomic status and other SDOH are related to participation in retinal and
renal screenings in diabetics (Fathy et al., 2016; Lee, 2018). Retinal screenings in people
with diabetes can reduce the incidence of severe vision loss by 94% (Schoenfeld et al.,
2001). However, many recently published diabetic retinopathy studies use old data and
show varying vision impairment rates (Leasher et al., 2016; Ting et al., 2016). An area
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that needs further research is examining improved medications that could contribute to
lower retinopathy rates.
Medication Adherence in Diabetics
Of the risk factors that people with diabetes face, medication adherence is the
easiest way to limit risks. While losing weight, reducing sugar intake, and exercising are
all techniques that a person with diabetes should use to reduce their risks from diabetes,
medication adherence should be the easiest and is one of the most significant ways to
help them keep their A1C levels under control. In newly diagnosed diabetics on
Metformin with reasonable adherence rates in the first year, HbA1c levels dropped by
0.75% (Nichols et al., 2016). Proper medication adherence leads to fewer Emergency
Department visits, better sugar control, fewer hospitalizations, and decreased overall
medical costs (Capoccia et al., 2015).
Because of the complications of diabetes, polypharmacy is common. However, the
need for multiple medications treating co-morbidities leads to lower levels of medication
adherence. The incidence of low adherence related to medication costs is 16% to 19%,
with medications costs the second most common factor in non-compliance in people with
diabetes following depression. (Kang et al., 2018). Improving health literacy levels and
numeracy skills are other ways to improve medication compliance in people with
diabetes (Nandyala et al., 2018).
Summary of Diabetes
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Diabetes is a disease of glucose metabolism. There are over 110 million diabetic
or pre-diabetic individuals in the US (National Institute of Diabetes and Digestive and
Kidney Diseases, 2017). The complications of diabetes include retinopathy,
cardiovascular complications, UTIs, and nephropathy, and multiple comorbidities. The
cost of treatment of diabetes in the US exceeded $80 billion in 2017, or $228 for every
citizen (American Diabetes Association, 2018b). While there are several proven
therapeutic modalities available to physicians for the treatment of diabetes, medication
compliance limits treatment effectiveness (Huang et al., 2018a). Even with the
implementation of Medicare Part D covering prescription drug costs, many people with
diabetes report that they are unable to afford copays and deductibles and are skipping
doses to compensate (Choi et al., 2017).
Medication Compliance
Introduction
Many people report substantial medication costs, particularly in chronic diseases
(Kesselheim et al., 2016). A recent Kaiser Foundation study found that one in four US
senior citizens found it difficult to pay for their prescriptions. Of interest, those
participating in that study said that prescription drugs made their lives better, but at an
unreasonable cost. Three in ten of the participants in this study said they are skipping
their medications because of cost (Kaiser Family Foundation, 2019). From 2010 to 2015,
prescription drug spending in the US increased from $8.7 billion to $32.8 billion.
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Specialty drugs account for 1% of prescriptions but 30% of spending (Anderson-Cook et
al., 2019).
What is Medication Compliance
There are five broad factors related to medication adherence or compliance,
including patient factors of medication knowledge and beliefs and the SDOH. Medication
issues such as how they are packaged, how complex it is to take or administer, cost
directly affect medication compliance. Factors related to a patient’s physician, such as
poor communication skills, lack of trust or dissatisfaction, and system-based factors
related to the patient's lack of follow-up, are pertinent to the compliance discussion.
Finally, other factors such as caregiver issues, no caregiver, or lack of perceived health
status improvement also contribute to adherence to medication therapy (Yap et al., 2016).
An estimated 20% of the population has to deal with medication compliance's
financial stresses (McHorney & Spain, 2011). When individuals are struggling to pay
their rent or provide food for themselves or their family, taking their medications takes a
back seat. They adopt new strategies such as skipping a month, reducing their daily
dosage such as only taking it once rather than twice a day, or taking a dose every other
day (Ippolito et al., 2017). These strategies may lead to poorer health outcomes and
statuses. One MCO has gone so far as to implement a Community Help Line to assist
individuals with food, rent, transportation, and utility payments because these are serious
issues for their population (Pruitt et al., 2018).
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Medication packaging plays a role in compliance. Efforts such as packaging each
dose individually in bubble packs, packaging all medications together that should be
taken at a prescribed time, and electronically controlled dispensers connected to
smartphones are all strategies that are being considered to help improve medication
adherence. Individual blister packs with medications taken by the time of day are one
attempt at improving compliance through packaging changes. Risks presented by similar
products such as pillboxes and pharmacist-provided multi-dose packaging have not been
thoroughly studied. These other methods do not overcome features such as ease of
opening the package or bottle and remembering to take the medication. A recent study of
different packaging systems found no compliance differences (Gilmartin-Thomas et al.,
2017).
Poor communication skills on the part of those prescribing medications are
another issue. This lack of communication by providers is of importance for those with
low health literacy. Because of their lack of understanding, low health literacy individuals
are notoriously non-compliant with their medications (Shiyanbola et al., 2018). The use
of the teach-back method is one way of overcoming compliance issues in patients,
especially those with low health literacy (Bussell et al., 2017; Dinh et al., 2016).
Lack of trust or dissatisfaction with providers contributes to low rates of
medication adherence. A study of individuals with hypertension looked at physician trust
and medication adherence. The authors found a positive relationship between physician
trust and medication adherence (Jneid et al., 2018). In a Mexican-American immigrant
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study, the authors found that improved trust in providers improved compliance after
educational programs (Baghikar et al., 2019). Brown et al. (2016) found that trust in the
health system is another factor in medication adherence.
System-based factors influence the follow-up of patients on their treatment
regimen. In Osteoporosis, patients with multiple physicians and physicians with poor
communication skills contributed to these patients' poor medication compliance (Yeam et
al., 2018). In a study of diabetics, the authors found that medication benefits and access
to care (among other factors) are system-based factors related to medication adherence
(Brown et al., 2016). In a meta-review of medication adherence in diabetes, hypertension,
and dyslipidemia, the authors found that only 59% of those studied were compliant with
their medication (Polonsky & Henry, 2016a). Other factors such as caregiver issues, no
caregiver, or perceived health status improvement contribute to poor medication
adherence.
Medication Adherence Importance
In clinical trials, researchers' assumption that participants are going to adhere to
their medication regimens may lead to incorrect results. The Vaginal and Oral
Interventions to Control the Epidemic study had to be halted when the researchers
discovered that 30% of biologic samples collected had no study medication present
(Marrazzo et al., 2015). In diabetes, adherence to medications is necessary for keeping
glucose and HbA1c within normal limits. Comorbidity risk is reduced with controlled
sugar levels, health statuses are improved, and costs are reduced.
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Adherence and persistence are both critical for people with diabetes to maintain
glucose control. However, there is conflicting evidence on the contribution of adherence
and persistence to care costs for diabetics. Chandran et al. (2015) found significant
overall healthcare costs in insulin pen compliance. Stuart et al. (2015), found that
although better medication adherence improved glucose control, savings may be offset by
increased medication costs. Finally, Busyman et al. (2015) found no change in costs
when looking at adherence and persistence.
Measurement Tools
Because medication adherence is an essential topic with health status and cost
implications, measurement is just as important. There are several tools for measuring
medication compliance. Among them is the Morisky Medication Adherence Scale,
Medication Possession Ratio (MPR), Proportion of Days Covered (PDC), and SEAMS.
These tests have been developed as improvements over previous methods or as tests for
particular conditions.
There are three different Morisky scales, the Morisky Medication Adherence
Scale-4 (MMAS-4, or the Medication Adherence Questionnaire (MAQ)), Morisky
Medication Adherence Scale-8 (MMAS-8), and the Morisky Green Levine scale
(MLGS). The MMAS-4 was the first medication-adherence test developed by David
Morisky and has yes/no answers. While it was the first test of its type, it has a low
Cronbach’s alpha of 0.61 (Morisky et al., 1986). To create a better tool, Morisky
developed the MMAS-8 test in 2008. This test consists of seven dichotomous responses
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and a single Likert scale question. The new test has a Cronbach’s alpha of 0.83 (Morisky
et al., 2008). The MMAS-8 is a widely used tool for measuring medication compliance
and is cited in 1985 studies when doing a Google Scholar search. The MLGS test
comprises four questions with yes/no answers, and the lower the score, the higher
adherence.
The MPR tests the relationship between the number of days covered and the
number of days in the measurement period, first mentioned in the literature in 1993 in a
study of diltiazem, a calcium channel antagonist (Skaer et al., 1993). In other words, it is
the days’ medication a person had on hand divided by the number of days being
measured. An issue with the MPR is that it can exceed 100% when a patient refills the
medication earlier than needed, and this surplus is counted in the days measured. It is a
widely used medication adherence measurement tool used to determine adherence in
comparing different medication delivery systems, hypertension, and medication regimen
complexity (Ho et al., 2017; Na et al., 2018). However, researchers have some dissension
on precisely what the MPR is and what it is measuring. In 2017, Sperber, Samarasinghe,
and Lomax suggested that the MPR should not be used as a static measure of medication
adherence but should be used only to examine adherence trends. They cited evidence of
its inability for direct use in studies and to compare values across studies. They suggested
that using the MRP with upper and lower bounds and not removing patients with limited
refills would make it a more valuable tool.
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With the MPR, it is possible to have values higher than 100%, and the PDC
addresses this issue. For example, if two medications are available to an individual for
180 days during a calendar 365-day period, their PDC value is 0.49. In this example, an
individual can possess 480 days of medication for 365 days, and their MPR value would
be 1.3. A value of 1.3 is neither reasonable nor possible (Patel, 2018).
The SEAMS test is 13 questions on a 3-point Likert-type scale, medication
compliance assessment tool. The original was a 21-question survey. This tool has been
validated for use; however, scoring this tool can be challenging (Lavsa et al., 2011).
Additionally, the length of time it takes to administer is an issue (Lam & Fresco, 2015).
SEAMS was developed in 2004 by a group of nurses looking for a medication adherence
tool that took into account health literacy (Risser et al., 2007). The SEAMS method has
been widely cited over the last 15 years.
In 2015, the CDC adopted the PDC measurement as their guide for researchers
examining medication adherence. The PDC measurement is supported by the Pharmacy
Quality Alliance and CMS and is the leading method for determining medication
adherence in large populations (Center for Disease Control, 2015). The PDC is a measure
of the proportion of doses that should have been taken compared to doses taken while the
MPR looks at the medications an individual had on hand.
Self-Assessment and Compliance
When researchers examine medication adherence based on self-assessment,
participants are aware of the goals of the research. For instance, in studying AIDS
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patients and their compliance with retroviral therapy, researchers found a discrepancy
between participant medication self-assessment and the drug's blood levels (Simoni et al.,
2014). While the AIDs study found discrepancies, a diabetes study comparing
medication self-assessment using the Medication Event Monitoring System (MEMS) and
HbA1c levels, researchers found validity and reliability of the evaluation tool based on
HbA1c levels suggesting that the type of disease may also be a factor in medication
compliance (Gonzalez et al., 2013). Over time, studies have found a significant
relationship between medication self-assessment and HbA1c levels in people with
diabetes (Tandon et al., 2015). However, others purport to show that self-assessment
tools are not valid as they do not correlate well with HbA1c levels (Cohen et al., 2010).
How Medication Adherence is Measured
There are two ways to measure medication adherence, direct and indirect
methods. Direct methods include examining levels of the drug in the bloodstream,
directly observing dosing, and looking for markers applied to the drug in biological
samples. Indirect methods include electronic methods counting bottle-opening, pillboxes,
and self-reporting. These indirect methods are less than ideal because of time
requirements, cost, or impracticability (McRae-Clark et al., 2015).
There are issues with the direct methods of measurement. For example, spot blood
levels only reflect dosage at a point in time, but not longitudinally. Direct oversight,
while helpful, means that someone must witness every dose taken; if not impossible to
do, it could be prohibitively expensive. Pill counts at a researcher’s office require that

56
participants bring in all their medications, which cannot be verified. This method cannot
determine if the medication was taken as prescribed. For example, a medication is
ordered three times daily; there is no way to determine if the participant took the
medication three times daily or all at once in the morning. Researchers only know that all
the medication was taken by count (McRae-Clark et al., 2015).
Indirect methods, such as electronic methods that automatically record when a
medication bottle is opened, may be accurate. However, they are expensive and can be
impractical (Gonzalez & Schneider, 2011). Pillboxes have the same issue. One can see
that medication is gone from its compartment, but it is impossible to know for sure that
the medication was consumed. Self-reporting mechanisms for medication adherence
depend entirely on the honesty of the one completing the form. It has been found that
participants in self-assessment tools tend to overstate their compliance. Other methods
commonly used in assessing compliance are based on pharmacy claims data. However,
this method has the same potential for error as the others do. Just because a person gets a
prescription filled, it does not mean that they will take it (McRae-Clark et al., 2015).
The NCQA has adopted the CDC PDC methodology as its way to determine
medication compliance. The PDC method suffers from the same problems as other
compliance methods, but Medicare and Medicaid have adopted it for help in determining
the financial rewards of those under the HEDIS quality mandates.
Current Medication Compliance Tools
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There are several different research tools for determining medication compliance. The
most common of these is the Morisky Self-Assessment tool. A Google Scholar search of
Morisky AND MMAS revealed 2340 studies citing this medication compliance
measuring method since 2016. Ideally, any medication compliance study would be by
some biological method that measures the quantity of drug in the blood. If measuring the
drug is not feasible, measuring a metabolic by-product or biological indicator such as
HbA1c would be ideal. Unfortunately, these are neither practical nor financially viable.
For now, the best method we have is either the PDC, MMAS-4, or MMAS-8 method.
Those covered under the HEDIS quality measures are going to have to use the PDC
measure.
Health System Quality Overview
Ernest Codman and Robert Dickinson were early 20th century surgeons who first
attempted to apply formalized, scientific-based quality to health care. Dr. Codman
developed an “End Result System” for hospitals to improve surgery centers' low quality
(Wrege, 1980). Frank Gilbreth, an efficiency expert, was added to the group to formalize
their ideas into measurable outcomes. The End Result system was a measuring stick of
the accepted level of outcomes used to measure patients' surgical outcomes.
Skipping ahead, in 2001, the Institute of Medicine developed the STEEP model of
quality (National Institute of Medicine, 2001). This model has been a driving force for
current models of quality adopted in the US. STEEEP or Safety, Timely care, Effective
care, Efficient care, Equitable care, and Patient-centered care represent the six domains of
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health care quality and are the framework for what is now known as the HEDIS
measures. One purpose of the HEDIS measures is to help make quality more transparent
and easier for health care consumers to understand (Agency for Healthcare Research and
Quality, 2018). However, little attention has been paid to patients in developing these
standards, nor were patients involved in creating the six domains of health.
Quality improvement systems currently in use include Plan, Do, Study, Act
(PDSA), Smart (SMART), Achievable, Relevant, and Time-bound and Continuous
Quality Improvement (CQI). Edward Deming developed the PDSA methods centered on
learning from actions taken. Deming worked in Japan during the post-war period and was
instrumental in improving the quality of Japanese products. PDSA is a rapid cycle model
where results feedback to actions, leading to study, then improvement. George Doran
first referenced the SMART system in 1980 (Doran, 1981). The SMART system is a way
to help clarify goals and ideas and is a way to get to those goals in an efficient and timely
manner. The CQI process encompasses many different techniques for improving quality.
The concept behind CQI is that it is a model for reducing or eliminating waste, improving
efficiency, and is an ongoing process to improve an organization's process.
NCQA HEDIS quality rating system
The Healthcare Effectiveness Data and Information Set or HEDIS are the most
used performance improvement measures in the US. Over 190 million people are
enrolled in MCO’s and other healthcare systems covered by the HEDIS measure quality
requirements (National Committee for Quality Assurance, 2019b). These quality
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measures cover six domains of health and 90 different measures. The six domains include
(National Committee for Quality Assurance, 2018a):
•
•
•
•
•
•

Effectiveness of Care.
Access/Availability of Care.
Experience of Care.
Utilization and Risk-Adjusted Utilization.
Health Plan Descriptive Information.
Measures Collected Using Electronic Clinical Data Systems

A weakness of these measures is that they do not sufficiently account for the
Social Determinants of Health. There is evidence showing that disparities in health and
socioeconomic factors contribute to clinical outcomes (Kind et al., 2014). While there
have been some adjustments in specific measures for Dually Eligible Medicare Members
(DSNP’s are eligible for Medicare and Medicaid) using the Categorical Adjustment
Index, there are still not adjusted. Evidence shows that adjustment of all socioeconomic
factors measures has value (J. Hu et al., 2018).
The HEDIS measures are the most widely used quality measurement tools for
healthcare providers and organizations in the US. They are being used to determine
financial rewards, which MCO’s get favored treatment in Medicaid state plans, and help
the public determine which MCO’s they want to belong to. The failure of the NCQA to
adjust the measures for socioeconomic status continues to present problems for MCO’s.
Others believe that board adjustments would contribute to reduced quality for the
disadvantaged. However, evidence disputes this claim.
HEDIS Comprehensive Diabetes Control (CDC)
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One of the HEDIS measures is the CDC measure, which has multiple
components, including HbA1c levels, eye care, and kidney monitoring. It is defined by:
1.
2.
3.
4.
5.

Hemoglobin A1c (HbA1c) testing.
HbA1c poor control (>9.0%).
Annual Eye exam (retinal) performed.
Annual Renal exam for Nephropathy.
Blood Pressure Control (<140/90 mm Hg, diastolic and systolic values
must be met to be compliant)

There have been some positive results from implementing this measure in
Medicare managed care programs. In comparing Medicare 2012 and 2017, retinopathy
rates improved by 5.1%, nephropathy rates improved 5.6%, the number of patients with a
completed HbA1c increased by 2.3%, and those with HbA1c levels less than 9% reduced
by 15.1% (National Committee for Quality Assurance, 2019a).
Proportion of Days Covered (PDC)
While the PDC is not a HEDIS measure specifically, it is used to determine
medication compliance in some HEDIS measures. The first reference to the PDC in the
literature was 2002 (Benner et al., 2002). Since then, there have been several different
recommendations for calculating the PDC with the current method, developed by the
Pharmacy Quality Alliance, having been validated by several sources. The PDC is
calculated by determining the number of days the medication should have been taken.
Then the number of doses actually taken by the number that should have been taken.
For patients on multiple medications, then only count the days when all meds are
available. Medicare considers a PDC value higher than 80% as a compliant rate.
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The PDC method is used in determining medication adherence in the HEDIS
measures and includes these medication classes, Renin-Angiotensin System Antagonists
(RASA), all classes of diabetes drugs, some psychotropics, and statins. The HEDIS
measures use the CDC version of the PDC in determining how well healthcare
organizations are doing at monitoring their members' medication adherence and should
be used in interventions for improving compliance. The Medicare CDC measure is
calculated based on all medications taken during the measurement year. For the studies
presented here, the PDC is calculated on an individual antihyperglycemic mediation
basis.

HEDIS Summary
The HEDIS metrics are the current step in the development of healthcare quality.
They cover 90 different aspects of healthcare quality and are used by Medicare,
Medicaid, and Commercial payers in determining quality ratings, bonus or penalty
payments, and are promoted to the public as a tool to help them determine which MA
plan they want to join. The NCQA reviews every health care provider under the HEDIS
measurements annually. The NCQA collects HEDIS results, and a substantial set of
information for researchers and others is in this data store. The NCQA uses this data in
identifying aspects of health that might lend themselves to quality measures. A National
Institutes of Medicine workshop examined if it is time to create health literacy measures
or if health literacy should be incorporated into existing measures (National Academies
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of Sciences Engineering Medicine, 2018). The jury is still out on the results of this
workgroup.
Star and HPR rating systems
Medicare Star Score Rating System
CMS uses the Medicare Star Score system to rate the performance of and
determine bonus payments for Medicare Advantage (MA) plans and other health care
providers. The rating system incorporates different quality measures taken from different
surveys done during the year. The surveys are the HEDIS measure, the Health Outcomes
Survey (HOS), and the Consumer Assessment of Healthcare Providers and Systems
(CAHPS). Each of these surveys measures different areas of compliance. Medicare
requires that all MCO’s submit these surveys on an annual basis. The Star Score rating
scale ranges from one to five in whole number increments.
The HEDIS quality measures look at the clinical aspects of care, including
clinical outcomes, participation in preventive screenings, and medication adherence.
Outcome evaluations in the HEDIS quality measures include diabetes measures that look
at how well blood glucose levels are controlled, whether statins are appropriately
prescribed, rates of depression, and how compliant individuals are with their medications.
The measures are updated annually, with changes announced in the release of a set of
technical notes. These notes identify precisely how each measure is calculated and what
changed in the calculation. Sometimes, new measures are promoted from a study status
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or retired from active status. Body Mass Index measurement is an example of this and is
being retired in the calendar year 2020.
Star Score Financial Awards and Penalties
Medicare wants to link MCO payments with quality. The 2012 Affordable Care
Act (ACA) included provisions that tied MCO payments to quality measures (Patient
Protection and Affordable Care Act, 2010). There are billions of dollars available to
MCO’s for improving their quality in both insurance and prescription drug plans.
Between 2012 and 2014, CMS paid out $10.9 billion in quality bonus payments (L&M
Policy Research, 2016).
The star ranking system provides penalties for MCO’s that do not reach a 3-star
rating. Payment penalties are in the form of lost bonuses and rebate payments. If a plan is
rated at one star, there is a loss of 9% of the contracted payment rate. For two stars, there
is a loss of 4.5% of contracted payment amounts. A three-star rating is neutral, and fourstar programs receive a 4.5% bonus, and 5-star programs receive a 5% bonus in addition
to rebates. Four and 5-star programs get an additional benefit in that they can enroll
members at times other than the Medicare Annual Election Period. However, MCO’s
cannot keep all of the bonus payments. Some of it must be returned to its members in
improved benefits (Elisver, n.d.). Having extra money to improve benefits makes higherquality plans more attractive to the public.
Medicaid Health Plan Rating System
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The Medicaid Health Plan Rating system (HPR) is based on HEDIS results,
CAHPS, and NCQA Accreditation standards scores (National Committee for Quality
Assurance, 2019c). The purpose of this rating system is to help states better choose the
MCO they contract with. The HPR rating scale ranges from one to five. The HPR system
follows the NCQA quality rankings ranging from 0 to 5, but unlike the Medicare Star
ranking system, the HPR system is ranked in 0.5 intervals.
A plan’s overall NCQA rankings are determined by a complicated set of rules
based on having a set amount of data to analyze, length of time the organization has been
established. Additionally, measures can be weighted from one to three, where process
measures have a value of one, and clinical measures are weighted at three. (National
Committee for Quality Assurance, 2018b). Any plan that submits HEDIS and CAHPS
surveys is eligible for ranking.
Health Plan Rating Financial Awards and Penalties
State Medicaid programs reward MCO’s in several ways. There is withhold
money that is returned at the end of the year. New members may be auto-assigned based
on a plan based on HPR ratings, with more members going to better plans, and finally,
liquidated damages. Medicaid Plans participating in a capitated payment program receive
withholds from payments until quality rankings are determined at the end of each year.
Plans receive back an amount of their withhold money based on their quality scores.
Some states choose to carve-out certain functions that their contracted MCO’s provide,
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such as pharmacy or dental benefits, and handle them within the state system rather than
the MCO.
Those who qualify for Medicaid are given a chance to choose the plan they want
to join. However, if they fail to do so, they are auto-assigned to a plan. Auto-assign is a
methodology that state Medicaid plans use to determine which participants are assigned
to which plans. These auto-assignment methodologies do vary from state to state (Smith
et al., 2015). Since 2015, 19 state Medicaid MCO’s contracts include quality
requirements and have withhold systems included in their contracts (Smith et al., 2019).
These withhold programs can include substantial amounts of money, reaching the $10’s
of millions in some states.
Medicare Low Income Subsidy (LIS) and Dually Eligible Special Needs (DSNP)
Programs
Individuals with a monthly income of less than $1650 for individuals and $2,175
for couples and limited assets are eligible for a Medicare Part D subsidy known as the
LIS program administered by Medicare under the Extra Help program. The program
helps pay for prescription costs, premiums, deductibles, and coinsurance $8.95 (Centers
for Medicare & Medicaid Services, n.d.). The program was established under the
Medicare Modernization Act, with 4.7 million enrolled in the LIS program in 2018
(Centers for Medicare & Medicaid Services, 2020a). LIS programs are only available for
those enrolled in a Medicare Advantage and Prescription Drug plans or Prescription Drug
Plan only, not traditional Medicare. Additionally, the LIS program eliminates the Donut
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Hole in Part D Medication coverage. The Donut Hole is a range of costs for medications
that are not covered by MA plans, generally between $3,000 and $4,500, where members
pay all of their prescription costs. The program's purpose is to take advantage of the
associated lower medical costs related to improved compliance (Kirkman et al., 2015).
While the LIS program attempts to address some health problems around income
inequality, it has some problems. The LIS program offers lower copays and premiums,
but the deductibles may be higher than before being on the LIS program, and the MA
formularies limit some medications. Both copays and deductibles are related to health
inequalities and medication adherence. One of the studies presented looks at how the LIS
program and medication compliance for individual antihyperglycemic medications
control HbA1c levels.
DSNP programs are designed for those below the poverty level and include those
in Medicare Part A and Part B and getting full Medicaid benefits, including Medicare
premium assistance. In the DSNP program, Medicare is the primary payor, and Medicaid
is the secondary payor. Medicaid also covers items and services not covered by Medicare
but covered by the state Medicaid program. States control the income limits, but it is
generally a requirement that the enrollee’s income is below the poverty level, currently
set between $12,760 and $44,120, depending on the number of individuals in the
household (U.S. Department of Health and Human Services, 2020). There are also asset
limitations for enrollment in the DSNP program. There are eight different participation
levels within the DSNP program (Centers for Medicare & Medicaid Services, 2020b).
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For the studies presented here, DSNP and LIS participation are used to measure
income and education levels or Social Determinants' indicators. A 2018 Health and
Human Services documented the relationship between DSNP enrollment and Social
Determinants issues (Sorbero et al., 2018). DSNP enrollees have an income at or below
the poverty level. LIS enrollees cannot be over 300% of the poverty level. Finally, we
have the other participants of this study who are not in either of these programs and will
be assumed to be not eligible for either of these programs. Therefore, we have a
categorical variable of income with non-participation at the highest level of income, LIS
at the middle level of income, 300% to 100% of the poverty level, and DSNP enrollees
the lower level of income either at or below the poverty level. Having actual income
levels would be a better approach, but the MCO does not collect that information, so we
use the data available in the best way we can.
Other Considerations in Analysis
The data used in these studies came from a large MCO and were analyzed as
secondary data. The individual variables used across these studies are:
Table 1
Predictor Variables, their type, and possible values
Variable Name
Unique member identifier.
Age
Sex
HBA1c level
Regional area of US
Deductible
Medication Class
Number of Hospital Visits

Variable Type
Nominal
Continuous
Categorical
Continuous
Categorical
Continuous
Ordinal
Ordinal

Possible Values
Format TBD by MCO
21-100
0=male,1=female
actual level
N, E, S, W
actual level
1-35
In days
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Mean Adjusted Medication PDC
Had Retinopathy Screening
Had Nephropathy Screening
Diabetes diagnosis time
Length of time in the plan
Plan type
Seeing an Endocrinologist
Had Myocardial Infraction
Is Blind
Has End-Stage Renal Disease
Had Urinary Tract infections
LIS enrollment
Dual enrollment

Continuous
Nominal
Nominal
Ordinal
Ordinal
Categorical
Nominal
Nominal
Nominal
Nominal
Nominal
Categorical
Categorical

0-1
0=no, 1=yes.
0=no, 1=yes.
In days
In days
1=PDP, 2=MA + PDP
0=no, 1=yes.
0=no, 1=yes.
0=no, 1=yes.
0=no, 1=yes.
0=no, 1=yes.
0=no, 1=yes
0=no, 1=yes

The generally accepted demarcation between an Urban and Rural area is a
population of more than 50,000. However, in 1910, the Census Bureau modified that
definition to include Urban Clusters as an area where the population threshold is between
2,500 and 50,000. For example, a small city located in a rural part of the country with
3,000 is considered an Urban Cluster. Those living outside of the city limits would be
considered living in a rural area (U.S. Census Department, n.d.).
There are nine diabetes medication classes used in treating type 2 diabetes based
on their mechanism of action (Feingold, 2019). Injectable medications are not included
because the PDC methodology cannot be used for injectables. For this study, we are only
looking at six of the nine classes included in the MCO formulary which include
Biguanides, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Thiazolidinediones,
Sulfonylureas, Meglitinide Analogues, Sodium-Glucose Co-Transporter 2 (SGLT2)
Inhibitors. Additionally, the six classes of commercially available combinations of
medications included in the MCO formulary used to treat type 2 diabetes are considered.
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These six combination classes are Meglitinide-Biguanide, SGLT2 Inhibitor - DPP-4
Inhibitor, Sodium-Glucose Co-Transporter 2 Inhibitor-Biguanide, SulfonylureaBiguanide, Dipeptidyl Peptidase-4 Inhibitor-Biguanide, Sulfonylurea-Thiazolidinedione.
The final issue to address in these dissertation studies is what four comorbidities
to use in the analysis. The EQ-5D score is a questionnaire that scores chronic conditions
in the United States and the United Kingdom with data taken from the Medical
Expenditure Panel Survey. This questionnaire is used for both cost-effectiveness studies
and public health modeling. Myocardial Infarction, Blindness, End-Stage Renal Disease,
and Urinary Tract Infections (UTI) are the four diabetes comorbidities that will be used in
these studies, and the following ICD-10 diagnosis codes for type 2 diabetes are being
used E11.40, E11.51, E11.29, E11.36, E11.21, E11.319, E11.65, E11.311, E11.39, E11.9
(Sullivan & Ghushchyan, 2016).
Predictive Analytics
Predictive Analytics is the use of statistics, data, and in some cases, machine
intelligence to predict future outcomes. Even though predictive analytics is a hot topic in
many fields, the concept has been around since the late 1700’s when Lloyds of London
used predictive analytics in determining risks around insuring goods or assets. We live in
a world of predictive analytics that includes foretelling our future purchase activities,
what we want to watch on TV, and how marketing efforts can influence voting (Bradlow
et al., 2017; Maca et al., 2016; Udanor et al., 2016). Predictive analytics in healthcare
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has grown in importance, particularly in predicting clinical and intervention outcomes
(Harris et al., 2016; Lin et al., 2017).
Healthcare big data and Electronic Health Records (EHR) are two areas where
predictive analytics are used extensively within healthcare. Big Data is defined as
voluminous and complex data beyond the ability of traditional data analytic systems. The
term is evolving to include predictive analytics or behavior analysis (Ongsulee et al.,
2018). Healthcare systems collect massive amounts of data on their members. MCO’s
have extensive claims data on their members, and government data sources are even more
significant. All these transactional data can be applied to predictive analytics to help
improve outcomes and health statuses.
Predictive analytics foretells outcomes and future needs for people with diabetes.
One study looking at readmission of people with diabetes used predictor variables such as
labs, number of medications, admission time, number of inpatient visits and found that
they are all predictive of future hospital admissions (Srinivasan, 2018). Having this kind
of data gives MCO’s tools for reducing future diabetic readmissions and reducing costs.
In an international study of flu vaccination rates in people with diabetes, predictive
analytics showed that it is necessary to account for country-specific behaviors when
creating flu vaccination interventions for people with diabetes (Liska et al., 2018).
Predictive analytics have been used to find future diabetics. It was found that
oversampling and the use of 16 predictors worked well in predicting both short and longterm patients at risk for diabetes (Talaei-Khoei & Wilson, 2018).
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While predictive analytics is mainstream in healthcare, caution must be exercised
in conclusions. With many free software applications for predictive analytics available,
analysis is as easy as downloading the application, plugging in the data, and looking at
the results. However, potential harm from these analytics is there and must be considered.
Determining clinical procedures based on analytics can be problematic at an individual
level. “The potential of prediction to influence decision making also implies the potential
for harm, through the dissemination of misinformation at the point of care. This potential
for harm from insufficiently validated models in a profit-driven market suggests the need
for oversight (Kent et al., 2018, p. 2).”
Studies one and two examine the association between HbA1c levels OAMC and
PDC and not whether HbA1c is controlled to PDC levels, and how financial assistance
programs impact PDC and HbA1c levels. For these studies using HbA1c as a continuous
variable is appropriate because the continuous variable gives much better granularity.
Also, for these two studies, examining HbA1c as a categorical variable would give too
large of variation in values and what would be meaningful value ranges? Finally,
determining proper and clinical appropriate ranges for a categorical HbA1c would be
difficult.

Variance Inflation Factors (VIF)
VIF is a statistical analysis that looks for collinearity. Collinearity is an effect
where two or more predictors are correlated or express the dependent variable's same
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effect. Collinearity may cause increased variance in predictors, produce models where a
sizeable R2 value is present even though no predictors are statistically significant,
confuses the direction of effect, and produce a model where small predictor changes
produce significant variances in the outcome (O'Brien, 2007).
A generally accepted value for VIF that expresses collinearity or multicollinearity
is 10. However, using this rule of thumb must include cautions. As related to these
studies, we must use caution in interpreting the VIF. One factor to consider is that some
of the medication classes are a combination of the single medication classes, which could
induce collinearity. Another factor to consider is that even if the regression predictors
show collinearity, we will only use one of the medication class predictors at a time. For
example, our regressions are designed for use when an individual is on one medication,
and we are attempting to predict their HbA1c level when they are changed to another
medication. In using the equation, all the other medications classes are removed from the
prediction because their value in the equation is 0, eliminating the potential for
interaction between medications.
Summary
Diabetes is one of the fastest-growing chronic diseases health care providers face,
and the comorbidities of diabetes are numerous and severe. Most of the blindness in the
country is related to diabetes, as is end-stage renal disease. Both impact individuals’
lives, their families and, in the case of renal disease, create substantial financial burdens.
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Medication adherence is a serious issue. Medical treatments have their foundation
in the use of medications. When prescribed and medications are not taken as directed, not
only do individuals face failed treatment plans, but physicians are generally not aware
that their patients are non-compliant and may misdiagnose problems. Determining
adherence is a tricky proposition as people tend not to be honest when completing
medication compliance surveys, furthering the difficulty of assessing adherence. The best
currently available tool for measuring medication adherence is the PDC.
While the current literature discusses medication compliance in people with type
2 diabetes, there are no studies to date that examine the relationship between the classes
of medications, compliance with those medications, and HbA1c levels. Additionally, no
studies have looked at this same relationship and the comorbidities of type 2 diabetes.
Finally, Medicare created financial supplement programs that lower deductibles and
copays. There are no studies to date examining the effectiveness of these programs in
lowering HbA1c levels. These are the gaps that these studies look to close.
MCO’s face financial penalties for not attaining set quality goals for diabetes and
medication adherence. Additionally, Medicaid MCO’s face populations with lower health
literacy levels, high rates of chronic conditions, and lower health statuses. Putting all this
together, we have the toxic mix of chronic diseases that are not understood by those that
have them, in part, due to low health literacy. We have diseases that require medication
adherence for successful treatment, people who tend to be non-compliant, and insurers
facing financial penalties if they do not show successful clinical outcomes in these

74
people. The study's purpose is to provide tools for healthcare organizations to identify
those at risk for higher HbA1c levels and at risk for the comorbidities of diabetes.
Overview of the Manuscripts
Manuscript 1 short description
This manuscript's title is “Medication Compliance by Drug Class as a Predictor of
HbA1c Values in Medicare Type 2 Diabetics.” Participants have type 2 diabetes and
were enrolled in a Medicare Advantage plan in 2018. The PDC is the medication
adherence methodology Medicare and Medicaid MCO use in measuring medication
compliance in members. The PDC is a ratio of the number of doses of a medication that
should have been taken over a measurement period of at least six months and calculated
from claims data readily available to MCO’s (Centers for Medicare & Medicaid Services,
2015). In diabetics, longer-term glucose values are measured by the HbA1c test. The
advantage of using the HbA1c level is that it correlates with the glucose levels over the
last several months. HbA1c has been the accepted method for monitoring glucose levels
since 2011 (Malkani & Mordes, 2011). This study's medications are six of the nine
classes of medications used in treating type 2 diabetes (Feingold, 2019). This study
provides a predictive tool to assist MCO in identifying members at risk for future
uncontrolled HbA1c levels based on their PDC. Linear regression analysis is appropriate
here because the outcome variable in this study, HbA1c level, is a continuous variable
expressed as a percentage.
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Studies show an association between PDC and HbA1c levels (Nichols et al.,
2016). One study showed that HbA1c levels are reduced by 0.6% in newly diagnosed
diabetics with a PDC greater than 80%, and in those with a PDC less than 80%, the
reduction was only 0.4% (Nichols et al., 2016). While other research has looked at
individual medication compliance using the PDC, none have made a comparison of the
six antihyperglycemic class medications and HbA1c and attempted to develop predictive
modeling around these classes of medications. Statistical analysis was used to determine
whether individual antihyperglycemic medication classes and the PDC can be used to
predict future HbA1c levels. Other medication compliance measures, MPR, and the
Morisky scores, have been used and have shown that medication compliance in diabetics
leads to lower levels of HbA1c (Capoccia et al., 2015). This study uses the PDC, the
current CMS, and CDC-recommended medication compliance method (Centers for
Medicare & Medicaid Services, 2015).
Manuscript 2 short description
Manuscript two examines the relationship between participation in Medicare LIS
and DSNP financial assistance programs and the PDC for the six classes of
antihyperglycemic medications on HbA1c levels. We only chose those who had taken
just one of the classes of antihyperglycemic medication classes during the year because
we are not able to relate HbA1c levels to a single medication if they took more than one
during the year. Medicare sets maximun income and asset levels for participation in these
mutually exclusive programs. One of the goals of these programs is to improve
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compliance and thereby reduce HbA1c levels. Study participants are in one of three
categories, those not in a subsidy program, those in a LIS program, and those in a DSNP
program. Linear regressions analyze the data to determine the effectiveness of these
programs in improving PDC rates and lowering HbA1c. As of this writing, there are no
peer-reviewed studies found that examine the effect of Medicare subsidy programs on
HbA1c levels in MA type 2 individuals with diabetics using the PDC methodology and
antihyperglycemic medication classes. The title for this manuscript is "Dually Eligible,
Low-Income Subsidy Enrollment, and Medication Compliance as Predictors of HbA1c in
Type 2 Diabetics."
Manuscript 3 short description
In manuscript three, we are analyzing medication compliance in the six classes of
antihyperglycemic medications, HbA1c levels, and examining whether they can be used
to predict four of the comorbidities, or combinations of comorbidities, of type 2 diabetes.
Diabetes is a chronic disease that produces a number of comorbidities so being able to
relate compliance with oral antihyperglycemic medciations or HbA1c to chances of
developing a comorbidity would be helpful to practitioners (Luo et al., 2017). To date,
there have been no peer-reviewed studies found looking at this topic. This study has
significance to the medical community in that it may find that certain classes, along with
the compliance of those medications, may do a better job at reducing the incidence of
comorbidities. We are only selecting participants taking one class of antihyperglycemic
medication during the year. The data will be analyzed using logistic regression because
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our outcome variables, comorbidity, or sets of comorbidities, are binary. This
manuscript's title is "Medication Compliance, HbA1c Predicting Comorbidities in
Medicare Type 2 Diabetics."
Significance
There are implications that can have tens of millions of dollars in penalties
associated with failure to meet Medicare quality goals. Of even more significance are the
medical costs associated with patients or members who do not comply with the HEDIS
standards of care. Third, there are the societal penalties of poorer health statuses
associated with individuals who are non-compliant with HEDIS diabetes measures.
These studies look at topics of clinical significance for the treatment of MCO
individuals with type 2 diabetes. There is a well-documented relationship between
individual medication compliance and HbA1c using the PDC. The first study looks to see
if there is a relationship between medication compliance and the different
antihyperglycemic medication classes and individual HbA1c levels. We examine
medication classes combined with compliance rates based on the PDC and determine if
this is an effective way of determining new medications when attempting to lower
HbA1c levels. We look to answer whether one medication with a lower compliance rate
more effectively reduces HbA1c levels than another medication with a higher compliance
rate. This study could be of significance given the medication compliance issues present
in those with diabetes.
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The second study looks at Medicare financial subsidy programs and the
relationship between these and HbA1c levels, which has little discussion in the literature.
One purpose of these programs is to help individuals make their copays and deductibles
for their prescription medications. In those with type 2 diabetes, this assistance has an
aim at improving medication compliance. In people with diabetes, medication
compliance equals better HbA1c control. This study looks to validate that premise.
Study three will examine the relationship between medication compliance, HbA1c
levels, and the incidence of four of the common comorbidities of diabetes, Blindness,
Urinary Tract Infections, Myocardial Infarctions, and End-Stage Renal disease. This
study's significance is to see if the combined relationship between HbA1c levels,
medication class, and compliance has different comorbid complications rates. Suppose
we find that even though there is a lower compliance rate for a class of medications, there
is a lower rate of comorbidities. In that case, this is a clinically significant finding for
future medication therapies showing that not only is a particular medication choice
important but that medication compliance should also be part of the clinical decision
process.
Summary
The HEDIS CDC measure has four subcategories: HbA1c under control (< 8%),
completing an HbA1c during the calendar year, controlled blood pressure (under 140/90),
and were there renal and retinal screening performed in the calendar year. MCO’s face
many barriers in getting their diabetic members to comply with these standards.
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However, controlling blood sugar and HbA1c levels is entirely up to individual
healthcare organization members.
Medicare and Medicaid adopted the HEDIS quality measures to determine the
financial rewards for healthcare organizations. These rewards can be significant, and
MCO’s struggle to get their members compliant with quality measures. The studies
presented establish relationships between medication compliance, oral antihyperglycemic
medication class, financial programs, and diabetes comorbidities. MCO’s can use this
evidence to helps improve individual health statuses and assist organizations earn or
recoup financial rewards to meet the HEDIS CDC measure requirements.

Part 2: Manuscripts
Medication Compliance by Drug Class as a Predictor of HbA1c Values in Medicare
Type 2 Diabetics
Robert Lazarchik
Walden University
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Abstract
Medication therapy is a crucial component in managing diabetes, yet compliance rates
only approach 50% after the first year of diagnosis. Managed Care Organizations (MCO)
face considerable financial stress with rewards and penalties reaching millions of dollars
for achieving set standards of care, including several diabetes measures. The Centers for
Disease Control (CDC) accepts the Proportion of Days Covered (PDC) as the current
research method for establishing medication compliance. The association between
medication compliance using the PDC and oral antihyperglycemic medication (OAMC)
and HbA1c levels has not been studied. This study aimed to determine the association
between medication compliance, as determined by the PDC, and six of the OAMCs. This
is the first study establishing the association between medication compliance, measured
by the PDC, and one of six OAMC and by not specific medications. Sample selection
included those over 21 years of age, took only one of six OAMCs, having an HbA1c
level completed, diagnosed with type 2 diabetes selected from the 2019 claims database
of a large MCO yielded 23,000 participants. Multiple regression analysis shows that as
PDC rates improve, Sulfonylurea Biguanides have 27 times more impact on HbA1c
control, and the DPP-Biguanide and Thiazolidinediones classes are ten times more
effective when compared to the Dipeptidyl Peptidase-4 (DPP-4) medication class. These
findings may help providers promote positive social change by establishing the
importance of considering patient compliance when making medication selection in
treating people with type 2 diabetes.
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Introduction
U.S. individual medication non-adherence costs for people with type 2 diabetes
are approximately $28,824 per year (Kennedy-Martin et al., 2017). There are several
methods for measuring medication compliance, but the most commonly used are the
Medication Possession Ratio (MPR) and the Proportion of Days Covered (PDC) (Cutler
et al., 2018). Both use algorithms that consider the proportion of prescribed medication
doses that should have been taken to the number taken. (Center for Disease Control,
2015). The Pharmacy Quality Alliance (PQA) created the current version of the PDC,
and the CDC has since endorsed it as acceptable for research purposes (Nau, 2012).
The use of dispensing data has been validated by the PQA and has been used in
the literature for the last twenty years (Martin et al., 2009). Having compliance
methodologies utilizing dispensing data, such as MPR or PDC, that can be extracted from
MCO claims data to measure compliance provides convenience and usability when
resources are limited. The first of these is the MPR. The MPR medication adherence
measurement tool is used to determine compliance in comparing different medication
delivery systems, hypertension, and medication regimen complexity (Ho et al., 2017; Na
et al., 2018). An issue with the MPR is that it may overstate compliance due to its
methodology. The PDC evolved from an effort to improve this weakness in the MPR and
in 2015, the CDC adopted the PDC measurement as their accepted methodology for
researchers examining medication compliance. The PDC’s advantage over other methods
is that it looks at how many doses of medication an individual should have taken during a

84
measurement period and not, as with the MPR, what they possessed. The PDC
measurement is now the leading method for determining medication adherence in large
populations (Center for Disease Control, 2015).
The National Committee for Quality Assurance (NCAQ) developed Healthcare
Effectiveness Data and Information Set (HEDIS), a set of quality measures affecting 190
million Americans, and is used by Medicare and State Medicaid programs in their quality
initiatives (National Committee for Quality Assurance, 2018a). Several of the HEDIS
quality measures use the PDC to measure medication compliance: D10
Medication Adherence for Diabetes Medications, D11 Medication Adherence for
Hypertension (RAS antagonists), D12 Medication Adherence for Cholesterol (Statins),
D14 Statin Use in Persons with Diabetes (SUPD) (Center for Disease Control, 2019).
Medicare set PDC level greater than 80% as an acceptable rate of compliance. Regression
analysis were performed on a mean adjusted PDC index for each of six classes, or the
combination of any of six classes of diabetes medications, Biguanides, Dipeptidyl
Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas, Thiazolidinediones, Meglitinide
Analogues, and Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors (these are the
classes with enough participants).
There are numerous studies in the literature establishing relationships between
medication adherence and HbA1c levels. One study used a modified PDC called the
Biologic Response Based Proportion of Days Covered (BRB-PDC) and found that
obtaining optimal PDC values in glycemic lowering medications during therapy initiation
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is related to lower HbA1c levels (Nichols et al., 2016). A 2016 meta-study found a
relationship between medication adherence in diabetics and HbA1c levels (Capoccia et
al., 2016). Other studies have established the association between the PDC measurement
and HbA1c levels (Polonsky & Henry, 2016; Ramos et al., 2018). However, no studies to
date have established the relationships between the PDC and antihyperglycemic
medication class. The purpose of this study is to determine what association exists
between the PDC and the individual classes of antihyperglycemic medications and
HbA1c levels.
Research Design and Methods
Creswell (2017) said that a quantitative approach is appropriate when a researcher
tries to establish relationships between dependent and independent variables. This is a
longitudinal retrospective study looking at 2019 MCO secondary data. Since the purpose
of this study is to determine the quantitative relationship between the PDC for the six
different classes of antihyperglycemic medications, individually and in combination
(independent variables), and HbA1c levels (dependent variable), the quantitative
approach is appropriate.
Research Questions:
RQ1: What is the relationship between the PDC and the antihyperglycemic class of
medication on HbA1c in Medicare type 2 diabetics while controlling for age, sex,
deductible, number of hospital visits, seeing an endocrinologist, participation in renal and
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retinal screenings, having a diagnosis of blindness, myocardial infarction, UTI, or endstage renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure?
H01: There is no statistically significant relationship between the PDC and the
Biguanides class of medications on HbA1c in Medicare type 2 diabetics while
controlling for age, sex, deductible, number of hospital visits, seeing an
endocrinologist, participation in renal and retinal screenings, having a diagnosis
of blindness, myocardial infarction, UTI, or end-stage renal disease, LIS
enrollment, DSNP enrollment, and controlled blood pressure?
H11: There is a statistically significant relationship between the PDC and the
Biguanides class of medications and HbA1c values in Medicare type 2 diabetics
while controlling for age, sex, deductible, number of hospital visits, seeing an
endocrinologist, participation in renal and retinal screenings, having a diagnosis
of blindness, myocardial infarction, UTI, or end stage renal disease, LIS
enrollment, DSNP enrollment, and controlled blood pressure.
H02: There is no statistically significant relationship between the PDC and the
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications and HbA1c values
in Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or endstage renal disease, LIS enrollment, DSNP enrollment, and controlled blood
pressure.
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H02: There is no statistically significant relationship between the PDC and the
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications and HbA1c values
in Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or endstage renal disease, LIS enrollment, DSNP enrollment, and controlled blood
pressure.
H12: There is a statistically significant relationship between the PDC and the
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications and HbA1c values
in Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or endstage renal disease, LIS enrollment, DSNP enrollment, and controlled blood
pressure.
H02: There is no statistically significant relationship between the PDC and the
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications and HbA1c values
in Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or endstage renal disease, LIS enrollment, DSNP enrollment, and controlled blood
pressure.
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H03: There is no statistically significant relationship between the PDC and the
Thiazolidinedione class of medications and HbA1c values in Medicare type 2
diabetics while controlling for age, sex, deductible, number of hospital visits,
seeing an endocrinologist, participation in renal and retinal screenings, having a
diagnosis of blindness, myocardial infarction, UTI, or end-stage renal disease, LIS
enrollment, DSNP enrollment, and controlled blood pressure.
H13: There is a statistically significant relationship between the PDC and the
Thiazolidinedione class of medications and HbA1c values in Medicare type 2
diabetics while controlling for age, sex, deductible, number of hospital visits,
seeing an endocrinologist, participation in renal and retinal screenings, having a
diagnosis of blindness, myocardial infarction, UTI, or end-stage renal disease, LIS
enrollment, DSNP enrollment, and controlled blood pressure.
H04: There is no statistically significant relationship between the PDC and the
Sulfonylureas class of medications and HbA1c values in Medicare type 2
diabetics while controlling for age, sex, deductible, number of hospital visits,
seeing an endocrinologist, participation in renal and retinal screenings, having a
diagnosis of blindness, myocardial infarction, UTI, or end-stage renal disease, LIS
enrollment, DSNP enrollment, and controlled blood pressure.
H14: There is a statistically significant relationship between the PDC and the
Sulfonylureas class of medications and HbA1c values in Medicare type 2
diabetics while controlling for age, sex, deductible, number of hospital visits,
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seeing an endocrinologist, participation in renal and retinal screenings, having a
diagnosis of blindness, myocardial infarction, UTI, or end-stage renal disease, LIS
enrollment, DSNP enrollment, and controlled blood pressure.
H05: There is no statistically significant relationship between the PDC and the
Meglitinide Analogues class of medications and HbA1c values in Medicare type 2
diabetics while controlling for age, sex, deductible, number of hospital visits,
seeing an endocrinologist, participation in renal and retinal screenings, having a
diagnosis of blindness, myocardial infarction, UTI, or end-stage renal disease, LIS
enrollment, DSNP enrollment, and controlled blood pressure.
H15: There is a statistically significant relationship between the PDC and the
individual Meglitinide Analogues class of medications and HbA1c values in
Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or endstage renal disease, LIS enrollment, DSNP enrollment, and controlled blood
pressure.
H06: There is no statistically significant relationship between the PDC and the
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of medications and
HbA1c values in Medicare type 2 diabetics while controlling for age, sex,
deductible, number of hospital visits, seeing an endocrinologist, participation in
renal and retinal screenings, having a diagnosis of blindness, myocardial
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infarction, UTI, or end stage renal disease, LIS enrollment, DSNP enrollment, and
controlled blood pressure.
H16: There is a statistically significant relationship between the PDC and the
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of medications and
HbA1c values in Medicare type 2 diabetics while controlling for age, sex,
deductible, number of hospital visits, seeing an endocrinologist, participation in
renal and retinal screenings, having a diagnosis of blindness, myocardial
infarction, UTI, or end-stage renal disease, LIS enrollment, DSNP enrollment,
and controlled blood pressure.
RQ2: What is the relationship between PDC and combinations of antihyperglycemic
classes of medications and HbA1c values in Medicare type 2 diabetics while controlling
for age, sex, deductible, number of hospital visits, seeing an endocrinologist, participation
in renal and retinal screenings, having a diagnosis of blindness, myocardial infarction,
UTI, or end-stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood
pressure?
H07: There is no statistically significant relationship between the PDC and the
Meglitinide-Biguanide Combinations class of medications and HbA1c values in
Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or end-
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stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood
pressure.
H17: There is a statistically significant relationship between the PDC and the
Meglitinide-Biguanide Combinations class of medications and HbA1c values in
Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or endstage renal disease, LIS enrollment, DSNP enrollment, and controlled blood
pressure.
H08: There is no statistically significant relationship between the PDC and the
SGLT2 Inhibitor - DPP-4 Inhibitor Combinations class of medications and
HbA1c values in Medicare type 2 diabetics while controlling for age, sex,
deductible, number of hospital visits, seeing an endocrinologist, participation in
renal and retinal screenings, having a diagnosis of blindness, myocardial
infarction, UTI, or end-stage renal disease, LIS enrollment, DSNP enrollment,
and controlled blood pressure.
H18: There is a statistically significant relationship between the PDC and the
SGLT2 Inhibitor - DPP-4 Inhibitor Combinations class of medications and
HbA1c values in Medicare type 2 diabetics while controlling for age, sex,
deductible, number of hospital visits, seeing an endocrinologist, participation in
renal and retinal screenings, having a diagnosis of blindness, myocardial
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infarction, UTI, or end-stage renal disease, LIS enrollment, DSNP enrollment,
and controlled blood pressure.
H09: There is no statistically significant relationship between the PDC and the
Sodium-Glucose Co-Transporter 2 Inhibitor-Biguanide class of medications and
HbA1c values in Medicare type 2 diabetics while controlling for age, sex,
deductible, number of hospital visits, seeing an endocrinologist, participation in
renal and retinal screenings, having a diagnosis of blindness, myocardial
infarction, UTI, or end-stage renal disease, LIS enrollment, DSNP enrollment,
and controlled blood pressure.
H19: There is a statistically significant relationship between the PDC and the
Sodium-Glucose Co-Transporter 2 Inhibitor-Biguanide class of medications and
HbA1c values in Medicare type 2 diabetics while controlling for age, sex,
deductible, number of hospital visits, seeing an endocrinologist, participation in
renal and retinal screenings, having a diagnosis of blindness, myocardial
infarction, UTI, or end-stage renal disease, LIS enrollment, DSNP enrollment,
and controlled blood pressure.
H010: There is no statistically significant relationship between the PDC and the
Sulfonylurea-Biguanide class of medications and HbA1c values in Medicare type
2 diabetics while controlling for age, sex, deductible, number of hospital visits,
seeing an endocrinologist, participation in renal and retinal screenings, having a
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diagnosis of blindness, myocardial infarction, UTI, or end-stage renal disease, LIS
enrollment, DSNP enrollment, and controlled blood pressure.
H110: There is a statistically significant relationship between the PDC and the
Sulfonylurea-Biguanide class of medications and HbA1c values in Medicare type
2 diabetics while controlling for age, sex, deductible, number of hospital visits,
seeing an endocrinologist, participation in renal and retinal screenings, having a
diagnosis of blindness, myocardial infarction, UTI, or end-stage renal disease, LIS
enrollment, DSNP enrollment, and controlled blood pressure.
H011: There is no statistically significant relationship between the PDC and the
Dipeptidyl Peptidase-4 Inhibitor-Biguanide class of medications and HbA1c
values in Medicare type 2 diabetics while controlling for age, sex, deductible,
number of hospital visits, seeing an endocrinologist, participation in renal and
retinal screenings, having a diagnosis of blindness, myocardial infarction, UTI, or
end-stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood
pressure.
H111: There is a statistically significant relationship between the PDC and the
Dipeptidyl Peptidase-4 Inhibitor-Biguanide class of medications and HbA1c
values in Medicare type 2 diabetics while controlling for age, sex, deductible,
number of hospital visits, seeing an endocrinologist, participation in renal and
retinal screenings, having a diagnosis of blindness, myocardial infarction, UTI, or
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end-stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood
pressure.
H012: There is no statistically significant relationship between the PDC and the
Sulfonylurea-Thiazolidinedione class of medications and HbA1c values in
Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or endstage renal disease, LIS enrollment, DSNP enrollment, and controlled blood
pressure.
H112: There is a statistically significant relationship between the PDC and the
Sulfonylurea-Thiazolidinedione class of medications and HbA1c values in
Medicare type 2 diabetics while controlling for age, sex, deductible, number of
hospital visits, seeing an endocrinologist, participation in renal and retinal
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or endstage renal disease, LIS enrollment, DSNP enrollment, and controlled blood
pressure.
Population and Study Sample
In longitudinal studies, participants are followed over long periods. Retrospective
study designs look at past events related to the subject of study (Caruana et al., 2015).
Longitudinal retrospective studies last over time while examining selected events at
different points during the study period. In this study, we will be looking at the
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relationship between various predictor variables and HbA1c levels. Participants were
selected based on enrollment in an MCO, having a type 2 diabetes diagnosis, over 21
years of age, taking only one class or combination class of antihyperglycemic
medications during the past 2019 year.
To calculate the minimum sample size needed for each of the research questions
G*Power, version 3.1.9.4, was used with an effect size of 0.15, an alpha error probability
of 0.05, a power of 0.95, to yield a recommended sample size of 89. The effect size was
determined based on findings from a meta-analysis of medication compliance studies
with different diseases, which found that studies with more than 85 participants and effect
sizes of 0.17 to 0.18 had high statistical power with P < 0.0001 (Foot et al., 2016). G*
Power's effect size is a method to quantify the differences between the test and control
groups and is based on Cohen’s effect size or the explained variance and error variance
(Cunningham & McCrum-Gardner, 2007). We chose a small effect size, which means the
difference between the two variances is not important, because the large sample size of
56,000 provides more than sufficient participants to achieve statistical power (Cohen,
2013).
Our sample includes individuals enrolled in a Medicare Advantage plan (MA)
with a type 2 diabetes diagnosis based on 2019 claims data. Participants are over twentyone and took only one of the six classes or a combination of antihyperglycemic
medications during 2019. Those who took more than one of the antihyperglycemic
medications classes in 2019 were removed from this study. Diagnoses were coded
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according to the ICD-10 World Health Organization International Statistical
Classification of Diseases and Related Health Problems. Cases were selected using the
ICD-10 diabetes diagnosis code of E11.9, claim data from pharmacy dispensing records
at outpatient pharmacies. The PDC measurement does not include those on insulin, so we
did not include members on insulin. MCO members were included in the study until
disenrollment, death, or the end of the study period. All the data provided by the MCO
was deidentified with a unique serial number that is with the released data.
We divided the sample group into two groups using a data-splitting technique
consisting of a learning group and a holdout group (Picard & Berk, 1990). We split our
samples into our learning group and holdout group, 70% into the learning used for
analysis, and 30% holdout used to test our analysis, based on Pang, H., & Jung, S. (2013).
We conducted our data analysis using SPSS version 27 using the standard p-value of <
0.05 to indicate statistical significance. Multiple linear regression analysis was used to
determine the effect each of the predictors has on the outcome variable, the continuous
HbA1c value, and determining which of the predictor variables has a statistically
significant effect on the outcome (Warner, 2013).
The American Diabetic Association established that any HbA1c value higher than
6.5% is considered diagnostic for diabetes (American Diabetes Association, 2018c).
Categorical variables were dummy coded for inclusion in these analyses. There are four
regressions in this study, first, medication compliance and the PDC, second,
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comorbidities, third, the PDC alone, and fourth, all of the items in Table 2 to determine
the regression equations for each of our research questions.
Table 2
Predictor Variables, their type, and possible values
Variable Name
Unique member identifier.

Variable Type
Nominal

Age
Sex

Continuous
Categorical

HBA1c level
Continuous
Regional area of US
Categorical
Medication Class
Categorical
Medication PDC (mean adj)
Continuous
Diabetes diagnosis time
Ordinal
Deductible
Ordinal
Number of Hospital visits
Ordinal
Seeing Endocrinologist
Categorical
Had Renal Screening
Categorical
Had Retinal Screening
Categorical
Had Myocardial Infraction
Categorical
Is Blind
Categorical
Has End-Stage Renal Disease
Categorical
Has Urinary Tract infections
Categorical
LIS enrollment
Categorical
Dual enrollment
Categorical
1
Controlled Blood Pressure
Categorical
1
Blood pressure under 140 systolic and 90 diastolic

Possible Values
Format TBD by
MCO
21-103
0=male,
1=female
actual level
N, E, S, W
1-35
0-1
In days
In days
0=no, 1=yes
0=no, 1=yes
0=no, 1=yes
0=no, 1=yes.
0=no, 1=yes.
0=no, 1=yes.
0=no, 1=yes.
0=no, 1=yes
0=no, 1=yes
0=no, 1=yes

Statistical Analysis
Regression results were validated using the HO1 group. The final regression equation
analysis includes looking at the individual predictor variables, checking correlations
between the outcome and predictor variables, and the R2 value. We will use a Chi-Square
test to compare predicted HbA1c values to actual HbA1c values in the HO1 group.
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Pearson’s correlation values tell us the direction and strength of the linear relationship
between two variables (Warner, 2013). Pearson’s correlation values of greater than 0.5
show significant levels of correlation between the variables. Values down to 0.3 and
above have small correlations but still significant enough to consider in the final
equation. Any predictor variable must have a p-value of less than 0.05 (Warner, 2013).
Pearson’s correlations can give us some insight into the R2 value produced by regression
analysis and are obtained by selecting a correlation from the SPSS interface and adding
all of the variables in the analysis.
R2 is a statistical value created by a regression analysis indicating how well the
predictor variables match the regression line (Warner, 2013). In human research, an R2
value greater than 0.2 is considered adequate. This value is somewhat lower than in other
kinds of research, but because of the effect of human behavior in the analysis, this lower
number is acceptable (Hair et al., 2011). HbA1c level, the outcome variable in this
analysis, is controlled by human behavior in medication compliance, following a
recommended diet, and quantity of exercise.
Collinearity, a type of regression interference defined as the potential for
correlations between a predictor variable, must be determined when doing regression
analysis. Multicollinearity is the condition where multiple predictors interfere with the
regression results. One assumption of regression is that all the predictor variables are
independent of each other, and each predictor has unique information about the outcome
variable. When one or more variables display collinearity, they may significantly impact
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the regression results and must be considered. Collinearity can cause issues where
standard errors appear high, or a Beta weight can have a direction that makes no sense
(Belsley, 1984). The method chosen for determining collinearity in this study is the
Variance Inflation Factor (VIF). VIF is a measure of the degree of standard error
inflation, where a VIF factor greater than 10 is indicative of collinearity (Weisberg, 2005,
p. 217). Our analysis checks VIF values using the SPSS collinearity diagnostics when
running the regression analysis. One method of addressing collinearity issues is to
remove a redundant variable (multiple variables predicting the same thing). Another
method of dealing with collinearity is to aggregate redundant variables into a single
variable (O’Brien, 2007). We used the Variance Inflation Factor to determine collinearity
or multicollinearity to determine which variables to remove from the analysis.
The equation for each regression analysis is the same as the fundamental equation
for a straight line, y = mx + b, where y is the predicted HbA1c value, b is the y-axis
intercept, and m is the coefficient for the statistically significant predictor variable. The
final equation will take the final form of y = b + coeff1*predictor1 value +
coeff2*predictor2 value + coeff3*predictor3 value + coeffN*predictorN value where
each of the predictors have a significance of less than 0.05. These final equations define
the different models from the research questions for predicting HbA1c values.
The data that support the findings of this study are available from the corresponding
author, but restrictions apply to the availability of these data used under license for the
current study, and so are not publicly available. Data are available from the
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corresponding author upon reasonable request and with permission of the MCO that
provided the data.
Results
The purpose of this quantitative research was to determine if there is an
association between medication compliance, as calculated by the PDC, oral
antihyperglycemic medication class, and HbA1c levels in Medicare individuals with type
2 diabetes while controlling for covariates such as age, sex, financial subsidy type,
comorbidities, hospital visits, and if they are seeing an endocrinologist. On September 29,
2020, a large, nationwide MCO agreed to provide the use of their client data for this
study. Approval for this study was received by the Walden University IRB, number 1030-20-0721525, on October 30, 2020. Two MCO Business Analysts produced
secondary, de-identified data compliant with HIPAA regulations using the enrollment
criteria for the study.
Data Collection and Cleaning
The initial data pull included members enrolled in a Medicare Advantage plan for
2019, over 21, diagnosed with type 2 diabetes, and took one or a combination of the six
antihyperglycemic medications classes. The initial data pull included 76,586 MCO
members. After eliminating those who had not had an HbA1c level completed during the
2019 calendar year and those who had taken more than one of the medication classes
either as a single class or a combination class during the year, the final count dropped to
22,638. This list was further divided into a learning group consisting of 70%, or 15,846
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members, and a test group of 30%, or 6,792 members. There was an error in the
methodology used to determine participation in the Low -Subsidy (LIS) program by the
MCO. There were members listed in both the LIS and DSNP programs simultaneously, a
situation that is not possible. To correct this problem a new variable in SPSS reflecting
the correct value for anyone in the LIS program sample was created for an adjusted LIS
variable where a member who showed in both a DSNP and LIS program was coded as in
a DSNP program while individuals showing in a LIS plan only were coded as in a LIS
program. We created dummy variables for the following categorical variables, region,
sex, and medication class.
Finally, PDC values were mean-centered providing better understanding of the
PDC value. In our new variables, a value of 0 indicates a real PDC value of 0.8581. This
centering technique allowed us to better see those who were above and below the mean
of each medication (Hayes, 2009, pp. 466-467).
Comparing Samples
The differences between the sample chosen for the study and the population not
selected were examined to find any differences that might explain the lack of HbA1c
levels. Of our total 2019 population, 76586, only 32307 had an HbA1c completed during
the year, with a compliance rate of 42%. We examined the two groups to try to find
evidence on why individuals did not have an HbA1c level during the year when HbA1c
levels are an integral part of a treatment plan.
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The independent samples T test from SPSS compares continuous predictors and
the Crosstabs function for comparing categorical predictors. The independent samples T
test is the correct test because we want to compare the means between those we included
in our analysis and those we did not. Additionally, one group's selection did not influence
the other group's selection (Peck et al., 2012).
We analyzed the continuous variables age, number of visits to an Endocrinologist,
the PDC value, and the number of hospital visits. Table 4 shows that PDC, Hospital
visits, and Endocrinologist visits all have a Levene's Test for Equality of Variances
significance level of less than 0.001 with equal variances not assumed. We can reject the
null hypothesis that these predictors' means are equal and accept the alternate hypothesis
that there are statistically significant differences in the two groups. The categorical
HbA1c value is the grouping variable using a value 0 for no test and 1 for having an
HbA1c level done during the measurement year, 2019. In Table 3 the Levene’s test for
age has a significance of 0.240; thus, we accept the null hypothesis that there are no
statistical differences between the groups ages. However, when we examine the T-Test
significance values for all the predictors in their appropriate row, we see that the p values
are all less than 0.05 and therefore, we can conclude that there are statistically significant
differences between the two groups.
To compare the categorical predictor values in the two groups, the crosstabs chisquare function of SPSS is the appropriate test. The HbA1c is used as a categorical value
in this analysis. A medication in the Thiazolidinediones or DPP class and having a
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Myocardial Infarction or blindness diagnosis showed no statistically significant
differences between the no HbA1c level done and had an HbA1c level done groups.
While there are statistically significant differences between the predictor values, there are
too many of them, and we did not have the correct data set to determine which ones
might contribute to better identify what differences, if any, contributed to not having an
HbA1c level completed during the year. And this examination is beyond the scope of this
discussion. Table 5 is a list of the predictors that show a statistically significant difference
between the two groups.
Table 3
Independent Samples Test
Levene's
Test for
Equality of
Variances
F

Sig.

df1

Sig.
(2tailed)

95% Confidence
Interval of the
Difference

0 36122
EVA
141.12
EVNA
4417
EVA
1.38 0.24 36607
EVNA
4809
EVA
12.95
0 36607
EVNA
5093

0
0
0
0
0.003
0.001

Lower
-0.042
-0.043
-2.075
-2.08
-0.448
-0.433

EVA
33.35
0 36607
Seeing
Endocrinologist
EVNA
4456
1 rounded to an integer
EVA - Equal variances assumed
EVNA - Equal variances not assumed

0.003

0.013

0.066

0.015

0.008

0.072

PDC
Age
Hospital
Visits

Upper
-0.031
-0.0301
-1.47
-1.466
-0.093
-0.107
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Table 4
Categorical Predictors vs. HbA1c level completed

Predictor
Taking Biguanide
Taking Thiazolidinediones
Taking DPP
Taking Sulfonylureas
Taking DPP Biguanide
Taking Sulfonylurea
Biguanide
Seeing Endocrinologist
Retinopathy screening
Nephropathy screening
BP Control
End Stage Renal Disease
Myocardial Infraction
UTI
Blindness
DSNP Program
LIS Program
No Financial Subsidy

No
A1c
2732
66
171
631
135

Had
A1c
25277
559
1297
4187
749

Pearson’s
ChiSquare
88.6
0.001
1.957
36.72
20.936

100
186
417
723
1137
2693
257
554
63
797
960
2121

415
1348
3748
7064
11459
20324
1984
5153
435
8939
7319
16473

42948
3.968
2.228
14.862
49.261
80.219
1.93
5.559
2.257
81.13
11.354
26.428

p-value
0.000
0.978
0.162
0.000
0.000

Cramer’s
V
0.049
0
0.007
0.032
0.024

0.000
0.046
0.000
0.000
0.000
0.000
0.165
0.018
0.133
0.000
0.001
0.000

0.034
0.01
0.008
0.02
0.061
0.047
0.007
0.012
0.008
0.047
0.018
0.027

Table 5
Statistically different predictors HbA1c group vs. No HbA1c group
Predictor
PDC
Hospital Visits
Seeing an Endocrinologist
Biguanide
Sulfonylureas
DPP Biguanide
Sulfonylurea Biguanide
Seeing Endocrinologist

Sig (p<0.05)
0.0001
0.0001
0.0001
0.0001
0.0001
0.0001
0.0001
0.046
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Retinopathy screening
Nephropathy screening
BP Control
End-Stage Renal Disease
UTI
DSNP Program
LIS Program
No Financial Subsidy

0.0001
0.0001
0.0001
0.0001
0.018
0.0001
0.001
0.0001

Descriptive Statistics
We ran a set of descriptive statistics for each of the medication classes and found
that combination classes did not have a sufficient number of members to provide
statistical power for analysis. Table 6 is a count of members taking each class of
medication.
Table 6
Count for each of the Classes and Combination of Classes
Medication Class
Biguanides
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Thiazolidinediones
Sulfonylureas
Meglitinide Analogues
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors
Meglitinide-Biguanide Combination
SGLT2 Inhibitor - DPP-4 Inhibitor Combinations
Sodium-Glucose Co-Transporter 2 Inhibitor-Biguanide Combination
Sulfonylurea-Biguanide Combinations
Dipeptidyl Peptidase-4 Inhibitor-Biguanide Combination
Sulfonylurea-Thiazolidinedione Combination
Thiazolidinedione-Biguanide Combination
DPP-4 Inhibitor-Thiazolidinedione Combination

Count
11713
601
214
2554
35
71
0
2
41
260
353
0
1
0
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Using G*Power, we calculated the need for a population of at least 89 members
for statistical power in calculations. Meglitinide Analogues, SGLT2 inhibitors,
Meglitinide-Biguanide Combinations, SGLT2 Inhibitor - DPP-4 Inhibitor Combinations,
Sulfonylurea-Thiazolidinedione Combinations, Thiazolidinedione-Biguanide
Combinations, and DPP-4 Inhibitor-Thiazolidinedione Combinations were eliminated
due to insufficient counts. Medication classes, their corresponding mean-centered PDC
value, the region of the country in which the member lives, and sex were dummy coded.
Tables 7 and 8 show the descriptive statistics for the group that did and the group that did
not have an HbA1c level taken during the 2019 calendar year.
Table 7
Descriptive Statistics for Members with an HbA1c level

Biguanide
DPP
Thiazolidinediones
Sulfonylurea
Sulfonylurea Biguanide
DPP Biguanide
Male
Age
DSNP
LIS
South
NE
NW
W
Deductible

Min
0
0
0
0
0
0
0
22
0
0
0
0
0
0
0

Max
1
1
1
1
1
1
1
101
1
1
1
1
1
1
415

Mean
.75
.04
.01
.16
.02
.02
.41
71.1
.32
.22
.85
.09
.02
.02
168

Std.
Deviation
.435
.194
.114
.369
.125
.146
.492
9.38
.466
.413
.354
.293
.134
.123
196
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HbA1c Level
4.10 15.50 6.59
Hospital Visits
0
91
2.78
Seeing Endocrinologist
0
1
.04
Retinopathy Screening
0
1
.10
Nephropathy Screening
0
1
.21
Blood Pressure Controlled
0
1
.94
End Stage Renal Disease
0
1
.49
Blindness diagnosis
0
1
.01
Myocardial Infarction diagnosis
0
1
.06
UTI diagnosis
0
1
.15
Mean Adj PDC
-.77
.14 .0006
PDC Value
0.094 1.000 0.8587
Biguanide Mean PDC
-.77
.14 .0007
DPP Mean PDC
-.73
.14 -.0016
Thiazolidinediones Mean PDC
-.68
.14 .0003
Sulfonylurea Mean PDC
-.76
.14 .0018
Sulfonylurea Biguanide Mean PDC
-.73
.14 .0004
DPP Biguanide Mean PDC
-.70
.14 -.0008
Count for all items is 15713
PDC values are mean adjusted with 0. 8587 as mean value.

0.98
5.42
.193
.306
.408
0.2253
.500
.112
.244
.358
.178
0.178
.152
.043
.0192
.0707
.0202
.0292

Table 8
Descriptive Statistics Members with no HbA1c level in 2019

Min
Male
Age
DSNP
LIS
South
NE
West
NW
Deductible

0
22
0
0
0
0
0
0
0

Max
1
103
1
1
1
1
1
1
415

Mean
.40
70.41
.30
.27
.62
.28
.04
.04
181

Std.
Deviation
.490
9.927
.459
.443
.484
.449
.187
.201
196
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Number of Hospital Visits
0
253
5.3
Seeing an Endocrinologist
0
1
.04
Retinopathy Screening
0
1
.06
Nephropathy Screening
0
1
.07
End Stage renal disease diagnosis
0
1
.47
Blindness diagnosis
0
1
.02
Myocardial Infarction
0
1
.07
UTI
0
1
.14
Blood Press Controlled
0
1
.16
Biguanides
0
1
.74
DPP
0
1
.05
Thiazolidinediones
0
1
.01
Sulfonylurea
0
1
.14
Sulfonylurea Biguanide
0
1
.01
DPP Biguanide
0
1
.03
Mean Adjusted PDC
-.7957
.1727 -.0009
Biguanide Mean Adj PDC
-.7957
.1727
.0010
DPP Mean Adj PDC
-.7461
.1727 -.0016
Thiazolidinediones Mean Adj PDC
-.6792
.1727
.0001
Sulfonylurea Mean Adj PDC
-.7403
.1727
.0014
Sulfonylurea Biguanide Mean Adj PDC
-.7382
.1727
.0001
DPP Biguanide Mean Adj PDC
-.7775
.1727 -.0011
PDC Value
.0315 1.0000
.8263
Count for all items is 23331
PDC values are mean adjusted with 0.8263 as mean value
Max PDC value of 0.1727 equals a PDC of 100% or full compliance

8.5
.194
.233
.250
.499
.124
.254
.347
.368
.436
.215
.117
.348
.104
.165
.2086
.1762
.0535
.0231
.0784
.0192
.0399
.2086

Regression Equations
The requirements for using multilinear regressions are a continuous outcome
variable, categorical or continuous predictors, normally distributed residuals, no
multicollinearity, and homoscedasticity must be present (Osborne & Waters, 2002). Our
outcome variable, HbA1c level, is measured as a continuous variable. PDC, deductible,
age, and hospital visits are all continuous. Sulfonylurea, Blindness, Retinopathy
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Screening, BP Controlled, Myocardial Infarction, LIS, DSNP, Thiazolidinediones, UTI,
DPP Biguanide, End-Stage Renal Disease, Male, DPP, Nephropathy Screening, seeing an
endocrinologist, and Sulfonylurea Biguanide are all categorical variables. We did find
multicollinearity with the regional variable and eliminated that predictor from our
analysis. Figure 2 shows normally distributed residuals in our data. Figure 3 verifies that
we have homoscedasticity in our data.
Figure 2
HbA1c Histogram
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Figure 3
HbA1c Scatterplot

Each of the six medication classes were recoded into binary variables. There was
sufficient sample size to include in our analysis the following medication classes,
Biguanide, DPP, Sulfonylurea Biguanide combination, Thiazolidinediones, Sulfonylurea,
and DPP Biguanide combination. From these regression analyses, we developed
predictive model equations for each of these medication classes. We included all
regression values, even if they are not statistically significant because even if a predictor
is not statistically significant, it has clinical significance (Schober et al., 2018). These
equations give us a model that predicts HbA1c values when switching from one
medication class to another. Use of the equation requires user input of the new
medication class wanted, the PDC for that class, and values for each covariate. The result
of the calculation is a predicted HbA1c value.
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In our first run of this analysis, we found multicollinearity among those living in
the country's south and NE regions based on the Variance of Inflation Factor (VIF)
values. Using a value of ten as the value to indicate a collinearity problem, the four
regional covariates Northeast, Northwest, South, and West were removed from our
regression analysis because of the collinearity problem.
Table 9
Multicollinearity values for South and NE region variables.
B
South
NE

0.15
0.308

Sig.
0.439
0.118

Lower
Bound
-0.23
-0.078

Upper
Bound
0.529
0.694

Tolerance

VIF

0.04 25.156
0.042 23.789

Table 10
Biguanide Medication Class as Reference Variable
Model Summary b

Model
1

R
.206a

R Square
0.043

Adjusted R
Square
0.039

Std. Error of
the Estimate
0.88371

a. Predictors: (Constant), Sulfonylurea, Thiazolidinediones Mean PDC, Blindness,
DPP Biguanide Mean PDC, DPP Mean PDC, Seeing Endocrinologist, Retinopathy
Screening, Sulfonylurea Biguanide Mean PDC, BP Controlled, Myocardial
Infarction, LIS, Thiazolidinediones, UTI, DPP Biguanide, Sulfonylurea Mean PDC,
End-Stage Renal Disease, Male, IsDPP2, Hospital Visits, Nephropathy Screening,
Age, Deductible, Sulfonylurea Biguanide, DSNP
b. Dependent Variable: HbA1c level

Table 11
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Coefficients with DPP as Reference

(Constant)
DPP
DPP Mean PDC
DPP Biguanide
DPP Biguanide Mean PDC
Sulfonylurea Biguanide
Sulfonylurea Biguanide Mean
PDC
Thiazolidinedione
Thiazolidinedione Mean PDC
Sulfonylurea
Sulfonylurea Mean PDC
Male
Age
DSNP
LIS
Deductible
Hospital Visits
Seeing Endocrinologist
Retinopathy Screening
Nephropathy Screening
End Stage Renal Disease
Blindness
Myocardial Infarction
UTI
BP Controlled
1
95% CI

B

Sig

Lower
Bound 1

7.031
0.057
0.169
0.191
-1.231
0.925

0
0.334
0.542
0.021
0.006
0

-1.797
-0.09
-0.814
0.274
-0.27
0.088
-0.004
-0.272
-0.092
0
-0.007
-0.071
0.045
0.005
-0.04
0.168
-0.031
-0.035
-0.207

6.829
-0.059
-0.375
0.029
-2.114
0.727

Upper
Bound 1
7.232
0.173
0.713
0.353
-0.35
1.123

1.076
1.035
1.024
1.014
1.346

0.039

-3.501

-0.09

1.343

0.375
0.183
0
0.112
0
0.001
0
0.004
0.003
0.001
0.208
0.189
0.832
0.094
0.078
0.504
0.27
0

-0.29
-2.013
0.212
-0.603
0.042
-0.007
-0.393
-0.155
0
-0.012
-0.18
-0.022
-0.042
-0.087
-0.019
-0.123
-0.097
-0.306

0.109
0.385
0.336
0.063
0.134
-0
-0.15
-0.03
0.001
-0
0.039
0.111
0.052
0.007
0.354
0.06
0.027
-0.11

1.011
1.003
1.084
1.024
1.059
1.108
7.032
1.228
6.62
1.081
1.034
1.08
1.081
1.121
1.004
1.032
1.054
1.017

Table 12
DPP Reference Model Summary

Model

R

R
Square

Adjusted R
Square

Std. Error of the
Estimate

VIF
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.212a
0.045
0.041
0.88287
a. Predictors: (Constant), Sulfonylurea, Thiazolidinediones Mean PDC,
Blindness, DPP Biguanide Mean PDC, Biguanide Mean PDC, Seeing
Endocrinologist, Retinopathy Screening, Sulfonylurea Biguanide Mean PDC,
BP Controlled, Myocardial Infarction, LIS, Thiazolidinediones, UTI, DPP
Biguanide, Sulfonylurea Mean PDC, End-Stage Renal Disease, Male,
Biguanide, Hospital Visits, Nephropathy Screening, Age, Deductible,
Sulfonylurea Biguanide, DSNP

Table 13
Coefficients with DPP as Reference
B
(Constant)
Biguanide
Biguanide Mean PDC
Thiazolidinediones
Thiazolidinediones Mean PDC
Sulfonylurea
Sulfonylurea Mean PDC
Sulfonylurea Biguanide
Sulfonylurea Biguanide Mean
PDC
DPP Biguanide
DPP Biguanide Mean PDC
Male
Age
DSNP
LIS
Deductible
Hospital Visits
Seeing Endocrinologist
Retinopathy Screening
Nephropathy Screening

Sig

Lower
Bound

Upper
Bound

1

1

VIF

7.076
-0.05
-0.055
-0.142
-0.814
0.223
-0.27
0.874

0
0.389
0.489
0.22
0.183
0
0.112
0

6.837
-0.165
-0.211
-0.368
-2.013
0.099
-0.603
0.648

7.315
0.064
0.101
0.085
0.385
0.347
0.063
1.099

5.064
1.02
1.298
1.003
4.281
1.024
1.75

-1.798
0.14
-1.232
0.088
-0.004
-0.268
-0.092
0
-0.008
-0.07
0.044
0.006

0.039
0.158
0.006
0
0.001
0
0.004
0.004
0.001
0.21
0.19
0.797

-3.502
-0.055
-2.116
0.042
-0.007
-0.39
-0.155
0
-0.012
-0.18
-0.022
-0.041

-0.094
0.335
-0.349
0.134
-0.002
-0.146
-0.029
0.001
-0.003
0.04
0.111
0.053

1.343
1.473
1.014
1.059
1.109
7.03
1.226
6.639
1.08
1.034
1.08
1.085
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End Stage Renal Disease
Blindness
Myocardial Infarction
UTI
BP Controlled
1
95% CI

-0.039
0.168
-0.031
-0.035
-0.205

0.1
0.077
0.505
0.263
0

-0.086
-0.018
-0.122
-0.097
-0.304

0.008
0.354
0.06
0.027
-0.107

1.121
1.004
1.032
1.054
1.019

Table 14
Sulfonylurea Biguanide Reference Model Summary b
Adjusted
Std. Error of the
Model
R
R Square
R Square
Estimate
1
.212a
0.045
0.041
0.88287
a. Predictors: (Constant), Sulfonylurea, Thiazolidinediones Mean PDC,
Blindness, DPP Biguanide Mean PDC, Biguanide Mean PDC, Seeing
Endocrinologist, Retinopathy Screening, DPP Mean PDC, BP Controlled,
Myocardial Infarction, LIS, Thiazolidinediones, UTI, DPP Biguanide,
Sulfonylurea Mean PDC, End-Stage Renal Disease, Male, Biguanide,
Hospital Visits, Nephropathy Screening, Age, Deductible, DPP, DSNP,
LIS
b. Dependent Variable: HbA1c continuous value
Table 15
Coefficients Sulfonylurea Biguanide Reference
B
(Constant)
Biguanide
Biguanide Mean PDC
DPP
DPP Mean PDC
Thiazolidinediones
Thiazolidinediones Mean PDC
Sulfonylurea

7.847
-0.819
-0.055
-0.763
0.17
-0.911
-0.814
-0.546

Sig

Lower
Bound

Upper
Bound

0
0
0.491
0
0.541
0
0.184
0

7.581
-0.991
-0.211
-0.966
-0.374
-1.171
-2.013
-0.724

8.113
-0.648
0.101
-0.559
0.714
-0.65
0.386
-0.368

VIF

11.358
1.02
3.31
1.035
1.719
1.003
8.88
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Sulfonylurea Mean PDC
DPP Biguanide
DPP Biguanide Mean PDC
Male
Age
DSNP
LIS
Deductible
Hospital Visits
Seeing Endocrinologist
Retinopathy Screening
Nephropathy Screening
End Stage Renal Disease
Blindness
Myocardial Infarction
UTI
BP Controlled

-0.271
-0.629
-1.232
0.088
-0.004
-0.275
-0.095
0
-0.007
-0.072
0.046
0.007
-0.04
0.167
-0.031
-0.035
-0.205

0.111
0
0.006
0
0.001
0
0.003
0.003
0.001
0.198
0.172
0.765
0.09
0.08
0.503
0.266
0

-0.604
-0.862
-2.115
0.042
-0.007
-0.397
-0.158
0
-0.012
-0.182
-0.02
-0.04
-0.087
-0.02
-0.123
-0.097
-0.303

0.062
-0.396
-0.348
0.135
-0.002
-0.153
-0.032
0.001
-0.003
0.038
0.113
0.054
0.006
0.353
0.06
0.027
-0.106

1.024
2.114
1.014
1.059
1.11
7.033
1.228
6.629
1.081
1.034
1.079
1.084
1.121
1.004
1.032
1.054
1.019

Table 16
Model Summary b
Model
1

R
.212a

R Square
0.045

Adjusted R
Std. Error of the
Square
Estimate
0.041
0.88287

a. Predictors: (Constant), Sulfonylurea Biguanide Mean PDC, DPP Biguanide
Mean PDC, DPP Mean PDC, Sulfonylurea Mean PDC, Biguanide Mean PDC,
BP Controlled, Myocardial Infarction, LIS, Thiazolidinediones, UTI, Seeing
Endocrinologist, DSNP, LIS, DPP Biguanide, Age, Male, DPP, Sulfonylurea,
Hospital Visits, Deductible, Sulfonylurea Biguanide, Biguanide, Mean PDC
b. Dependent Variable: HbA1c level

Table 17
Coefficients Thiazolidinediones as Reference a
B

t

Sig

Lower
Bound

Upper
Bound

VIF
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(Constant)
DPP
DPP Mean PDC
DPP Biguanide
DPP Biguanide Mean
PDC
Sulfonylurea Biguanide
Sulfonylurea Biguanide
Mean PDC
Sulfonylurea
Sulfonylurea Mean PDC
Biguanide
Biguanide Mean PDC
Male
Age
DSNP
LIS
Deductible
Hospital Visits
Seeing Endocrinologist
Retinopathy Screening
Nephropathy Screening
End Stage Renal Disease
Blindness
Myocardial Infarction
UTI
BP Controlled

6.929
0.154
0.169
0.288

47.12
0
1.326 0.185
0.609 0.543
2.215 0.027

6.641
-0.073
-0.375
0.033

7.218
0.381
0.713
0.542

4.117
1.035
2.52

-1.231

-2.73 0.006

-2.114 -0.347

1.014

1.021

7.184

0

0.742

1.299

2.668

-1.797

-2.067 0.039

-3.501 -0.093

1.343

0.37
-0.27
0.097
-0.055
0.089
-0.004
-0.271
-0.093
0
-0.008
-0.07
0.044
0.006
-0.04
0.168
-0.032
-0.035
-0.206

3.535
-1.592
0.954
-0.691
3.775
-3.321
-4.354
-2.911
2.951
-3.37
-1.241
1.303
0.249
-1.664
1.772
-0.686
-1.113
-4.085

0.165
-0.603
-0.102
-0.211
0.043
-0.007
-0.393
-0.156
0
-0.012
-0.179
-0.022
-0.041
-0.086
-0.018
-0.123
-0.097
-0.305

11.77
1.024
15.41
1.02
1.059
1.11
7.042
1.229
6.64
1.081
1.034
1.08
1.085
1.121
1.004
1.032
1.054
1.019

0
0.111
0.34
0.49
0
0.001
0
0.004
0.003
0.001
0.215
0.193
0.803
0.096
0.076
0.493
0.266
0

0.576
0.063
0.297
0.101
0.135
-0.002
-0.149
-0.031
0.001
-0.003
0.04
0.111
0.053
0.007
0.355
0.059
0.027
-0.107

Table 18
Sulfonylurea Model Summary b
Model
1

R
.212a

R Square
0.045

Adjusted R
Square
0.041

Std. Error of the
Estimate
0.88287
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a. Predictors: (Constant), Sulfonylurea Biguanide Mean PDC, DPP Biguanide
Mean PDC, DPP Mean PDC, Thiazolidinediones Mean PDC, Biguanide
Mean PDC, BP Controlled, Myocardial Infarction, LIS, Thiazolidinediones,
UTI, Seeing Endocrinologist, DSNP, LIS, DPP Biguanide, Age, Male, DPP,
Hospital Visits, Deductible, Sulfonylurea Biguanide, Biguanide, Mean PDC
b. Dependent Variable: HbA1c level
Table 19
Coefficients Sulfonylurea as Reference a
B
(Constant)
DPP
DPP Mean PDC
DPP Biguanide
DPP Biguanide Mean
PDC
Sulfonylurea
Biguanide
Sulfonylurea
Biguanide Mean PDC
Biguanide
Biguanide Mean PDC
Thiazolidinedione
Thiazolidinedione
Mean PDC
Male
Age
DSNP
LIS
Deductible
Hospital Visits
Seeing Endocrinologist
Retinopathy Screening
Nephropathy Screening
End Stage Renal
Disease

t

Sig

Lower Upper
Bound Bound

VIF

7.293 66.184
0
-0.21 -3.298 0.001
0.169 0.608 0.543
-0.08 -0.875 0.381

7.077
-0.336
-0.375
-0.246

7.509
-0.085 1.25
0.713 1.035
0.094 1.125

-1.23

-2.115

-0.348 1.014

0.658

-2.732 0.006
6.323

0

0.454

0.862

-1.8

-2.069 0.039

-3.503

-0.094 1.343

-0.27
-0.05
-0.36

-8.446
0
-0.682 0.495
-3.416 0.001

-0.328
-0.21
-0.563

-0.204 1.478
0.102 1.02
-0.152 1.068

-0.82

-1.331 0.183

-2.014

0.385 1.003

0.088
-0
-0.27
-0.09
0
-0.01
-0.07
0.045
0.005

3.729
-3.329
-4.339
-2.865
2.949
-3.293
-1.244
1.312
0.217

0
0.001
0
0.004
0.003
0.001
0.213
0.19
0.828

0.042
-0.007
-0.392
-0.155
0
-0.012
-0.18
-0.022
-0.042

-0.04

-1.656 0.098

-0.086

0.134
-0.002
-0.148
-0.029
0.001
-0.003
0.04
0.111
0.052

1.43

1.058
1.11
7.044
1.228
6.64
1.079
1.034
1.08
1.084

0.007 1.121
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Blindness
Myocardial Infarction
UTI
BP Controlled

0.167
-0.03
-0.04
-0.21

1.757 0.079
-0.672 0.502
-1.11 0.267
-4.091
0

-0.019
-0.123
-0.097
-0.305

0.353
0.06
0.027
-0.107

1.004
1.032
1.054
1.019

Table 20
DPP Biguanide Model Summary b
Model

R

R Square

1 .212a

Adjusted R Square

0.045

0.041

Std. Error of
the Estimate
0.88287

a. Predictors: (Constant), Sulfonylurea Biguanide Mean PDC, Sulfonylurea
Mean PDC, DPP Mean PDC, Thiazolidinediones Mean PDC, Biguanide
Mean PDC, BP Controlled, Myocardial Infarction, LIS, Thiazolidinediones,
UTI, Seeing Endocrinologist, DSNP, LIS, Sulfonylurea, Age, Male, DPP,
Hospital Visits, Deductible, Sulfonylurea Biguanide, Biguanide, Mean PDC
b. Dependent Variable: HbA1c level
DPP Biguanide Model Summary b
Std. Error
of the
Estimate
1 .212a
0.045
0.041
0.88287
a. Predictors: (Constant), Sulfonylurea Biguanide Mean
PDC, Sulfonylurea Mean PDC, DPP Mean PDC,
Thiazolidinediones Mean PDC, Biguanide Mean PDC,
BP Controlled, Myocardial Infarction, LIS,
Thiazolidinediones, UTI, Seeing Endocrinologist,
DSNP, LIS, Sulfonylurea, Age, Male, DPP, Hospital
Visits, Deductible, Sulfonylurea Biguanide, Biguanide,
Mean PDC
b. Dependent Variable: HbA1c level
Model

R

R Square

Adjusted R
Square

Table 21
Coefficients DPP Biguanide as Reference a
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t

Sig

Lower
Bound

Upper
Bound

-0.034
0.008

55.155
-1.578
0.616

0
0.115
0.538

6.99
-0.352
-0.373

7.505
0.038
0.715

3.036
1.035

0.102

5.502

0

0.457

0.962

2.195

-0.03

-2.067

0.039

-3.503

-0.093

1.343

-0.009
-0.103
-0.038

-0.685
-2.6
-2.351

0.493
0.009
0.019

-0.211
-0.376
-0.559

0.101
-0.053
-0.051

1.02
10.085
1.637

-0.017

-1.327

0.184

-2.012

0.388

1.003

0.024

0.683

0.495

-0.111

0.229

8.021

-0.02

-1.592

0.111

-0.604

0.063

1.024

0.048
-0.044
-0.146
-0.041
0.095
-0.044

3.772
-3.342
-4.396
-2.953
2.954
-3.374

0
0.001
0
0.003
0.003
0.001

0.043
-0.007
-0.396
-0.158
0
-0.012

0.135
-0.002
-0.152
-0.032
0.001
-0.003

1.059
1.11
7.04
1.228
6.641
1.081

-0.016

-1.256

0.209

-0.18

0.039

1.034

0.017

1.289

0.197

-0.023

0.11

1.08

0.003

0.205

0.837

-0.042

0.052

1.085

-0.022

-1.689

0.091

-0.087

0.006

1.121

0.022
-0.009
-0.014
-0.052

1.771
-0.685
-1.104
-4.138

0.077
0.493
0.269
0

-0.018
-0.123
-0.097
-0.308

0.355
0.059
0.027
-0.11

1.004
1.032
1.054
1.019

Beta
(Constant)
IsDPP2
DPP Mean PDC
Sulfonylurea
Biguanide
Sulfonylurea
Biguanide Mean PDC
Biguanide Mean PDC
Biguanide
Thiazolidinediones
Thiazolidinediones
Mean PDC
Sulfonylurea
Sulfonylurea Mean
PDC
Male
Age
DSNP
LIS
Deductible
Hospital Visits
Seeing
Endocrinologist
Retinopathy
Screening
Nephropathy
Screening
End Stage Renal
Disease
Blindness
Myocardial Infarction
UTI
BP Controlled

VIF
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Using these regression results to create equations for each medication class, one of the medication
classes as a reference variable and left out of the analysis. Running the DPP to Biguanide
regression to determine how well the equation predicted biguanide levels there were 1925
members from the test list on a biguanide medication used as our base group. Both sets of data
showed normal distributions—however, significant differences in minimum and maximum values
as seen in figures 4 and 5.

Figure 4
HbA1c Distribution
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Figure 5
Predicted HbA1c distribution

There were statistically significant differences between the actual and predicted HbA1c levels, as
demonstrated in Table 22. Kurtosis analysis shows that the predicted values have a different
distribution of values at the distribution tails, and we see this in the predictive values. The ends of
the distribution are much lower values than those in the actual data. Table 23 shows the SPSS
interclass correlation function results with the two-way mixed model and absolute agreement
selected. The two-way mixed model is appropriate for this analysis because there is a randomly
selected sample, the values are fixed, and we selected absolute agreement because we want to see
how well the regression can predict an HbA1c values. There is very little correlation between
either single or average measure tests. Finally, there is no statistically significant correlations as
the p-value for the average measurements was 0.088.

Table 22
HbA1c Actual vs. Predicated

N

Valid

HbA1cValue
1925

Predicted
1925
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Missing

0
6.502
6.300
0.8686
2.587
0.056
12.480
0.112
4.2
14.7

Mean
Median
Std. Deviation
Skewness
Std. Error of Skewness
Kurtosis
Std. Error of Kurtosis
Minimum
Maximum

0
5.776
5.800
0.1767
0.167
0.056
0.551
0.112
5.1
6.7

Table 23
Intraclass Correlation Coefficient
95%
Confidence
Interval

Single
Measures
Average
Measures

F Test with True Value 0

Intraclass
Lower
b
Correlation
Bound
.031a -0.014

Upper
Bound
0.075

Value
df1
1.064 1924

df2
1924

Sig
0.088

.060c -0.028

0.140

1.064 1924

1924

0.088

Two-way mixed-effects model where people effects are random and measures
effects are fixed.
a. The estimator is the same, whether the interaction effect is present or not.
b. Type C intraclass correlation coefficients using a consistency definition.
The between-measure variance is excluded from the denominator variance.
c. This estimate is computed assuming the interaction effect is absent because
it is not estimable otherwise.
Discussion
Data analysis answered both research questions in the affirmative, that in making
medication change decisions for oral antihyperglycemics, considering both the new
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medication and patient compliance rate is important. Research question one asks if there
is a relationship between PDC calculated for individual antihyperglycemic class of
medications and HbA1c values in Medicare MCO members with type 2 diabetes while
controlling for age, sex, LIS enrollment, DSNP enrollment, and seeing an
endocrinologist? Research question two asks if there is a relationship between PDC
index calculated for individual, commercially available combination, antihyperglycemic
class of medications and HbA1c values in Medicare MCO members with type 2 diabetes
while controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan type,
LIS enrollment, and DSNP enrollment? Figure 6 is a simple slopes graph looking at the
relationship between the reported HbA1c level and the mean adjusted PDC (the zero
value is a PDC of 85%) for each of the medication classes with a sufficient sample
population to analyze.
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Figure 6
HbA1c Simple Slopes

Table 24
Simple slope Equation and R2
Medication Class
Biguanide
DPP
DPP-Biguanide
Thiazolidinediones
Sulfonylurea
Sulfonylurea-Biguanide
X=mean centered PDC value

Equation
y = 6.53 - 0.16*x
y = 6.48 – 0.09*x
y = 6.78 - 0.94*x
y = 6.4 - 0.83*x
y = 6.82 - 0.25*x
y = 7.4 - 2.49*x

R2 Value
0.057
0.024
0.699
0.632
0.128
0.914

R2 values are given as a percent, range from 0% to 100%, and indicate the degree of
correlation between the predicted HbA1c value and the actual HbA1c value. Generally,
the higher the value of R2, the better the correlation between the PDC, medication class,
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and the predicted HbA1c values. Low R2 values, less than 0.25, indicate low effect size,
less than 0.255 indicate medium effect size, and above 0.75 are related to a high effect
size (Hair et al., 2011). Figure 6 demonstrates that at high levels of compliance, above
85%, there is not a significant difference in HbA1c values. However, as compliance rates
drop, there is a difference in medication effectiveness on HbA1c levels. Three of the
medication classes showed poor predictive value based on the data, Biguanide, DPP, and
Sulfonylurea, all with R2 values less than 0.25. Showing mean to high predictive value
were DPP-Biguanide, Thiazolidinediones, and the Sulfonylurea Biguanide combinations.
The Sulfonylurea Biguanide combination showed the highest R2 value at 0.914.
An analysis of the regression equations showed that they did not fit well. The
DPP to Biguanide and Thiazolidine to DPP Biguanide regressions were performed using
the reliability analysis function of SPSS. Neither of the predicted values was close to the
actual HbA1c values with p values = 0.088. One explanation for this failure to predict
HbA1c levels accurately is due to the inability to correlate the HbA1c level and
medication compliance.
Clinical Indications of this Study
This preliminary study examines the potential association between the PDC and
medication class and its effect on HbA1c levels. The results support the hypothesis that a
provider must consider medication compliance rates when selecting an oral
antihyperglycemic medication. For example, figure 6 demonstrates that for patients who
are non-compliant with their medications, the Sulfonylurea Biguanide combination may
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not be the best therapeutic route considering the higher HbA1c levels at lower
compliance rates compared to the other medications. The DPP class of medications
shows consistent HbA1c control across all PDC values with a slope of only 0.09 (this
means that for each unit increase in compliance, HbA1c drops by 0.09). Assuming no
effect from medication side effects, the DPP class may be best for controlling HbA1c as
it is not as affected by PDC as the other medication classes. However, these conclusions
can only be used to show that a relationship exists between medication compliance, the
class of medication taken, and medication compliance. A detailed study of this is needed
because the precisely relationship between the HbA1c level was completed compared to
when the medication was taken cannot be established.
While this study showed little statisticaly significance with low R2 values, it does
demonstrate clinically significant differences in the associations between OAMC, PDC
and HbA1c levels. Schober et al., (2018), discusses differences in core temps postsurgery. The authors said:

“Researchers need to define and to support what they consider a minimal
clinically important effect, and journal editors, reviewers, and readers need
to assess whether this seems reasonable. Note that an important effect does
not necessarily have to be large. For example, a small effect on mortality
can make a huge difference not only for individual patients but also for
society if a large percentage of patients is affected by the condition.”
Finally, in coversations with my my personal physician and Justin Zaghi,
Medical Director for Heal and Board Certified Internist, about what they consider
clinically significant changes in HbA1c. Both told me that a 0.5% decrease from
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medication would be considered significant by them (J. Zaghi, S. Hartl, personal
communication, January 2021).

Limitations of the Study
Several biases arise with this study. Because we only had data on Medicare
Advantage individuals, the results are limited to people with type 2 diabetes and in a
Medicare Advantage plan. Because we had a large group that did not have an HbA1c
level completed, our results might be biased towards those who are overall more
compliant, i.e., if they had an HbA1c level done then they could be more compliant
towards their medication consumption. These results are of interest because both groups
showed average medication compliance rates of over 80%. These findings are different
from previously published studies indicating that people with diabetes are around 50%
compliant with the medications (Wang et al., 2013). Second, we are not able to directly
relate medication compliance with exact HbA1c draw dates. Therefore, we have to
interpret the data with caution; however, what is shown by the data is that our hypothesis
that providers must consider both the medication and compliance rate when making
therapeutic decisions is valid. Finally, because we could not relate the HbA1c level to
particular medications, we had to remove those who took more than one
antihyperglycemic medication during the year. This data is preliminary, and our results
should be considered with caution. Better controlled studies where HbA1c levels can
definitively be associated with medication compliance are needed. Additionally, this
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study only looks at those on single medication therapy. Many people with diabetes take
multiple medications, and these should be examined.
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Abstract
Individual medication nonadherence costs for each type 2 diabetic are approximately
$28,000 per year. Costs are the second most common reason for individual type 2
diabetic medication nonadherence, with one in four Americans having difficulty paying
for their medications. As a result, Medicare instituted the Low-Income Subsidy (LIS)
program and a Dually Eligible Special Need Program (DSNP) to improve medication
compliance through reduced financial burden. The purpose of this study is to determine
whether financial assistance programs improve medication compliance, as calculated by
the Proportion of Days Covered (PDC), or HbA1c levels in people with type 2 diabetes.
This is a longitudinal retrospective study utilizing secondary claims data from a large
nationwide Managed Care Organization with a sample size of 23,000. Linear regression
analysis identified the effects of Low-Income Subsidy (LIS) and Dually Eligible Special
Needs Program (DSNP) programs combined with medication compliance on lowering
HbA1c levels. While both LIS and DSNP programs have statistically significant effects
on HbA1c levels and medication compliance, their overall effect is minimal, with R2
values below 1%, indicating that their goal of improving health status has not been met.
These findings indicate that a review of the LIS and DSNP program's goal of improving
medication compliance should be further studied.
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Introduction
Diabetes is the seventh leading cause of death in the US, affecting 34 million
diagnosed people with diabetes and another 88 million with prediabetes (Centers for
Disease Control and Prevention, 2020). Additionally, some individuals do not know that
they have diabetes, and many physicians are unsure of what indicates prediabetes
(National Institute of Diabetes and Digestive and Kidney Diseases, 2017; Tseng et al.,
2017). One out of four dollars spent on healthcare in the US is spent on diabetes or any of
the comorbidities associated with diabetes, including heart disease, stroke, nephropathies,
and retinopathies (National Institute of Diabetes and Digestive and Kidney Diseases,
2018; Riddle & Herman, 2018).
Medication compliance in individuals with diabetes is an important part of their
therapeutic regimen (Huang et al., 2018). One issue that faces those with diabetes is the
cost of antihyperglycemic medications (Kang et al., 2018; Kennedy-Martin et al., 2017).
Lower compliance rates in those with diabetes result in lower health statuses and increase
morbidity and mortality. People with diabetes are notoriously non-compliant, and in their
first year after diagnosis, almost half missed 80% of their doses (Cramer, 2004).
Medication compliance is a complex issue requiring patients to purchase and take their
medications on a prescribed dosing schedule.
Individuals with diabetes and lower socioeconomic statuses have higher
medication non-compliance (Nam et al., 2011). One way to increase compliance is to
reduce copays and deductibles for those with a financial need. Reducing copays by 36%
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reduces the number of non-compliant patients by 30%, which can be offset by reducing
medical costs such as hospitalizations (Zeng et al., 2010). Income and asset-based
subsidy programs are a tool for improving medication compliance, reducing overall
medical costs, and improving health statuses. There are two subsidy programs that
Medicare implemented intending to improve medication compliance. Low-Income
Subsidy (LIS) programs are for those in Medicare Part D programs and Dually Eligible
Special Needs Programs are for those who qualify for both Medicare and Medicaid. Both
programs are administered by Managed Care Organizations (MCO) and are not available
with traditional Medicare.
The 2018 Medicare Modernization Act created the LIS program and covered 4.7
million enrollees. This program subsidized Part D for prescription costs, premiums,
deductibles, and coinsurance (Centers for Medicare & Medicaid Services, n.d.). The
program is part of the Medicare Extra Help initiative, where those participating must
have a monthly income of less than $1650 for individuals and $2,175 for couples, and
they must have limited assets. The LIS program is only available to those in a Medicare
Advantage plan and is not available to traditional Medicare patients. The LIS program
eliminates Part D's donut hole provision, a gap in coverage lying between initial coverage
limits and the catastrophic-coverage threshold as determined by the MCO. The purpose
of the LIS program is to reap the benefits of lower overall medical costs through
improved medication compliance (Kirkman et al., 2015).
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Both copays and deductibles add to health inequalities and lower medication
adherence rates. While the LIS program attempted to address some of the issues around
health inequalities, there are still problems. While the program subsidizes lower copays
and premiums, deductibles may be higher, and there may be limited medication coverage
depending on the MCO formulary.
The DSNP program is a set of special needs programs implemented by Congress
in 2003 based on Medicaid enrollment, income, and asset levels, with the first DSNP
program started in 2006. In 2013, the Affordable Care Act (ACA) modified DSNP
programs to require that MCO’s have a contract with State Medicaid plans to improve the
integration of Medicare and Medicaid benefits. The ACA set up a list of eight elements
state Medicaid programs must include to maintain DSNP participation eligibility
(Archibald et al., 2019).
Medicare is considered the primary payor, and Medicaid is the secondary payor
for DSNP programs. Additionally, services not covered by Medicare may be covered by
Medicaid for DSNP enrollees. Individual states set the income and asset limits, but it is
generally a requirement that the enrollee’s income is below the poverty level, currently
set between $12,760 and $44,120, depending on the number of individuals in the
household (U.S. Department of Health and Human Services, 2020). Asset limitations
also apply.
A 2018 Health and Human Services report documented the relationship between
DSNP enrollment and Social Determinants of Health (SDOH) issues with income levels
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being a part of the SDOH (Sorbero et al., 2018). DSNP programs set income
requirements at or below the poverty level, and LIS programs are generally from the
poverty level to 300% of the poverty level. Therefore, we have three sets of income
levels, and we treat these as a categorical variable in this study. The categorical income
variable comprises those not participating in an assistance program at the first level of
income, LIS at the second with a value of 100% to 300% of the poverty level, and DSNP
enrollees being at the third level of income, either at or below the poverty level. Having
actual income levels would have been a better approach, but the MCO does not collect
income data.
Research Design and Methods
According to Creswell and Creswell, 2017, a quantitative approach is used when a
researcher tries to establish relationships between variables. The purpose of this study is
to examine the relationship between enrollment in a financial assistance program and
medication compliance in one of six classes of antihyperglycemic medications and
HbA1c levels. Ideally, an individual with diabetes should have an HbA1c level below
6.5%, the threshold for a diagnosis of diabetes (American Diabetes Association, 2018).
Covariates for this study include age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, and living in Urban or Rural counties. The research questions for this
manuscript are:
RQ3: Is there a relationship between the type of subsidy plan enrollment (LIS or DSNP),
PDC Medication Compliance rate for one of the six classes of individual
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antihyperglycemic medications on HbA1c levels in Medicare type 2 diabetics while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, and
living in Urban or Rural County?
H013: There is no statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Biguanide class of medications, and HbA1c levels in Medicare type 2 diabetics
while controlling for age, sex, diabetes diagnosis time, length of time in MCO,
Plan type, and living in Urban or Rural County.
H113: There is a statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Biguanide class of medications, both individually and in combination, and HbA1c
levels in Medicare type 2 diabetics while controlling for age, sex, diabetes
diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural
County.
H014: There is no statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications, both individually
and in combination, and HbA1c levels in Medicare type 2 diabetics while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, and living in Urban or Rural County.
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H114: There is a statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications, and HbA1c levels
in Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis
time, length of time in MCO, Plan type, and living in Urban or Rural County.
H015: There is no statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Thiazolidinedione class of medications, and HbA1c levels in Medicare type 2
diabetics while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, and living in Urban or Rural County.
H115: There is a statistically significant relationship the type of subsidy plan
enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Thiazolidinedione class of medications, and HbA1c levels in Medicare type 2
diabetics while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, and living in Urban or Rural County.
H016: There is no statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of medications, and
HbA1c levels in Medicare type 2 diabetics while controlling for age, sex, diabetes
diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural
County.
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H116: There is a statistically significant relationship the type of subsidy plan
enrollment (LIS or DSNP), PDC Medication Compliance rate for the SodiumGlucose Co-Transporter 2 (SGLT2) Inhibitors class of medications, and HbA1c
levels in Medicare type 2 diabetics while controlling for age, sex, diabetes
diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural
County.
H017: There is no statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Sulfonylureas class of medications, and HbA1c levels in Medicare type 2
diabetics while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, and living in Urban or Rural County.
H117: There is a statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Sulfonylureas class of medications, and HbA1c levels in Medicare type 2
diabetics while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, and living in Urban or Rural County.
H018: There is no statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Meglitinide Analogues class of medications, and HbA1c levels in Medicare type 2
diabetics while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, and living in Urban or Rural County.
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H118: There is a statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Meglitinide Analogues class of medications, and HbA1c levels in Medicare type 2
diabetics while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, and living in Urban or Rural County.
RQ 4: Is there a relationship between the type of subsidy plan enrollment (LIS or DSNP),
PDC Medication Compliance rate for one of the six classes of combined
antihyperglycemic medications, and HbA1c levels in Medicare type 2 diabetics while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, and
living in Urban or Rural County?
H019: There is no statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Meglitinide-Biguanide Combinations class of medications, and HbA1c levels in
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time,
length of time in MCO, Plan type, and living in Urban or Rural County.
H119: There is a statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Meglitinide-Biguanide Combinations class of medications, both individually and
in combination, and HbA1c levels in Medicare type 2 diabetics while controlling
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, and living
in Urban or Rural County.
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H020: There is no statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the SGLT2
Inhibitor - DPP-4 Inhibitor Combinations class of medications, both individually
and in combination, and HbA1c levels in Medicare type 2 diabetics while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, and living in Urban or Rural County.
H120: There is a statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the SGLT2
Inhibitor - DPP-4 Inhibitor Combinations class of medications, and HbA1c levels
in Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis
time, length of time in MCO, Plan type, and living in Urban or Rural County.
H021: There is no statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Sodium-Glucose Co-Transporter 2 Inhibitor-Biguanide class of medications, and
HbA1c levels in Medicare type 2 diabetics while controlling for age, sex, diabetes
diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural
County.
H121: There is a statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Sodium-Glucose Co-Transporter 2 Inhibitor-Biguanide class of medications, and
HbA1c levels in Medicare type 2 diabetics while controlling for age, sex, diabetes
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diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural
County.
H022: There is no statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Sulfonylurea-Biguanide class of medications, and HbA1c levels in Medicare type
2 diabetics while controlling for age, sex, diabetes diagnosis time, length of time
in MCO, Plan type, and living in Urban or Rural County.
H122: There is a statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Sulfonylurea-Biguanide class of medications, and HbA1c levels in Medicare type
2 diabetics while controlling for age, sex, diabetes diagnosis time, length of time
in MCO, Plan type, and living in Urban or Rural County.
H023: There is no statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Dipeptidyl Peptidase-4 Inhibitor-Biguanide class of medications, and HbA1c
levels in Medicare type 2 diabetics while controlling for age, sex, diabetes
diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural
County.
H123: There is a statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Dipeptidyl Peptidase-4 Inhibitor-Biguanide class of medications, and HbA1c
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levels in Medicare type 2 diabetics while controlling for age, sex, diabetes
diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural
County.
H024: There is no statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Sulfonylurea-Thiazolidinedione class of medications, and HbA1c levels in
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time,
length of time in MCO, Plan type, and living in Urban or Rural County.
H124: There is a statistically significant relationship between the type of subsidy
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the
Sulfonylurea-Thiazolidinedione class of medications, and HbA1c levels in
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time,
length of time in MCO, Plan type, and living in Urban or Rural County.
Longitudinal studies are done over time, with data collection done at different
times during the study period, while retrospective studies look at past events. The sample
was taken from 2019 claims data of those enrolled in a large nationwide MCO in this
study with a size of 23,000 participants. Using G*Power, version 3.1.9.4, an effect size of
0.15, an alpha error probability of 0.05, a power of 0.95, the recommended sample size is
89. In a meta-analysis of medication compliance studies with different diseases, including
diabetes, the authors found that studies with more than 85 participants had high statistical
power. The authors also found that effect sizes in the studies reviewed was 0.17 to 0.18
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with p < 0.0001. Based on this meta-study, a value of 0.15 was used (Foot et al., 2016).
G* Power's effect size quantifies the differences between the test and control groups
(Cunningham & McCrum-Gardner, 2007). We selected participants who have taken only
one of the six classes of antihyperglycemic medications during 2019 and who have had
an HbA1c level done during the year. We excluded individuals who may have taken
more than one medication class because we cannot associate an HbA1c level draw times
when multiple medications are taken.
The study population was selected from a large nationwide MCO claims database
and include members of the MCO who are:
1. Over 21
2. Have type 2 diabetes
3. Enrolled in either a Medicare Advantage (MA) or Prescription Drug Plan
(PDP) in 2019
4. Took only one of the six classes of antihyperglycemic medications or a
combination of classes.
All the data provided by the MCO were deidentified before release to the researcher.
Each member was assigned a unique serial number that is part of the released data. After
analysis, if the MCO wants to do further studies, the research data can be mapped back to
individual members with an assigned serial number.
Type 2 diabetes diagnoses were coded according to the ICD-10 World Health
Organization International Statistical Classification of Diseases and Related Health using
E11.8. Claim data will be chosen from pharmacy dispensing records, and the medication
start date is the date of the first antihyperglycemic medication dispensing. The PDC
measure excludes those on insulin, so these patients are not included.
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Linear regressions were performed on each research question. We split our
sample into a learning group consisting of 70% of our total sample and a testing group
consisting of 30% of the total sample using a split-sample validation technique (Pang &
Jung, 2013). The learning group, L1, is the sample we used to develop the model, and the
test group, HO1, is the one we used to test the model. We analyzed the predicted HbA1c
values with the actual HbA1c values using a Chi-Square test.
One potential interference with regression analysis is collinearity. In regressions,
each predictor must identify a unique effect on the outcome variable. In this study, we
address the issue of collinearity in two different ways. Using the SPSS linear regression
analysis, an absolute value greater than 0.8 indicates collinearity between predictors.
In the SPSS regression we utilized the Collinearity diagnostics function to provide
a Variance Inflation Factor (VIF). VIF is a measure of the degree of standard error
inflation, where a VIF factor greater than 10 is indicative of collinearity (Weisberg, 2005,
p. 217). For this study, the unit of analysis is the member.
Table 25 is a listing of the data variables and data types used in the analysis.
Table 25
Predictor Variables, their type, and possible values
Variable Name
Unique member identifier.
Age
Sex
HBA1c level
Deductible
Medication Class
Medication PDC
In DSNP Program

Variable Type
Nominal
Continuous
Categorical
Continuous
Continuous
Ordinal
Continuous
Nominal

Possible Values
Format TBD by MCO
21-100
0=male,1=female
actual level
0 - 410
1-35
0-1
0=no, 1=yes
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In LIS program
Plan type
Had Myocardial Infraction
Is Blind
Has End-Stage Renal Disease
Has Urinary Tract infections
Income Indicator

Nominal
Categorical
Nominal
Nominal
Nominal
Nominal
Categorical

0=no, 1=yes
1=PDP, 2=MA + PDP
0=no, 1=yes.
0=no, 1=yes.
0=no, 1=yes.
0=no, 1=yes.
0=DSNP, 1=LIS, 3=Neither

The predictive model equation will be determined by picking the predictors with a
p-value is < 0.05. The equations for each of the research questions will be created by
using the fundamental equation for a straight line, y = mx + b, where y is the HbA1c
value, b is the y-axis intercept, and m is the coefficient for a statistically significant
predictor variable. The final equation will take the final form of y = b +
coeff1*predictor1 value + coeff2*predictor2 value + coeff3*predictor3 value +
coeffN*predictorN value. The direction and strength of a linear relationship between two
variables can be determined by Pearson’s correlation (Warner, 2013). Values greater than
0.5 show significant levels of correlation between the variables. Values approaching 0.3
have small correlations but still significant enough to consider in the final equation. Any
predictor variable used must have a p-value of less than 0.05. Pearson’s correlations can
give us some insight into the R2 value produced by regression analysis because it gives us
a feeling for the strength of effect (Hair et al., 2011). Pearson’s correlation values are
obtained by selecting a correlation from the SPSS interface and adding in all of the
variables in the analysis.
R2 is a statistical value created by a regression analysis indicating how well the
predictor variables match the regression line (Warner, 2013). The models' R2 value
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indicates the quality of the fit of the data to the line created by the regression. In human
research, an R2 value greater than 0.2 is considered adequate. This value is somewhat
lower than in other kinds of research, but because human behavior is included in the
analysis, this lower number is acceptable (Hair et al., 2011). Plots of the data are
necessary to determine bias in the data. If the data is evenly dispersed around the
regression line, then linear regression is appropriate. If the data is not evenly dispersed,
then a non-linear approach is better (Warner, 2013).
Results
The purpose of this quantitative research was to determine the effect of Medicare
DSNP or LIS programs on medication compliance or HbA1c levels in people with type 2
diabetes while controlling for covariates such as age, sex, comorbidities, hospital visits,
and if they are seeing an endocrinologist. On September 29, 2020, a large, nationwide
MCO provided, and corporate compliance approved the use of their data. Approval for
this study was received from the Walden University IRB, number 10-30-20-0721525, on
October 30, 2020. Two MCO Business Analysts produced de-identified, secondary
claims data.
Sample Selection
Our analysis included a total population of 15,713. Of that population, 4995 are in
a DSNP program, and 3434 are in a LIS program. The study group included members
over 21, have only taken 1 of the oral antihyperglycemic medication classes in 2019, and
have had an HbA1c level taken during the calendar year. In reviewing the data, we found
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an issue in the MCO data on how LIS and DSNP program participation was determined.
When members went from a LIS program to a DSNP program, the system did not remove
them from the LIS program, so our data showed them in both programs. To correct this,
we created a new adjusted LIS variable where members who were in both programs were
shown as in the DSNP program only.
A mean centering technique was used to better understand the PDC values
(Hayes, 2009, pp. 466-467). A mean adjusted PDC was created by taking the individual
PDC value and subtracting the overall mean PDC of 0.8583. A not in a subsidy program
dummy variable was used as the reference variable for the in a LIS, DSNP, or no
financial aid predictor.
Because of insufficient members taking the Meglitinide Analogues, SGLT2
inhibitors, Meglitinide-Biguanide Combinations, SGLT2 Inhibitor - DPP-4 Inhibitor
Combinations, Sulfonylurea-Thiazolidinedione Combinations, ThiazolidinedioneBiguanide Combinations, and DPP-4 Inhibitor-Thiazolidinedione Combinations, we
eliminated these medication classes from our data. Table 26 is a count of the members
taking each of the classes used in the study.
Table 26
Count for each of the Classes and Combination of Classes
Medication Class
Biguanides
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Thiazolidinediones
Sulfonylureas
Sulfonylurea-Biguanide Combinations

Count
11743
615
208
2559
248
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Dipeptidyl Peptidase-4 Inhibitor-Biguanide Combinations

340

Two multiple regressions were run on the data. The first one looked at the effect
of being in a LIS or DSNP program on HbA1c levels. The second one looked at the effect
of being in either program on the interaction between PDC and medication class. Our
first two regressions indicated that LIS and DSNP programs have a statistically
significant effect on HbA1c levels and PDC. However, the R2 values were minimal and
insignificant, 0.3% for HbA1c levels and 0.5% for overall PDC. Our final regression
analysis for each medication class's mean adjusted PDC values again showed statistical
significance but insignificant R2 values. Tables 27 and 28 are the HbA1c regression
analysis results, and Table 29 is the individual mean adjusted PDC regressions R2 values
and regression results. We did not include any of the covariates in our analysis because
of the low R2 values we found when running regressions on the programs alone. Only the
DPP Biguanide medication class showed an R2 value of any significance at 5%.
Additional covariates would only give us the covariates' effect and not by HbA1c or
PDC, our predictors of concern. No collinearity was present with a VIF value of 1.150
for all of the regressions performed.
Table 27
HbA1c Model Summary

Model

R

R
Square

Std.
Adjusted Error of
R
the
Square Estimate
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.055a

1

0.003

0.003

0.99438

a. Predictors: (Constant), Adj LIS,
DSNP_INDICATOR

Table 28
HbA1c Analysis Coefficients a

Unstandardized
Coefficients

95.0%
Confidence
Interval for B

Standardized
Coefficients

Std.
B
Error
Beta
Model
6.650
0.010
Constant
0.015
-0.059
-0.126
DSNP
-0.050
0.017
-0.021
LIS
a. Dependent Variable: HbA1c level

t
682.504
-8.313
-2.916

Lower
Bound
6.631
-0.156
-0.084

Sig.
0.000
0.000
0.004

Upper
Bound
6.670
-0.097
-0.016

Table 29
Regression Analysis for Each of the Medication Classes PDC Values.
95.0%
Confidence
Interval for B

Medication class
Biguanides
DSNP
LIS
DPP
DSNP
LIS
Thiazolidinediones
DSNP
LIS

Adjust
ed R2
value
0.008

Unstand
ardized
B

VIF
Sig

Lower

Upper

-0.030
-0.033

0.000
0.000

-0.036
-0.040

-0.024 1.150
-0.026 1.150

0.148
0.124

0.000
0.000

0.112
0.084

0.184 1.150
0.163 1.150

-0.14
0.009

0.564
0.722

-0.06
-0.58

0.033 1.150
0.04 1.150

0.071

0.001
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Sulfonylureas
DSNP
LIS
Sulfonylurea-Biguanide
DSNP
LIS
DPP Biguanide
DSNP
LIS

0.007
-0.033
-0.023

0.000
0.002

-0.047
-0.038

-0.200 1.150
-0.009 1.150

-0.028
-0.024

0.165
0.261

-0.069
-0.066

0.012 1.150
0.018 1.150

0.107
0.105

0.000
0.000

0.065
0.055

0.149 1.150
0.154 1.150

0.001

0.050

Discussion
Our analysis indicates that while the DSNP and LIS financial subsidy programs
have statistically significant effects on HbA1c and medication compliance measured by
the PDC, they have a minimal overall effect on these measures with R2 values below 1%.
Our analysis demonstrates that both research questions' null hypothesis can be accepted
and that there is no significant relationship between these subsidy programs and either
PDC or HbA1c levels. Our results are the same as those of a 2012 study in that we found
little difference in medication compliance based on MPR, whether an individual was in a
LIS subsidy program or not, and even where there were differences, those differences
were of little clinical significance (Stuart et al., 2012).
CMS implemented these plans to help participants by reducing their financial
burden from deductibles and copays, particularly the LIS program which is designed
solely for this purpose. The DSNP program covers more than just medication costs. Our
primary findings indicate that participation in either a LIS or DSNP program does not
significantly affect either medication compliance, measured by the PDC, or HbA1c
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levels. However, caution should be used in interpreting these results. Because of our large
sample size, one would expect to see statistical significance in the predictors. However,
there is little clinical significance in these programs, as demonstrated by the minimal R2
values.
Limitations of the Study
The results of this analysis of financial subsidy programs can only be applied to
people with diabetes and not to other chronic conditions. Additionally, there are
difficulties in relating PDC values to someone actually consuming a medication as
directed. In this study we have to assumed that purchased medications are equal to
consumed medications. Smaller sample size research that closely monitors HbA1c levels
and PDC are needed to examine the effects of these subsidy programs on other
morbidities. It was beyond the scope of this study to examine whether increased subsidies
would positively impact compliance and reduce HbA1c levels, and further research is
needed to clarify these issues. Finally, because we examined only members who took
one of the medication classes, there may be positive effects for those taking more than
one class of these medications.
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Abstract
Cardiovascular disease is the number one killer of Americans, and one-third of
blindness worldwide is related to diabetes. However, less than one-third of people with
diabetes are compliant with their antibiotic therapy treating a UTI, and diabetes is the
most common cause of end-stage renal disease in the US. Medication is a primary
therapeutic modality in the treatment of diabetes that reduces the incidence of these
comorbidities, yet compliance rates are as low as 50%. The Proportion of Days Covered
(PDC) is the accepted method for determining medication compliance. The purpose of
this study is to determine the associations between antihyperglycemic medication class
PDC rates and HbA1c levels and four of the diabetes comorbidities, vision impairment,
renal disease, myocardial infarction, and urinary tract infections. A sample of 22,000
adults over 21 years of age, who took only one of six oral antihyperglycemic medication
classes, had an HbA1c reported during the year, and diagnosed with type 2 diabetes were
selected from the 2019 claims database of a large MCO. There are statistically significant
relationships between HbA1c, compliance, and comorbidities but, the highest strength of
effect found was 0.5%. It may indicate a need to look at different predictors such as those
related to the Social Determinants of Health, none of which were included. These results
are similar to other studies using different methods of measuring medication compliance.
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Introduction
Thirty-four million Americans are diagnosed with diabetes, and another 88
million have pre-diabetes. Many pre-diabetic individuals do not know they have the
disease (Centers for Disease Control and Prevention, 2020; National Institute of Diabetes
and Digestive and Kidney Diseases, 2017). The Center for Disease Control (CDC) has
undertaken programs to address the issue of prediabetes diagnosis by Primary Care
Providers (PCP) (Li et al., 2013). In 2017, Tseng et al. found that only six percent of
PCP’s recognized all the risk factors that should initiate a prediabetes screening, and only
17% correctly identified the laboratory parameters for diagnosing prediabetes. Twenty
percent of all U.S. healthcare costs can be related to the treatment of diabetes and its
complications, and diabetes is the seventh leading cause of death in the US (National
Center for Chronic Disease Prevention, 2016).
Effective management of people with type 2 diabetes includes supporting efforts
that improve medication compliance. The comorbidities of diabetes result from micro and
macrovascular changes leading to reduced health statuses. Macrovascular complications
include congestive heart failure, myocardial infarction, stroke, and coronary artery
disease. Microvascular complications include neuropathy, retinopathy, and nephropathy.
One person dies every 37 seconds from cardiovascular disease which is the leading killer
in the United States. (Heron, 2017). Hyperglycemia induces the formation of glycated
end products, the production of oxygenated free radicals, and increased rates of
glomerular filtration, all leading to comorbidities of diabetes (Vlassara, 1992). Long-term
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comorbidity risks in people with diabetes increase as HbA1c levels increase, so
consistent control of HbA1c levels is imperative for comorbidity control (Luo et al.,
2017).
Diabetic retinopathy is the most common microvascular complication of diabetes
(Antonetti et al., 2012). Across the world, one-third of people with diabetes are affected
by retinopathy, a leading cause of vision loss in 20 to 74-year-olds. Risk factors for
retinopathy include duration of diabetes, HbA1c levels, and blood pressure control
(Solomon et al., 2017; Yau et al., 2012). Progression of retinopathies at four to six years
post-diagnosis range from 24.1% to 38.9% and increase to 64.1% and 83.1 % in 16-year
and 25-year follow-ups (Lee et al., 2015).
Diabetes is the most common cause of end-stage renal disease (ESRD) in the US.
Due to the increased longevity in people with diabetes, comorbidity rates are increasing,
and those diagnosed with ESRD are accepted in treatment centers where they have not
been in the past (Molitch et al., 2004). Twenty to forty percent of all people with diabetes
develop some nephropathy, yet it rarely develops in people with type 1 diabetes within
the first ten years of diagnosis (Gall et al., 1991). Annual albuminuria screenings are
recommended for all people with diabetes.
The risk of Urinary Tract Infections increases with age, poor HbA1 control,
immune system compromise, and poor bladder emptying due to neuropathies. Those who
have diabetes have a higher incidence of UTI’s and the infections they get are more
severe than those who do not have diabetes (de Lastours & Foxman, 2014). In some
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cases, UTIs can lead to death due to pyelonephritis (Saleem & Daniel, 2011). UTI’s have
been traced to the neuropathies associated with diabetes (Brown et al., 2005). Less than
35% of those with diabetes and a UTI are compliant with their antibiotic therapies and
UTIs can increase total health care costs by 53% (Davis-Ajami et al., 2019).
Medication compliance in those with diabetes is an essential part of their therapy.
However, in those diagnosed with diabetes, compliance rates fall around 50% (Wang et
al., 2013). Forty-five percent of diabetics fail to achieve adequate HbA1c or blood sugar
control (Polonsky & Henry, 2016). Medication compliance is the best way to reduce the
risks of diabetes complications (Nichols et al., 2016). Because of the multiple
complications of diabetes, polypharmacy is common and presents additional problems for
providers. The incidence of noncompliance related to medication cost is 16% and is the
second most common reason for non-compliance in people with diabetes. The Social
Determinants of Health, medication packaging, poor communication skills, low health
literacy levels, a lack of trust in providers, and belief that the medications they are
prescribed do not help their diabetes all contribute to poor HbA1c and glucose level
control (Gilmartin-Thomas et al., 2017; Pruitt et al., 2018; Shiyanbola et al., 2018).
The currently accepted method of calculating medication compliance is using the
Proportion of Days Covered (PDC). The CDC adopted the PDC as the recommended
medication compliance methodology for researchers in 2015 with the PDC supported by
the Pharmacy Quality Alliance and CMS and is the leading method for determining
medication adherence in large populations (Center for Disease Control, 2015). The
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NCQA has accepted the PDC method of measuring medication compliance in their
HEDIS measures. Medications used in treating type 2 diabetes are separated into nine
classes based on their mechanism of action (Feingold, 2019). Only six of these classes,
both as individual classes and commercially available combinations of classes are
analyzed in this study To date, there is little in the literature studying the relationship
between classes of antihyperglycemic medications, HbA1c levels, and comorbidities.
One purpose of this study is to examine relationships between various classes of
antihyperglycemic medications, compliance with these medications, and the
comorbidities of diabetes.
Research Design and Methods
When a researcher wants to establish the relationships between variables, a
quantitative approach is appropriate (Creswell & Creswell, 2017). The purpose of this
study is to examine the relationships between antihyperglycemic medications, HbA1c
levels, the PDC and the comorbidities of diabetes, Myocardial Infarction, Blindness, EndStage Renal Disease, and Urinary Tract infections and a set of covariates including age,
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP
enrollment, and living in Urban or Rural County as defined by the Census Bureau. The
research questions for this manuscript are:
RQ5: Is there a relationship between the PDC calculated for individual
antihyperglycemic class of medications and HbA1c values on the top four type 2 diabetes
comorbidities of Myocardial Infarction, Blindness, End-Stage Renal Disease, and Urinary
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Tract infections, both individually and in combination, in Medicare type 2 diabetics while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS
enrollment, DSNP enrollment, and living in Urban or Rural County as defined by the
Census Bureau.
H025: There is no statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the top
four Medicare type 2 diabetes comorbidities of Myocardial Infarction, Blindness,
End-Stage Renal Disease, and Urinary Tract infections while controlling for age,
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment,
DSNP enrollment, and living in Urban or Rural County.
H125: There is a statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the top
four Medicare type 2 diabetes comorbidities of Myocardial Infarction, Blindness,
End-Stage Renal Disease, and Urinary Tract infections while controlling for age,
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment,
DSNP enrollment, and living in Urban or Rural County.
H026: There is no statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the top four Medicare type 2 diabetes comorbidities of
Myocardial Infarction, Blindness, End-Stage Renal Disease, and Urinary Tract
infections while controlling for age, sex, diabetes diagnosis time, length of time in
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MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H126: There is a statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the top four Medicare type 2 diabetes comorbidities of
Myocardial Infarction, Blindness, End-Stage Renal Disease, and Urinary Tract
infections while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H027: There is no statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the top four Medicare type 2 diabetes comorbidities of Myocardial Infarction,
Blindness, End-Stage Renal Disease, and Urinary Tract infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H127: There is a statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the top four Medicare type 2 diabetes comorbidities of Myocardial Infarction,
Blindness, End-Stage Renal Disease, and Urinary Tract infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
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H028: There is no statistically significant relationship between the PDC index
calculated for the Sulfonylureas class of medications and the top four Medicare
type 2 diabetes comorbidities of Myocardial Infarction, Blindness, End-Stage
Renal Disease, and Urinary Tract infections and HbA1c values while controlling
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS
enrollment, DSNP enrollment, and living in Urban or Rural County.
H128: There is a statistically significant relationship between the PDC index
calculated for the Sulfonylureas class of medications and HbA1c values and the
top four Medicare type 2 diabetes comorbidities of Myocardial Infarction,
Blindness, End-Stage Renal Disease, and Urinary Tract while controlling for age,
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment,
DSNP enrollment, and living in Urban or Rural County.
H029: There is no statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the top four Medicare type 2 diabetes comorbidities of Myocardial Infarction,
Blindness, End-Stage Renal Disease, and Urinary Tract infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H129: There is a statistically significant relationship between the PDC index
calculated for the individual Meglitinide Analogues class of medications and
HbA1c values and the top Medicare four type 2 diabetes comorbidities of
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Myocardial Infarction, Blindness, End-Stage Renal Disease, and Urinary Tract
infections while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H030: There is no statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the top four Medicare type 2 diabetes
comorbidities of Myocardial Infarction, Blindness, End-Stage Renal Disease, and
Urinary Tract infections while controlling for age, sex, diabetes diagnosis time,
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living
in Urban or Rural County.
H130: There is a statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the top four Medicare type 2 diabetes
comorbidities of Myocardial Infarction, Blindness, End-Stage Renal Disease, and
Urinary Tract infections while controlling for age, sex, diabetes diagnosis time,
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living
in Urban or Rural County.
H031: There is no statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Myocardial Infarction and HbA1c while
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controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H131: There is a statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Myocardial Infarction while controlling
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS
enrollment, DSNP enrollment, and living in Urban or Rural County.
H032: There is no statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the Medicare type 2 diabetes comorbidity of Myocardial
Infarction while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H132: There is a statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the Medicare type 2 diabetes comorbidity of Myocardial
Infarction while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H033: There is no statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
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the Medicare type 2 diabetes comorbidity of Myocardial Infarction while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H133: There is a statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the Medicare type 2 diabetes comorbidity of Myocardial Infarction while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H034: There is no statistically significant relationship between the PDC index
calculated for the Sulfonylurea class of medications and HbA1c values and the
comorbidity of Myocardial Infarction in Medicare type 2 diabetics while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H134: There is a statistically significant relationship between the PDC index
calculated for the Sulfonylurea class of medications and the comorbidity of
Myocardial Infarction and HbA1c values in Medicare type 2 diabetics while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H035: There is no statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the comorbidity of Myocardial Infarction in Medicare type 2 diabetics while
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controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H135: There is a statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the comorbidity of Myocardial Infarction in type 2 diabetics while controlling
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS
enrollment, DSNP enrollment, and living in Urban or Rural County.
H036: There is no statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the comorbidity of Myocardial Infarction in
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time,
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living
in Urban or Rural County.
H136: There is a statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the comorbidity of Myocardial Infarction in
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time,
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living
in Urban or Rural County.
H037: There is no statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the
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Medicare type 2 diabetes comorbidity of Blindness while controlling for age, sex,
diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP
enrollment, and living in Urban or Rural County.
H137: There is a statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Blindness while controlling for age, sex,
diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP
enrollment, and living in Urban or Rural County.
H038: There is no statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the Medicare type 2 diabetes comorbidity of Blindness
while controlling for age, sex, diabetes diagnosis time, length of time in MCO,
Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H138: There is a statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the Medicare type 2 diabetes comorbidity of Blindness
while controlling for age, sex, diabetes diagnosis time, length of time in MCO,
Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
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H039: There is no statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the Medicare type 2 diabetes comorbidity of Blindness while controlling for age,
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment,
DSNP enrollment, and living in Urban or Rural County.
H139: There is a statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the Medicare type 2 diabetes comorbidity of Blindness while controlling for age,
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment,
DSNP enrollment, and living in Urban or Rural County.
H040: There is no statistically significant relationship between the PDC index
calculated for the Sulfonylurea class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Blindness while controlling for age, sex,
diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP
enrollment, and living in Urban or Rural County.
H140: There is a statistically significant relationship between the PDC index
calculated for the Sulfonylurea class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Blindness while controlling for age, sex,
diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP
enrollment, and living in Urban or Rural County.
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H041: There is no statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the Medicare type 2 diabetes comorbidity of Blindness while controlling for
age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS
enrollment, DSNP enrollment, and living in Urban or Rural County.
H141: There is a statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the comorbidity of Blindness in Medicare type 2 diabetics while controlling
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS
enrollment, DSNP enrollment, and living in Urban or Rural County.
H042: There is no statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the comorbidity of Blindness in Medicare
type 2 diabetics while controlling for age, sex, diabetes diagnosis time, length of
time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban
or Rural County.
H142: There is a statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the comorbidity of Blindness in Medicare
type 2 diabetics while controlling for age, sex, diabetes diagnosis time, length of
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time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban
or Rural County.
H043: There is no statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H143: There is a statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H044: There is no statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the Medicare type 2 diabetes comorbidity of End-Stage
Renal Disease while controlling for age, sex, diabetes diagnosis time, length of
time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban
or Rural County.
H144: There is a statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the Medicare type 2 diabetes comorbidity of End-Stage
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Renal Disease while controlling for age, sex, diabetes diagnosis time, length of
time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban
or Rural County.
H045: There is no statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H145: There is a statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H046: There is no statistically significant relationship between the PDC index
calculated for the Sulfonylurea class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H146: There is a statistically significant relationship between the PDC index
calculated for the Sulfonylurea class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while
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controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H047: There is no statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H147: There is a statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the comorbidity of End-Stage Renal Disease in Medicare type 2 diabetics
while controlling for age, sex, diabetes diagnosis time, length of time in MCO,
Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H048: There is no statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the comorbidity of End-Stage Renal Disease
in Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis
time, length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and
living in Urban or Rural County.
H148: There is a statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
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medications and HbA1c values and the comorbidity of End-Stage Renal Disease
in Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis
time, length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and
living in Urban or Rural County.
H049: There is no statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Urinary Tract Infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H149: There is a statistically significant relationship between the PDC index
calculated for the Biguanides class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Urinary Tract Infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H050: There is no statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the Medicare type 2 diabetes comorbidity of Urinary Tract
Infections while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
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H150: There is a statistically significant relationship between the PDC index
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications
and HbA1c values and the Medicare type 2 diabetes comorbidity of Urinary Tract
Infections while controlling for age, sex, diabetes diagnosis time, length of time in
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H051: There is no statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the Medicare type 2 diabetes comorbidity of Urinary Tract Infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H151: There is a statistically significant relationship between the PDC index
calculated for the Thiazolidinedione class of medications and HbA1c values and
the Medicare type 2 diabetes comorbidity of Urinary Tract Infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H052: There is no statistically significant relationship between the PDC index
calculated for the Sulfonylurea class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Urinary Tract Infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
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H152: There is a statistically significant relationship between the PDC index
calculated for the Sulfonylurea class of medications and HbA1c values and the
Medicare type 2 diabetes comorbidity of Urinary Tract Infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H053: There is no statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the Medicare type 2 diabetes comorbidity of Urinary Tract Infections while
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.
H153: There is a statistically significant relationship between the PDC index
calculated for the Meglitinide Analogues class of medications and HbA1c values
and the comorbidity of Urinary Tract Infections in Medicare type 2 diabetics
while controlling for age, sex, diabetes diagnosis time, length of time in MCO,
Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural
County.
H054: There is no statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the comorbidity of Urinary Tract Infections in
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time,

188
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living
in Urban or Rural County.
H154: There is a statistically significant relationship between the PDC index
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of
medications and HbA1c values and the comorbidity of Urinary Tract Infections in
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time,
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living
in Urban or Rural County.
This is a quantitative longitudinal retrospective study using 2019 secondary
claims data from a large nationwide MCO. According to Creswell (2017), a longitudinal
study is appropriate when a researcher is looking for relationships between predictor and
outcome variables. This longitudinal retrospective study examines the relationships
between the comorbidities of diabetes, medication compliance with antihyperglycemic
medications, and HbA1c levels as predictors, along with multiple covariates. The study
population is approximately 23,000 are over 21, currently diagnosed with type 2 diabetes,
enrolled in either a Medicare Advantage (MA) plan during the 2019 calendar year, had an
HbA1c level done during 2019, and took only one of the six classes of antihyperglycemic
medications or a combination of classes.
All the data provided by the MCO were deidentified before release to the
researcher. Each member is assigned a unique serial number that was included with the
released data. After analysis, if the MCO wants to do further studies, the research data
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can be mapped back to individual members using the serial number assigned. Using
G*Power, version 3.1.9.4, an effect size of 0.15, an alpha error probability of 0.05, a
power of 0.95, the recommended sample size is 89. In a meta-analysis of medication
compliance studies with different diseases, the authors found that studies with more than
85 participants had high statistical power. The authors also found that effect sizes in the
studies reviewed was 0.17 to 0.18 with P < 0.0001. Based on this meta-study, we chose a
value of 0.15 (Foot et al., 2016). G* Power's effect size is a method to quantify the
differences between the test and control groups and is based on Cohen’s effect size or the
explained variance and error variance (Cunningham & McCrum-Gardner, 2007). With
23,000 participants, this study has more than sufficient participants to achieve statistical
power. The entire sample population will be used for each research question. We
excluded individuals who may have taken more than one medication class because we
cannot associate an HbA1c level with multiple medications.
The ICD-10 World Health Organization International Statistical Classification of
Diseases and Related Health Problems is used to determine a diagnosis of diabetes. We
will use the ICD-10 code of E11.9 for this data pull. Pharmacy records were pulled from
claims data, and demographic data came from other in-house databases. The medication
start date will be the date of the first dispensing of an antihyperglycemic medication.
Members are split between a learning group, L1, and a holdout group, HO1, which is
those in the plan during 2019 following a data-splitting technique (Picard & Berk, 1990).
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Income and asset levels are implied from participation in either a Low-Income
Subsidy (LIS) or a Dually Eligible Special Needs Program (DSNP) program. The
eligibility requirements for DSNP plans are that income levels be less than the poverty
level. For enrollment in a LIS program, income levels must be between the poverty level
and 300% of the poverty level. We created a categorical variable with three items
indicating the three different income levels of our participants. The third level is those not
in one of these programs with an income above 300% of the poverty level.
Analysis of the data was conducted using SPSS version 27 with a standard pvalue of < 0.05 to indicate statistical significance. Logistic regression analysis was used
to determine the effect each of the predictors on the outcome variable, and we can us
statistical significance to determine which of the variables are predictive of an outcome
(Warner, 2013). Logistic regressions are used to explain relationships between a binary
outcome variable, in this case, comorbidities of diabetes, and ordinal, nominal, or ratio
predictor variables (Wagner, 2016). For logistic regression, the outcome variable must be
binary, so we used binary variables in defining the comorbidities of interest.
The sample was split into learning groups and testing groups for each of the
research questions. The sample was split with 70% to the learning group and 30% to the
testing group (Pang & Jung, 2013). Predictions will be made on each testing group model
and then run a Chi-Square test on the actual comorbidities’ incidence and the predicted
comorbidities incidence to determine our predictive model's validity.
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In running regressions, caution is necessary, and collinearity must be examined.
In regression analysis, each predictor variable must represent a unique effect on the
outcome variable. When two or more predictors conflict and have the same effect on the
outcome variable, collinearity is present. We addressed collinearity using the SPSS
bivariate correlation function where a positive collinearity absolute value greater than 0.8
indicates collinearity. Additionally, we included the collinearity diagnostics in the
regression analysis using a VIF value greater than 10 to indicate a collinearity problem.
Table 30
Predictor Variables, their type, and possible values
Variable Name
Unique member identifier.
Age
Sex

Variable Type
Nominal
Continuous
Categorical

HBA1c level
Seeing an Endocrinologist
Medication Class
Medication PDC
Deductible
Had Myocardial Infraction
Is Blind
Has End-Stage Renal Disease
Has Urinary Tract infections
LIS enrollment
Dual enrollment

Continuous
Categorical
Ordinal
Continuous
Continuous
Nominal
Nominal
Nominal
Nominal
Continuous
Continuous

Possible Values
Format TBD by MCO
21-100
0=male,
1=female
actual level
0=no, 1=yes
1-35
0-1
$0 - $415
0=no, 1=yes.
0=no, 1=yes.
0=no, 1=yes.
0=no, 1=yes.
0=no, 1=yes
0=no, 1=yes

Each of these predictive model equations was determined by picking the
predictors where their p-value is < 0.05. The equations for each of the research questions
will be created using the fundamental equation for a straight line, y = mx + b, where y is
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the HbA1c value, b is the y-axis intercept, and m is the coefficient for a statistically
significant predictor variable. The final equation will take the final form of y = b +
coeff1*predictor1 value + coeff2*predictor2 value + coeff3*predictor3 value +
coeffN*predictorN value. This final equation will define the model for predicting either
renal or retinal screening participation. The direction and strength of a linear relationship
between two variables can be determined by Pearson’s correlation (Warner, 2013).
Values greater than 0.5 show significant levels of correlation between the variables.
Values approaching 0.3 have small correlations but still significant enough to consider in
the final equation. Any predictor variable used must have a p-value of less than 0.05.
Pearson’s correlations can give us some insight into the R2 value produced by regression
analysis because it gives us a feeling for the strength of effect (Warner, 2013). Pearson’s
correlation values are obtained by selecting a correlation from the SPSS interface and
adding all of the analysis variables.
R2 is a statistical value created by a regression analysis indicating how well the
predictor variables match the regression line (Warner, 2013). The models' R2 value
indicates the quality of the data's fit to the line created by the regression. In human
research, an R2 value greater than 0.2 is considered adequate. This value is somewhat
lower than in other kinds of research, but because human behavior is included in the
analysis, this lower number is acceptable (Hair et al., 2011). Plots of the data are
necessary to determine bias in the data. If the data is evenly dispersed around the
regression line, then a regression is appropriate. If the data is not evenly dispersed, then a

193
non-linear approach is better (Warner, 2013). An analysis of Pearson’s and the R2 value
will be conducted in the same manner as for the learning group.
Results
The purpose of this study is to determine what relationships exist between four of
the comorbidities of type 2 diabetes, myocardial infarction, renal disease, blindness, and
urinary tract infections, and HbA1c, medication class, and the PDC value. Our original
sample size was 37,363. We removed those who did not have an HbA1c level reported
for 2019, leaving a final sample size of 22,638. We then split this into a learning group of
15,845 and a testing group of 6,793. Table 31 is a list of predictors available in the data
and the count for each. Because the regression analysis requires that each predictor
entered have a value, many of our regressions either had no cases or too few for statistical
power.
Table 31
Predictor variable Counts
Predictor
Biguanide
DPP
Thiazolidinedione
Sulfonylurea
Sulfonylurea Biguanide
DPP Biguanide
Male
Female
DSNP Plan
LIS Plan
No Subsidy
Seeing Endocrinologist

Count
11743
597
206
2574
228
367
6482
9363
5151
3432
7262
623
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Retinopathy screening
Nephropathy screening
Controlled Blood Pressure

1639
3346
5896

We ran individual binary logistic regressions, using SPSS version 27, with endstage renal disease, blindness, myocardial infarction, and UTI as the outcome variables,
and each of the medication class PDC’s as the predictor variables. Table 32 shows the
outcome of those regressions for each of the comorbidities and each of the means
adjusted medication class PDC values. We then removed the models that did not show
any statistical significance and where we had case counts less than 89, as number derived
by G*Power.
For many of the regressions that included all of our predictors, we could not get
enough cases to complete a regression analysis. Table 32 show the results of running
additional regressions where we could get enough cases.
Table 32
Binary Regression of Comorbidity and Medication PDC values

Outcome
Variable
Renal Disease

PDC Predictor
Total PDC
Biguanide
DPP
Thiazolidinediones
Sulfonylurea
Sulfonylurea
Biguanide
DPP Biguanide

Chi
Square
Model
Sig
0.000
0.001
0.460
0.942
0.018

Count
(1)
3681
2113
260
80
1048

0.141
0.094

44
58

Sig
Exp(B)
0.000
1.556
0.001
1.592
0.460
0.745
0.942
1.060
0.019
1.728
0.170
0.109

6.381
3.554
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Blindness

Myocardial
Infarction

UTI

Total PDC
Biguanide
DPP
Thiazolidinediones
Sulfonylurea
Sulfonylurea
Biguanide
DPP Biguanide

0.565
0.583
0.020
0.536
0.007

207
140
11
6
39

0.569
0.858
0.014
0.514
0.025

1.259
1.312
0.059
0.278
30.346

0.538
0.346

5
2

0.581
0.454

9.064
126.53

Total PDC
Biguanide
DPP
Thiazolidinediones
Sulfonylurea
Sulfonylurea
Biguanide
DPP Biguanide
Total PDC
Biguanide
DPP
Thiazolidinediones
Sulfonylurea
Sulfonylurea
Biguanide
DPP Biguanide

0.009
0.114
0.004
0.266
0.776

1007
648
59
11
248

0.008
0.110
0.003
0.239
0.775

0.631
0.703
0.180
0.186
0.898

0.645
0.427
0.778
0.909
0.453
0.412
0.874

12
17
2460
1735
128
35
460

0.633
0.446
0.778
0.909
0.449
0.402
0.875

0.433
2.849
0.968
0.983
0.700
0.444
1.048

0.065
0.267

28
48

0.107
0.258

23.059
0.445

Table 33
Binary Regression of Comorbidity and Significant Medication PDC Values with
Covariates

Outcome
Variable
Renal
Disease

PDC Predictor

Total PDC
Age
Deductible

Chi
Square
Count
Model
Sig
0.000

3529

Sig

Exp
(B)

0.183

0.109

1.201

0.059
-0.002

0.000
0.000

1.060
0.998

Coeff
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LIS
DSNP
HbA1c Level
Seeing Endocrinologist
Hospital Visits
Retinopathy Screening
Nephropathy Screening
Gender (F reference)
Biguanide PDC
Age
Deductible
LIS
DSNP
Gender (F reference)
HbA1c Level
Seeing Endocrinologist
Hospital Visits
Retinopathy Screening
Nephropathy Screening
Constant
Sulfonylurea PDC
Age
Deductible
LIS
DSNP
HbA1c Level
Seeing Endocrinologist
Hospital Visits
Retinopathy Screening
Nephropathy Screening
Gender (F reference)
Myocardial
Infarction

Total PDC
Age
Deductible
LIS
DSNP

0.000

2103

0.000

677

0.000

1003

0.026
0.628
-0.200
0.043
0.055
-0.161
0.111
0.226
0.163
0.052
-0.002
0.004
0.599
0.136
-0.029
0.086
0.027
0.109
0.511
-5.269
0.405
0.490
-0.002
-0.030
0.590
-0.111
-0.026
0.041
0.091
0.371
0.344

0.623
0.000
0.332
0.116
0.116
0.183
0.187
0.000
0.271
0.000
0.000
0.955
0.000
0.007
0.318
0.005
0.000
0.176
0.000
0.000
0.000
0.000
0.000
0.795
0.005
0.003
0.533
0.000
0.543
0.001
0.000

1.027
1.874
0.980
1.044
1.056
0.851
1.118
1.254
1.117
1.053
0.998
1.004
1.820
1.146
0.971
1.089
1.027
1.115
1.667
0.005
0.030
1.051
0.998
0.971
1.804
0.895
0.974
1.042
1.095
1.449
1.410

-0.479

0.008

0.620

0.024
-0.001
0.067
0.232

0.000
0.100
0.458
0.141

1.025
0.999
1.069
1.261
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Gender (F reference)
Seeing Endocrinologist
Hospital Visits
Retinopathy Screening
Nephropathy Screening
HbA1c Level
Constant

0.698
0.043
0.055
-0.161
0.111
0.006
-4.9360

0.000
0.116
0.116
0.183
0.187
0.849
0.000

2.009
1.044
1.056
0.851
1.118
1.006
0.007

Discussion
HbA1c levels consistently show no statistical significance related to the four
comorbidities examined here, UTI, MI, blindness, and renal disease. These findings are
not what we expected, nor what has been published in the literature (Luo et al., 2017).
The discrepancy could be related to our lack of understanding of the relationship between
comorbid diagnosis date and when HbA1c levels were drawn, and when the comorbid
diagnosis was made. Additionally, we do not have HbA1c levels over time.
The analysis showed that being in a DSNP program doubles the chances of renal
disease compared to those not in a financial subsidy program while controlling for
covariates. However, this is not surprising, as ESRD is one of the diagnoses needed for
eligibility into a DSNP program. We also found that males have a two times greater
chance of having an MI than females when controlling for the other covariates, matching
the literature, where women generally have heart attacks 7 to 10 years later than males
(Liakos & Parikh, 2018; Maas & Appelman, 2010). However, we did not see any
differences in mean age by gender as demonstrated in Table 34, but we have 30% more
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females in the study than males who may have contributed to females having a greater
risk of MI than males in our data.
Table 34
Mean Age by Gender
Gender
Female
Male
Total

Mean
71.30
70.59
71.01

N
Composition
9363
59%
6482
41%
15845

Std. Deviation
9.470
9.414
9.453

Our analysis did not uncover any significant relationships other than what has
been found in previously published studies (however, these studies were not looking at
specific comorbidities of diabetes). We did not have enough members with comorbidity
and covariates to do as complete an analysis as we wanted, nor were we able to develop
any predictive models for the same reason. We did have enough members to find the R2
values to be so low as to render our models insignificant.
Limitations and Future Areas for Study
There are several limitations to this study related to the comorbidities of type 2
diabetes. Our data did not give the length of time since any of the comorbidities were
diagnosed. Our data did not provide when HbA1c levels were completed, which may
have affected our results. Additionally, we are not able to relate HbA1c levels to
comorbidities.
The insignificance of our R2 values, where we could get one, indicates that we are
looking at the wrong covariates. The SDOH are gaining popularity in the literature so an
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area of future study would be to look at how the SDOH impact the four comorbidities
examine here. There is evidence for the relationship between the SDOH and diabetes
(McBrien et al., 2017).
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Part 3 : Summary
Introduction
The first of the three studies presented here examined the relationship between
medication compliance in six of the antihyperglycemic medication classes and HbA1c
levels in people with type 2 diabetes. The second study examined the effectiveness of
financial subsidies on medication compliance and HbA1c levels in people with type 2
diabetes. The third study examined the relationship between the comorbidities of type 2
diabetes and medication compliance. The individuals in all these studies came from a
large, nationwide MCO, have a diagnosis of type 2 diabetes, were taking one of six
medication classes of antihyperglycemic medications, or a combination of them, took
only one of these during the year, and had at least one HbA1c level done during the year.
Participants were chosen from the claims database of a large, national MCO from 2019.
Of the original 56,000 potential MCO members for this study, final counts varied from
22,000 to 15,000, depending on the study. All studies have sufficient members to achieve
statistical power.
The study results demonstrate clinically significant findings in the relationship
between medication compliance and the medication a person with diabetes consumes. It
shows that practitioners should consider how compliant their patient is when considering
a medication regimen. In part, Medicare created the LIS and DSNP programs to improve
medication compliance by reducing copays and deductibles. Study two demonstrated
that this is not the case. Additionally, these programs do not appear to affect HbA1c
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levels, the ultimate goal of therapy. Finally, the third study was unable to establish any
relationships between four of the comorbidities of diabetes and medication compliance in
people with type 2 diabetes.
Summary of Findings
Study one demonstrated that medication compliance should be a factor when
providers decide which medications they are going to use to treat their patients. We
found that the Sulfonylurea-Biguanide combination, slope1 = -2.49, is most sensitive to
compliance, demonstrating that the Sulfonylurea-Biguanide class of medications should
be avoided in patients providers feel, or will be, non-compliant. However, the DPP class
of medications, slope = -0.09, Biguanide class, slope = -0.16, and Sulfonylurea class,
slope = -0.25, are the least affected by medication compliance. Thiazolidinediones, slope
= -0.83, and DPP-Biguanides, slope = -0.94, are moderately affected by medication
compliance compared to the other classes discussed here. Finally, we demonstrate that
with compliance rates above 85%, each of these medication classes' effectiveness is
similar.
In part, Medicare instituted the LIS and DSNP programs that reduce copays and
deductibles to improve medication compliance and in people with diabetes, thereby
reducing HbA1c levels. While we had statistically significant findings that these
programs affect compliance and HbA1c levels, the R2 values were all less than 1%,

1

Slope is for each unit increase in PCD, HbA1c changes by slope value units. Slopes are
all negative showing that as compliance increases HbA1c levels fall.
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indicating that their effect is insignificant. Our findings are similar to another study
conducted in 2012 that used the MPR compliance method and not the PDC method for
calculating compliance as used in this study.
Our third study examined the relationship between HbA1c levels and four of the
comorbidities of diabetes, UTIs, MI’s, ESRD, and blindness. Our findings conflict with
the published literature, but our evidence is conflicting. For example, those in a DSNP
program showed double the chance of having renal disease when compared to those not
getting financial assistance. However, having an ESRD diagnosis is one of the predicates
of being in a DSNP program, and we did not have diagnosis dates to include in our
analysis. We did find that males had two times greater chance than females of having an
MI, and we did not find any differences when examing age.
Interpretation of Findings
In our study of the relationship between HbA1c and medication compliance, we
found a statistically significant relationship. This study's findings reveal that during the
clinical medication therapy decision-making process for people with type 2 diabetes,
providers should consider how compliant their patients are in taking their medications
and considering the medication class to prescribe. Most significantly, we found that the
Sulfonylurea-Biguanide combination should be reserved for patients who will be more
than 85% compliant to maintain acceptable HbA1c levels. We also found that the DPP,
Sulfonylurea, and Biguanide classes of medication are not affected much by compliance,
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so these would be good therapy choices for patients that providers feel will be noncompliance in taking their medications.
In examining the LIS and DSNP program's effects on medication compliance and
HbA1c levels, we found that while there is a statistically significant relationship, these
relationships' strength is minimal at best (R2 < 1%). The purpose of these programs is to
help reduce the financial burdens that may lead to medication non-compliance. However,
the evidence does not support this.
Our final study found little evidence establishing a relationship between UTIs,
MI’s, blindness, or ESRD. Our findings in this study were unexpected as it is not
consistent with past studies on the comorbidities of diabetes. However, these studies did
not look specifically at medication compliance and these comorbidities. There could be
several explanations for this discrepancy. First, this is not a long-term study, there are
other factors than what we looked at that contribute to the comorbidities, and we only had
a single HbA1c level taken during one year.
Limitations of Study
We identified several limitations for all these studies. We could not associate the
date an HbA1 level was obtained and medication compliance rates, possibly skewing our
results. We found statistically significant relationships that the R2 values were low with
values less than 5%. We did not have access to the social determinant of health data at a
member level. We tried a multilevel analysis at a zip code level but did not get any
statistical significance. Because we found relatively low R2 values throughout our

212
studies, further studies need to examine how the social determinant of health fit into the
relationships between medication compliance and HbA1c and the comorbidities of
diabetes. While we found indications of strong relationships between medication class
and HbA1c levels, smaller studies are needed where compliance and medication class can
be more closely associated with HbA1c levels. Finally, we only looked at people with
diabetes who took a single medication during 2019. People with diabetes are also on
multiple medications during the year or switched from one medication to another. These
cases are also deserving of closer scrutiny with more closely controlled studies
Individual
Eighty-five million Americans have been diagnosed with diabetes, and another 30
million have been diagnosed with pre-diabetes, constituting one-third of the country's
population. Diabetes costs the US hundreds of billions of dollars in medical costs each
year and is one of the most prominent US's chronic diseases. Medication therapy is a
crucial component for a person with diabetes, and compliance with their medications is
the primary component of that regimen. These studies provide new evidence for
practitioners when making therapy decisions showing them that not only is the class of
medication selected essential but that the compliance level of their patient must be just as
important a factor in medication selection. Additionally, the studies show that the
Medicare financial incentive program aimed at improving compliance is not having the
desired impact and the need for future studies of the LIS and DSNP (pharmacy part)
programs.

213
Clinical
Primarily related to practitioners is study one. This study provides evidence on the
importance of compliance when instituting a medication therapy plan. We showed that
the ability of different medications to control HbA1c levels is statistically related to how
compliant their patient will be. We showed that some medication classes are susceptible
to compliance, and others a not affected much by compliance rates. We showed that for
compliant patients (over 80% of the time), there is not much difference in the effect of
compliance on HbA1c control. Provider medication decisions are essential in finding
ways to control their patients' blood sugar levels. Controlled blood sugars result in lower
societal medication costs, better health statuses, and lowered diabetes complications for
people who have diabetes.
Societal
The societal costs from diabetes are significant including financial, burdens on the
healthcare system and the effects of poor health statuses of people with diabetes. The
financial costs are borne by insurers, payors, and those without insurance individuals.
Lost work productivity contributes to the financial costs of diabetes, and for those
without sick, benefits may add to lowered health statuses.
We found that Medicare’s financial programs aimed at improving compliance rates are
not having the desired effect. We demonstrated that a reevaluation of these programs
should be considered, and new approaches are needed. These financial programs do not
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contribute to improved compliance or lowered HbA1c levels as designed, and there
should be consideration for allocating these resources differently.
Implications for Social Change
Individual
Eighty-five million Americans have been diagnosed with diabetes, and another 30 million
have been diagnosed with pre-diabetes constituting one-third of the country's population.
Diabetes costs the US hundreds of billions of dollars in medical costs each year and is
one of the most prominent US chronic diseases. Medication therapy is a crucial
component for a person with diabetes, and compliance with their medications is the
primary component of that regimen. These studies provide new evidence for
practitioners when making therapy decisions showing them that not only is the class of
medication selected essential but that the compliance level of their patient must be just as
important a factor in medication selection. Additionally, the studies show that the
Medicare financial incentive program aimed at improving compliance is not having the
desired impact and the need for future studies of the LIS and DSNP (pharmacy part)
programs.
Clinical
Primarily related to practitioners is study one. This study provides evidence on the
importance of compliance when instituting a medication therapy plan. We showed that
different medications' ability to control HbA1c levels is statistically related to how
compliant their patient will be. We showed that some medication classes are susceptible
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to compliance, and others a not affected much by compliance rates. We also showed that
across patients compliant with their medications (over 80% of the time), there is not
much difference in HbA1c control based on different medications. These decisions are
essential in provider’s efforts in finding ways to control their patients' blood sugar levels.
Controlled blood sugars result in lower societal medication costs, better health statuses,
and lowered diabetes complications for people who have diabetes.
Societal
The societal costs from diabetes are significant including financial, burdens on the
healthcare system and the effects of poor health statuses of people with diabetes.
Financial costs fall on insurers, payors, and those individuals without insurance. Lost
work productivity contributes to the financial costs of diabetes, and for those without
sick, benefits may add to lowered health statuses.
We found that Medicare’s financial programs aimed at improving compliance
rates are not having the desired effect. We demonstrated that a reevaluation of these
programs should be considered, and new approaches are needed. These financial
programs do not contribute to improved compliance or lowered HbA1c levels as
designed, and there should be a reconsideration to allocating these resources differently.
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